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Abstract
Texture analysis has been proposed recently as an imaging biomarker in the field of oncology. The
previously published work has shown promising results in relating tumour heterogeneity to patient
survival. Yet, a standardised texture analysis method has not been established, and the physiological
implications of the extracted textural features are not well understood. An understanding of tumour
image texture is crucial before such a method could be utilised in clinical settings.
In this thesis, the author presents methodology developed to generate optimised three-dimensional
voxel-based CT texture maps (3D-VTM) to examine regional heterogeneity information within
tumours and their relation to tumour metabolism measured as 18F-fluoro-deoxy glucose (18F-FDG)
Positron Emission Tomography (PET) distributions. Ten patients diagnosed with advanced non-small
cell lung cancer (NSCLC) were investigated. For optimal texture information decoding, an optimised
quantisation method is presented. The texture feature that reflects heterogeneity and which showed
correlation with patients survival was chosen for this thesis. To account for respiratory motion effects,
an in-house designed phantom was used to characterise the effects of motion on texture analysis and
consequently adapt our method in that regard.
To quantify the relationship between CT tumour image heterogeneity and the 18F-FDG uptake
distribution, the overlap fraction (OF) and Dice similarity coefficient (DSC) were calculated. The 3D-
VTMs produced from CT tumour images using our proposed image information optimisation method
have shown a clear textural pattern within tumours that correlates with the 18F-FDG distribution.
These produced 3D-VTMs showed that regions with low CT heterogeneity within the tumour overlap
with regions of high 18F-FDG uptake (>50% SUVmax). The OF between >50% SUVmax volume
and low entropy region is as high as 84% with a mean of 65%±12 and the DSC is 75% with a mean
of 60%±11.
The potential clinical application of our proposed method in radiotherapy dose painting is demon-
strated. Three dose painting plans based on i) CT tumour image heterogeneity, ii) tumour 18F-FDG
uptake distribution and ii) the combination of both were created. The dose painting plans were com-
pared to the current standard of uniform dose plan and against each other. The results demonstrated
the feasibility of dose escalation in advanced NSCLC conforming to normal tissue clinical constraints
where the difference in dose received by the organs at risk (OARs) in the created plans were not
viii
statistically significant. Moreover, the results showed the possibility of covering the 95% of the high
18F-FDG uptake regions within the tumour with 95% of the prescribed dose when planning based on
intratumoural heterogeneity measured from CT images.
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Chapter 1
Introduction and Background
1.1 Introduction
Radiotherapy has seen rapid development in the last few decades with delineation of target volumes
becoming more precise, due to improvements in medical imaging modalities [117]. In the field
of radiation oncology, medical images are used to diagnose, stage, plan and assess the response
of tumours to treatment [117]. Today, using computed tomography (CT) to guide radiotherapy
planning is considered to be the gold standard. In addition to its high image resolution (≈1mm),
radiotherapy treatment planning systems (TPS) rely on Hounsfield units (HU) obtained from CT for
dose calculations. Yet, CT based radiotherapy planning relies on qualitative information from CT
images where quantitative measurements are usually confined to determining tumour size in three
dimensions. Even though tumours have been shown to be biologically heterogeneous, radiotherapy
planning is still often based on TNM staging. The TNM system is used to stage cancer: a letter and a
number are assigned to each letter in the TNM system, where T stands for the tumour, referring to its
size; N stands for node and represents the status of lymph node involvement; and M is for metastasis,
providing information on whether the cancer has spread to other parts of the body [26]. Given the
increased evidence of intra-tumoural heterogeneity and the observed diversity of patients’ response
to treatment, the field of oncology has been striving for personalized treatment, based on prognostic
information of a tumour’s response to treatment.
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In recent years, nuclear medicine imaging, especially positron emission tomography (PET) has
been increasingly utilised in the field of oncology as a source of quantitative measurements regarding
tumour biology. Fluoro-deoxy-glucose labeled with flourine-18 (18F-FDG) PET imaging has probably
made a greater contribution to radiotherapy planning in regards to assessing response to treatment
than other functional imaging modalities including functional magnetic resonance imaging (fMRI).
The wide availability, high sensitivity and the relatively well established protocols and quantification
methods of 18F-FDG PET have led to its subsequent popularity in the field of oncology [112].
Even though several studies have reported 18F-FDG PET to be a predictor for a tumour’s response
to treatment [23][64][158][19][109][65][81][144][111][63], the standardised uptake value (SUV)
remains semi-quantitative, challenged by changes in tumour volume, uptake time and kinetics of the
uptake and subsequently the distribution of the tracer [63][78].
Limitations in existing imaging modalities and the concept that radiological images hold more
information than is being utilised has led to increased interest in the field of radiomics. Radiomics
refers to quantitative feature extraction from radiological images and their use to generate meaningful
data [85]. In cancer therapy, assessing tumour heterogeneity in relation to survival by extracting
textural features has emerged in the past few years as a potentially useful tool. Algorithms have
been proposed in the literature to increase the predictive power of existing imaging modalities by
extracting tumour textural features based on intensity values. The findings showed that tumour
textural heterogeneity correlates with treatment outcome and overall patient survival [10]. Yet, the
field suffers from a lack of a standardised approach to perform texture analysis leading to confounding
results. Image quantisation is one of the crucial factors in extracting textural information and a
validated standarised method has not been established in the published literature. Moreover, texture
analysis is challenged by the limited clinical validation and the unclear physiological mechanism
underpinning such findings [10]. Even though the proposed methodologies are still in their early
stages of development, suffering from expected shortcomings and faced with various challenges, the
presented results are promising. The benefits of employing a quantitative post-processing algorithm
on routinely acquired patients images to predict response to treatment or to provide meaningful
information about tumour function, if established to be valid, would be numerous.
In this chapter, I present an overview of the main concepts in the field of radiotherapy including
the clinical process of radiotherapy treatment and treatment planning techniques. An overview of CT
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and PET imaging modalities is also presented. Additionally, the role of textural analysis in the field of
radiotherapy is reviewed. And finally, an outline of the thesis structure is summarised.
1.2 External Beam Radiotherapy
Radiotherapy is one of the main treatment modalities in the field of oncology. In radiotherapy, ionising
radiation is used to kill malignant cells. Cell killing is caused by DNA damage to the cancer cells. The
aim of radiotherapy is to deliver a radiation dose as high as possible to the tumour while minimising
the radiation dose to the surrounding healthy tissue to minimise tissue damage [128]. In external
beam radiotherapy (EXBRT) or teletherapy, a linear accelerator (LINAC) is used to generate a beam
of ionising radiation (photon or electron) of energy range of typically 4-20 Megavoltage (MeV) [132].
The radiation output from the LINAC is delivered in terms of monitor units (MU), 1 MU from the
LINAC is measured as 1cGy (Gy is the unit for radiation dose as absorbed in unit mass) using a
monitor chamber in a 10x10cm2 field size at a depth point in a water phantom [105].
The therapeutic use of X-rays started with the use of the conventional X-ray machines with
kilovoltage energies treating only superficial lesions. With the advances in technology, the modern
linear accelerators are able to deliver higher energies of typically 4-20 MeV and treat deeply located
tumours. Furthermore, most modern LINACS are equipped with an image guiding system based on
cone beam CT (CBCT) to obtain an image of the patient before delivering the treatment allowing
precise treatment delivery. An example of a modern linear accelerator is presented in figure (1.1).
1.2.1 Radiotherapy Treatment for Lung Cancer
Lung cancer is the second most common cancer in men and women and is the leading cause of cancer
mortality in the UK [26]. Based on the pathology, lung cancer is divided into small cell lung cancer
(SCLC) and non-small cell lung cancer (NSCLC). In the UK, SCLC comprises 12% of lung cancer
diagnosis while NSCLC comprises 87%. For inoperable non-small cell lung cancer (NSCLC), the
treatment of choice is a combination of chemotherapy and radiotherapy. For early stage inoperable
peripheral NSCLC, the treatment of choice is stereotactic ablative radiotherapy (SABR). SABR is
an external beam radiotherapy technique where accelerated schedules (known as hypofractionation)
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Fig. 1.1 An example of a modern linear accelerator showing the main parts of the linac [146].
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Fig. 1.2 A schematic illustration of the branching of the bronchus which is known as the bronchial
tree [26].
for delivering the dose is employed: 3 fractions of 18Gy, 5 fractions of 12Gy or 8 fractions of 7.5Gy
[74]. This technique requires high precision in tumour localisation in order to reduce the uncertainty
and allow a delivery of a very high radiation dose to the tumour. Tumour images are acquired before
each session in SABR to ensure an accurate delivery of the dose. The local control for patients treated
with SABR has been reported to be as high as 90% at 3 years [28]. However, SABR treatment is only
the standard treatment for peripheral tumours not central lung tumours. Central lung tumours are
defined as tumours within 2cm of the region surrounding the branching of the bronchus, known as the
bronchial tree as shown in figure (1.2). A high radiation dose to the bronchial tree has been reported
to cause high grade toxcicity in patients treated with SABR for central tumours [28] [89].
Thus, for inoperable central NSCLC, the treatment of choice is the conventional chemoradiother-
apy treatment with a dose of 64Gy delivered in 32 fractions. The prognosis of advanced inoperable
NSCLC treated with conventional EXBRT is as low as 10%.
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1.3 The Main Steps of Radiotherapy Treatment
The delivery of radiotherapy treatment involves three main steps; imaging and volume definition,
treatment planning and treatment delivery. These steps will be discussed in the following sections.
1.3.1 Imaging and Volume Definition
Imaging is the first step in radiotherapy and it is fundamental in ensuring accurate treatment planning
and delivery. In imaging, the patient position is decided taking into account the treatment area. For
example, lung patients are usually positioned supine (lying facing upwards) with their arms up away
from the treatment area. Reference marks or tattoos are used to ensure position reproducibility through
the treatment course. During this step, patient tumour images are acquired to be used for treatment
planning. Currently, the treatment planning and dose calculations are based on CT images, thus a
planning CT scan is acquired for the patient in the treatment position [79].
For volume definition, the radiation oncologist contours the tumour and the critical structures
known as organs at risk (OAR) on the obtained CT images. The tumour is delineated as a part of
three volumes; the gross tumour volume (GTV), the clinical target volume (CTV) and the planning
target volume (PTV). GTV is the radiologically visible tumour while the CTV includes the visible
tumour and the sub-clinical microscopic extension of the malignant disease. Although a margin
of ≈5mm around the GTV is often used to countour the CTV, the CTV can be adjusted based on
clinical judgment. To account for set-up uncertainties, internal organ motion and patient movement, a
margin of typically 1-2cm is added to the CTV to create the planning target volume (PTV) [2][76].
Alternatively, an internal margin (IM) can be added to the CTV to compensate for physiological
variations due to internal organ movement; this volume is known as the internal target volume (ITV).
The PTV is then grown from the ITV with a margin designed to account for set up uncertainties and
patient movement only. A schematic illustration of the target volumes is presented in figure (1.3).
1.3.2 Treatment Planning
In this step, the planning CT scan and the contoured structures are transferred into the treatment
planning system (TPS). In the computerised TPS, radiation fields are arranged in a way that delivers
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Fig. 1.3 A schematic illustration of the target volumes in radiotherapy.
the prescribed dose to the PTV while keeping the normal tissue dose within the acceptable limit. In
3D conformal radiotherapy, the TPS sets the radiation fields based on the 3D projection of the PTV
in the direction of the radiation beam. These fields are physically achieved by the programmable
multi-leaf collimator (MLC) component of the linac. The MLC is a device that is attached to the
linac’s gantry head and it is made of "leaf" pairs. The leaves are made of a high atomic number
material mostly tungsten. Modern linacs could have 80-160 leaves with a typical leaf width of 5mm.
The leaves are programmed to produce the radiation field. The beams angles are determined in a way
that the overlap between the PTV and the surrounding tissue is minimal [79].
The dose deposition in tissue is calculated based on the electron density inferred from the CT
numbers. The delivered dose is visualised by isodose line; line connecting points receiving the same
dose; those lines are superimposed on the CT images. To measure the dose received by each structure
volume, dose volume histograms (DVH) are generated. Figure (1.4) demonstrates an example of a
typical 3D plan for lung cancer showing the target volume and the superimposed isodose lines [79].
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Fig. 1.4 A radiotherapy plan showing the isodose lines superimposed on the CT images in three views.
The green region is the PTV. The orange isodose line represent the volume that is covered by the 95%
of the prescribed dose. The top view is the axial image, the bottom right in the sagittal image and the
bottom left is the coronal image.
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1.3.2.1 Intensity Modulated Radiotherapy
3D conformal radiotherapy has the ability to shape the dose distribution yet it is limited by the high
dose regions caused by the overlapping of the conformal beams. To overcome this issue, in the late
1990s intensity modulated radiotherapy (IMRT) was introduced. IMRT allows the dose to vary within
the treatment field to better shape the dose distribution preventing high overlap regions. In IMRT,
the radiation fluence is modulated across the beam in such a way it conforms to the 3D shape of the
target while keeping the dose to normal tissue to a minimum. This is achieved by using multiple
non-uniform beams to deliver a uniform dose to the target by either using multiple static fields with
different shapes and angles (step-and-shoot technique) or by dynamically changing the MLC leaves
while irradiating (sliding window technique) [105].
In IMRT planning, the directions, shapes and weights of the beams are optimised in such a way
that the combination of the non-uniform beams will add up to a uniform dose distribution within the
target volume. Due to the complexity of the task at hand, this optimisation is achieved using inverse
planning. In inverse planning, firstly the planning objectives of dose constraints for normal tissues
and target volume are set. An iterative optimisation algorithm is implemented to adjust the beams
parameters to generate a dose distribution that conforms to the desired objectives. The agreement
between the set objectives and the generated dose distribution is assessed by an objective function.
The desired solution to this optimisation problem is a dose distribution that minimises the objective
function [79][105].
IMRT has wide applications in most aspects of radiotherapy because of its ability to create multiple
targets and multiple avoidance structures allowing the treatment of different targets simultaneously to
different doses. By delivering radiation with greater precision, IMRT has been shown to minimise
acute treatment-related morbidity, making dose escalation feasible which may ultimately improve
local tumour control [105].
1.3.2.2 Volumetric Modulated Arc Therapy
Even though IMRT has a huge impact on the precision of treatment planning and improvement of
local control, it suffers from challenging limitations. IMRT treatment planning and quality assurance
is more complex and requires more time. The longer treatment sessions of IMRT compromises
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patients comfort and the stability of their position. Furthermore, IMRT requires more monitor units to
be delivered from the linac which raises concerns about exposure to low dose radiation with risks of
radiation-induced malignancy. Volumetric Modulated Arc Therapy (VMAT) is a form of an IMRT
treatment that has been introduced recently to overcome some of these limitations. In VMAT, the
intensity modulated radiotherapy is delivered while the gantry is dynamically rotating around the
patient. VMAT benefit over IMRT is the reduction of treatment time, increasing treatment efficiency
and the reduction of monitor units [129]. The treatment planning process used in VMAT is similar to
that of IMRT.
For advanced lung tumours, the reduction in treatment time offered by VMAT could be beneficial
in regards to minimising the intrafraction respiratory motion effects on treatment delivery [129].
Moreover, for advanced lung cancer treatment, a study by Jiang et al. 2011 [75] reported that using
partial arcs in VMAT showed more sparing (lower dose) to normal lung tissue than using a single arc
or IMRT.
1.3.3 Treatment Delivery
The course of radiotherapy treatment is delivered over a number of sessions known as fractions.
Fractionation is a significant principle in radiotherapy and it is based on the five R’s of radiobiology.
1.3.3.1 The Five R’s of Radiobiology
Fractionation is mostly governed by five principles known as the five R’s of radiobiology or radiother-
apy; repair, reoxygenation, repopulation, redistribution and radiosensitivity.
Repair refers to post irradiation cell damage repair, and it is the basis of fractionation in radio-
therapy. In the linear quadratic (LQ) theory, the cell will be inactivated due to DNA damage caused
by ionising radiation. The cell kill is caused by two components: a component where the kill is
proportional to the total dose D (linear) and a component that is proportional to the square of the
dose D2 (quadratic). The linear component is represented by αD and the quadratic components is
represented by βD2. In these terms, α and β are constants where α accounts for the irreparable cell
damage and β for repairable damage. The probability of cell surviving (S) an irradiation event can be
expressed by Poisson statistics as shown in equation (1.1).
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S = exp(−αD−βD2) (1.1)
The ratio α/β gives the dose when the linear and quadraic components are equal. By taking the
log of S, αD= βD2 and consequently D=α/β . Having a high α/β (5-10Gy) indicates cells with low
capability of repairing sublethal damage which is a characteristic of tumour cells. While a low α/β
(1-4Gy) indicates cells with the ability to repair sublethal damage which is a characteristic of normal
tissue. This difference between tumour cells and normal tissues is the rationale for fractionation. The
survival curves in figure (1.5) shows the crossover between the two types of tissue is around 5Gy,
meaning, a delivery of a dose higher than that will cause damage to the normal tissue. Yet, a higher
dose is needed to kill tumour cells thus, a higher radiation dose is delivered in low dose fractions.
This leaves enough time for normal tissue to repair the sublethal damage while the sublethal damage
of tumour cells will accumulate over fractions. Based on clinical data, 3Gy is an accepted value for
α/β for many normal tissue and 10Gy α/β for typical tumours, yet these values vary between tissue
and tumour types. The LQ model is the most used clinically since it is shown to fit experimental data
and works well for low doses (<10Gy per fraction). Yet, the accuracy of the LQ model at high doses
is debatable [79].
Reoxygenation, oxygen is a known radiosensitiser thus cells that are oxygen deprived (hypoxic)
are more resistant to radiation. It has been reported in the literature that a large proportion of tumours
are hypoxic, this leads to the oxygenated tumour cells being destroyed first hence increasing the
surviving fraction of hypoxic tumour cells. In-vivo experiments showed that allowing time for tumour
cells to reoxygenate decreased the numbers of the hypoxic cells making the tumour more sensitive to
radiation [79].
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Fig. 1.5 The survival fraction curve for early responding tissue (tumour tissue) and late responding
tissue (normal tissue) [105].
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Fig. 1.6 The phases of cell cycle [110].
Repopulation, tumour cells repopulate much faster than normal tissue, thus the treatment frac-
tionation should be scheduled in a way that will allow the normal tissue to repair while minimising
the tumour repopulation effect [79].
Redistribution, cell division happens in a cycle that has four phases as explained in figure (1.6).
Studies have shown cells to be more sensitive to radiation in the G2 and mitotic phase while being
most resistant at the synthesis phase. Redistribution benefits can be achieved if the radiation dose
was delivered when the tumour cells are in the mitotic phase when they are most sensitive. Yet, this
is usually not accounted for when designing fractionation since it is not practically obtainable [79].
However, treating at several different time-points increases the probability of catching each cell at it
most sensitive at some point during the treatment course.
Radiosensitivity refers to the intrinsic radiosensitivity of cells meaning the ability of a cell to
sustain radiation damage. Tissues vary in their ability to reproduce; cells with high division and
metabolic rate that are non-specialised, such as lymphoid, bone marrow and reproductive (ovaries and
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testes) organs are most intrinsically radiosensitive, while highly specialised tissues such as muscle
and mature bones are least radiosensitive.
1.3.3.2 Image Guided Radiotherapy
In radiotherapy treatment delivery, image guided radiotherapy (IGRT) is usually employed. In IGRT,
the patient is imaged before and/or during treatment allowing a precise verification of treatment
position and treatment delivery. Most modern linacs are equipped with an image guiding system
based on cone beam CT (CBCT). The main difference between CBCT and the conventional diagnostic
systems is that CBCT uses a cone radiation beam. The conventional CT scanners uses a fan beam to
acquire multiple slices of the patient, while the CBCT images a whole volume in one rotation [127].
Furthermore, CBCT provides the option of using a low energy beam (range of 40-125kVp) compared
to the higher energy range used in the conventional CT scanners [8].
Although IGRT ensures the geometric accuracy of treatment delivery and offers the possibility of
re-optimising the treatment plans, the increased time on the treatment couch and increased radiation
exposure to the patients are the main disadvantages.
1.4 Imaging for Radiotherapy
1.4.1 Anatomical Imaging
Following the clinical introduction of CT in the 1970s, radiotherapy treatment has become mainly
based on CT images for diagnosis/staging, planning and follow up [40]. Nonetheless, CT images have
sub-adequate soft tissue contrast, are negatively affected by the presence of metal implants and expose
the patient to ionising radiation. Hence, the use of Magnetic Resonance Imaging (MRI) became a
more popular modality in the field of radiotherapy. MRI uses electromagnetic radiofrequency (RF)
to image tissues. The proton in the hydrogen nucleus is positively charged and has an intrinsic spin.
When the hydrogen atom is placed within a strong magnetic field, the hydrogen proton spin will
align with the magnetic field. The MR machine delivers a RF pulse that perturbs the alignment of the
hydrogen nuclei. When the RF pulse is suspended, the hydrogen atoms in the human body will start to
re-align to the external field (recovery). Hydrogen atoms in different tissues have a different recovery
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time and that provides the MRI contrast. MRI has the advantage of using non-ionising radiation and
having an excellent soft tissue contrast. However, MRI is costly, not as available as CT and doesn’t
provide electron density information needed for radiotherapy planning. Yet, in recent years there
has been great interest in integrating MRI into the radiotherapy workflow with the emergence of
MRI based planning systems [137]. Currently, CT imaging stays the gold standard for radiotherapy
treatment planning.
CT scanners provide anatomical 3D images displayed using Hounsfield Units. Hounsfield Units
are obtained by linearly transforming the X-ray attenuation coefficients (µ) of tissue based on the µ
of water as shown in equation (1.2).
HU = 1000× µtissue−µwater
µwater
(1.2)
The current CT systems are volumetric systems with an X-ray source and multiple detector rows
allowing the scanning of an entire volume in seconds. Modern CT scanners are spiral CTs; the X-ray
projection takes a spiral path while the table moves axially which allows volumetric fast scanning.
The CT system collects the X-ray transmission profiles through the patient from multiple views. The
numbers in the CT image matrix are related to the X-ray attenuation of the tissue. Using a filtered
back projection (FPB) algorithm, cross-sectional CT images are reconstructed based on the acquired
X-ray transmission profiles through the patient. In FPB, the scanned data are converted from the
object space into the Radon space in what is know as a sinogram. In the sinogram, each profile
projection angle from the spatial domain is represented by one line in the frequency domain known as
the Fourier slice theorem [40]. An illustration of the Fourier slice theorem is shown in figure (1.7)
For an image f (x,y), Radon transform (R) could be simply explained as a series of offset lines
integral for each angle in the image as shown in figure (1.8).
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Fig. 1.7 The Fourier Slice Theorem. The Fourier Slice Theorem described the relationship between an
image and its views in the frequency domain. In the spatial domain, each view is found by integrating
the image along rays at a particular angle. In the frequency domain, the spectrum of each view is a
one-dimensional "slice" of the two-dimensional image spectrum [123].
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Fig. 1.8 The geometry of Radon transform [1]. The angle between the projection line and the x-axis is
θ .
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Mathematically, the Radon transform could be expressed as in equation (1.3), where the slope of
the line projection is p and the intercept is τ .
R(p,τ) =
∫ ∞
−∞
f (x, px+ τ)dx (1.3)
The more applicable form of Radon transform using the delta function δ is presented in equation
(1.4). In equation (1.4), the angle and the offset of the projection line are θ and r respectively.
R(r,θ) =
∫ ∞
−∞
∫ ∞
−∞
f (x,y)δ (xcosθ + ysinθ − r)dxdy (1.4)
The sinogram (the output of the Radon transform) is then filtered with a high pass filter (such as
ramp filter) to reduce blurring before it is back projected to reconstruct the image. Back projection
is done using the inverse Radon transform presented in equation (1.5), where f
′
is the filtered data.
Figure (1.9) shows the main steps in FBP.
f (x,y) =
∫ ∞
0
f
′
(xcosθ + ysinθ)dθ (1.5)
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Input Image
Ramp Filter
Radon Transform
Reconstructed Image
Inverse Radon Transform
Fig. 1.9 The main steps in filtered back projection [1].
1.4.2 Functional Imaging
CT imaging provides anatomical and morphological information but given that tumour’s sensitivity to
radiation is affected by a number of biological factors (oxygenation level, clonogenic density and rate
of proliferation) [150], medical imaging techniques that allow visualisation and mapping of a certain
biological or functional process has great potential in the field of radiation oncology. Although some
CT imaging technique such as CT perfusion and Blood-oxygen-level dependent contrast magnetic
resonance imaging (BOLD-MRI) provides functional information, Positron Emission Tomography
(PET) has made a greater contribution to radiotherapy treatment than the other functional imaging
modalities.
PET involves injecting the patient with a positron-emitting radiopharmaceutical and detecting
the resultant emissions to image a biochemical process. The decaying radiopharmaceutical causes
electron- positron annihilations where each annihilation produces 2 gamma rays (each 511 keV and at
an angle of 180◦ from each other). The resultant pair of gamma (γ) rays is detected by two opposing
detectors in the PET scanner; this is known as true coincidence. The line along which the event must
have occurred is termed line of response (LOR). By combining the parallel LOR’s, a projection of the
radioactivity distribution can be acquired and stored in a sinogram. The final sinogram is a collection
of counts detected at each angle at a specific radial distance in the field of view (FOV). Figure (1.10)
shows an illustration of the imaging principles in PET.
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Fig. 1.10 Imaging principle of PET: (a) The annihilation of a positron and an electron; (b) The line of
response (LOR) [44].
To obtain the final image and quantify the radioactivity concentration from the measured projec-
tions, a reconstruction algorithm is applied. The most common reconstruction algorithm for PET
images is Order Subsets Expectation Maximization (OSEM). OSEM is an iterative reconstruction
method that is an accelerated version of the Maximum Likelihood-Expectation Maximisation (ML-
EM) algorithm. The EM is used to find the estimate that will maximise the likelihood that leads
to the observed emissions. The ML-EM estimates the annihilation events distribution rather than
directly reconstructing the image. The ML-EM starts with initital sets of model parameters ragarding
the emissions, usually a uniform distribution. The estimated projections are then compared to the
measured projections. Based on the ratio between the two, a correction term is calculated and used for
the new estimate parameters. This process is repeated until a solution is converged leading to a very
slow process. In OSEM, the acquired projections are grouped into subsets based on the projection
angles, where the image is updated with each iteration until a solution is converged. The image is
updated as many times as the number of the subsets. OSEM has the advantage of faster process time
compared to ML-EM algorithm [71].
The acquired PET images are usually displayed superimposed with CT images to complement
the functional information with anatomical structure. PET/CT scanners are equipped with a CT
component. The PET and CT images are acquired sequentially at the same session and at the same
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patient position. More importantly, the acquired CT scan is used for attenuation correction for the
PET image. The attenuation correction is needed due to the loss of detection of the annihilated
electron-positron γ-rays true coincidence which can be caused by the absorption of the γ-rays in
the body or their scattering outside the field of view of the detector. This leads to decreased image
counts and consequently increased noise, distortion and artefacts in the image. Since attenuation is
more likely in the areas deeper in the body, those areas will have decreased activity while regions of
low attenuation like the surface of the body will have a higher activity count. This is corrected for
by obtaining an attenuation correction map from the CT component of the PET scan by calculating
the attenuation coefficients from the CT transmission profiles at the energy of the radioactive source
emissions. Consequently, the attenuation correction map is an emission attenuation map calculated
from the CT image. The attenuation correction map is saved into a sinogram and incorporated into
the PET image reconstruction process [13].
In the field of radiation oncology, most commonly, the radioisotope fluorine-18 is used to label
fluorodeoxyglucose, resulting in the radiotracer 18F-FDG which reflects glycolysis and metabolism.
18F-FDG PET imaging is currently accepted within the field of oncology for staging tumours and
evaluating response to treatment given tumours are highly metabolic and will have a high uptake. The
voxel intensity of a PET image is a measure of the radioactivity concentration in the imaged region.
To quantify the radioactivity concentration, the Standardised Uptake Value (SUV) is calculated as
shown in equation (1.6). This corrects for the variations in the injected activity and patients’ weight.
SUV =
Radioactivity concentration in tissue(MBq/Kg)
Activity injected (MBq)/body weight (Kg)
(1.6)
The SUV value within a region is often reported as either the maximum value (SUVmax) or the
mean value (SUVmean) within the region of interest. SUVmax is less affected by intra-interobserver
variability than SUVmean yet it is more affected by noise [151]. Generally, an SUV≥2.5 is considered
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malignant tissue [67]. However, given that 18F-FDG reflects glycolysis, high metabolic tissues within
the body will have a high uptake such as the brain and the myocardium. Moreover, inflammatory or
infectious tissue will also have a high uptake which might lead to false positives. Another consideration
is the partial volume effect; it is observed when the size of the lesion is less than two to three times the
resolution of the scanner, this usually causes the lesion to appear less active. Considering the patient
history and the corresponding CT image when interpreting PET images is fundamental [67].
Despite the non-specificity of 18F-FDG, it is the most common radiotracer used in cancer imaging
due to its high sensitivity and wide availability [112]. 18F-FDG PET imaging has been validated exten-
sively in the literature and has shown a correlation to treatment outcome, hence it has been suggested to
be the imaging modality to inform dose painting in radiotherapy [23][64][158][19][109][65][81][144][111]
[63][6].
1.5 Dose Painting
Traditionally, delivery of a homogenous dose distribution to the tumour was desirable. However,
tumours have been shown to be biologically heterogeneous in regards to their cellular density,
proliferation and oxygenation [148][91]. To account for the tumours’ biological heterogeneity in
radiotherapy planning, Ling et al. [91] proposed the concept of biological dose painting in 2000.
The authors hypothesized delivering a heterogeneous dose distribution to the tumour volume based
on the spatial variation of the biological characteristics of the tumour (cellular density, proliferation
and oxygenation). In biological dose painting, the dose distribution will be sculptured to escalate
dose to sub-volumes of increased tumour burden and increased resistance to radiation within the
tumour. The authors referred to these sub-volumes as biological tumour volumes (BTV). To identify
BTV, the authors suggested the utilisation of upcoming molecular and functional imaging modalities
such as PET and magnetic resonance imaging and spectroscopy (MRI/MRS). The authors argue that
dose escalation to the BTV while conforming to normal tissue constraints is achievable by the use of
the IMRT planning technique. IMRT is an inverse planning technique that has a superior physical
conformity to conventional techniques in delivering higher dose to the target volume while minimising
dose to normal tissue. The physical conformity of IMRT allows the delivery of a non-uniform dose
distribution which conventional techniques cannot achieve [91]. Overall, the proposed concept by
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Ling et al. [91] did not address the applicability and technical feasibility of biological dose painting.
Rather, it was a theoretical concept in need of extensive investigations and clinical validations.
Yet, since the introduction of biological dose painting, the field of radiotherapy has been striving
for personalized radiotherapy treatment planning based on patient specific radiobiological param-
eters. In 2002, an inverse planning approach incorporating functional imaging data into the dose
optimisation algorithm was proposed by Xing et al. [155]. The authors suggested dose escalation to
abnormally metabolic regions within the tumour. To achieve an inhomogeneous dose distribution,
dose is assigned to voxels based on their functional importance (FI) level [155]. Studies by Chao
et al. [29] and Alber et al. [9] investigated the possibility of prescribing a heterogeneous dose
distribution based on signal intensity obtained from PET studies using hypoxia tracers copper-diacetyl-
bismethylthiosemicarbazone (Cu-ATSM) and 18F-fluoromisonidazole (FMISO) respectively. While
Chao et al. [29] suggested to selectively boost the dose to the hypoxic sub-volume, Alber et al. [9]
proposed an optimisation algorithm where dose is distributed based on dose efficiency distribution
obtained from tumours’ biological images where each voxel is assigned a number in the target volume
based on expected effect of radiation on tumour tissue at that point. The presented algorithm will shift
the dose towards a low dose efficiency point [9].
The above studies [155][29][9] suggested a linear dose escalation to sub-volumes based on
functional image signal intensity while conforming to normal tissue constraints. This approach is
based on the argument that increasing dose to the tumour will increase cell killing and consequently
improve tumour control probability (TCP). While the argument is commonly accepted, the level of
dose escalation required to achieve a significant increase in TCP is yet to be determined.
The first theoretical framework integrating spatial variation of radiobiological parameters known
to influence radiotherapy treatment (cell density, proliferation, and oxygenation) into IMRT planning
was presented in 2005 by Yang and Xing [159]. The authors suggested a continuous dose distribution
to maximise cell killing, where the overall TCP is a product of the TCP of each individual voxel in the
tumour. This framework was adopted by South et al. in 2008 [125]. The authors [125] proposed an
analytical approach to derive patient-specific radiobiological parameters (cell density, proliferation and
oxygenation) so the approximation of the radiobiological parameters by Yang and Xing is eliminated
[159][125]. The effect of varying biological parameters values on dose per voxel was investigated
by [125]. As reported by the authors, oxygenation has the most significant effect on dose per voxel
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when compared to proliferation rate and clonogen density. The level of dose necessary to overcome
hypoxia resistance was estimated by quantifying oxygen distribution per voxel from the uptake of
hypoxia specific PET tracer FMISO. The oxygenation level was correlated to FMISO uptake and
dose level using animal data and simulation studies [113][131]. The authors showed that TCP can
be improved by re-distributing the dose to areas exhibiting high level of hypoxia. The maximum
TCP was shown to be achieved using 2-5 dose levels. Yet, in some cases of high level of hypoxia
in head and neck tumours, maximum TCP could not be achieved due to normal tissue constraints
[125][126][124]. Even though the study presents a very promising optimisation technique based on
improving TCP per voxel, where a relationship between hypoxia and dose level is established, it
presented a relatively high level of uncertainty given the extracted mathematical relationship between
FMISO uptake, oxygenation and dose is based on animal and simulation studies. Furthermore, the
reported results are based on a small cohort (3 patients) and lacks clinical validation.
Given that tumour hypoxia has been shown to be mostly related to loco-regional failure and
resistance to radiation [108][149], several studies [33][62][161] have been focusing on dose painting
based on boosting hypoxic sub-volumes. In addition, the considerable availability and validation of
hypoxia radiotracers such as 18F-fluoromisonidazole (FMISO), 18F-fluoroazomycin (FAZA), and
Cu-ATSM enhanced their application in biological dose painting studies [130][166].
Previously discussed studies [155][29][9][159][125][33][62][161] suffer from similar common
pitfalls of biological dose painting. Biological dose painting based on specific radiobiological
parameters is hindered by the lack of available clinical data to establish a mathematical relationship
between tracer uptake, radiobiological parameter and the required radiation dose. Furthermore,
reoxygenation and repopulation processes are usually neglected. In addition, limitations of the
available tracers in regards to their sensitivity and specificity would influence the resulted distribution
and should be accounted for.
Faced with challenges in using a specific biological radiotracer, multiple studies have been
investigating the concept of biological dose painting based on 18F-FDG. Some researchers have
attempted to associate 18F-FDG uptake to a specific biological phenomenon. A correlation of
18F-FDG uptake and hypoxia was investigated by [115][31][88]. The results showed no significant
association. Another attempt was conducted by Sauter et al. [118] to correlate 18F-FDG uptake to
blood volume and blood flow measurements from CT perfusion scans for patients diagnosed with
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NSCLC. The authors reported no relation between perfusion and metabolism of glucose in large
tumours yet an inverse correlation with mediastinal lymph nodes was found. The authors concluded
that 18F-FDG uptake in tumours’ cells is a complex process between hypoxia, perfusion and glucose
metabolism and cannot be attributed to a specific biological phenomenon [118].
Although a quantitative relationship between 18F-FDG uptake and the biology of the tumour
could not be established, Aerts et al. [6] suggested it to be a suitable tracer for dose painting. The
authors base the claim on the wide availability of 18F-FDG, well established standardised protocols
of 18F-FDG PET imaging, and the stability exhibited by tracer uptake during radiotherapy treatment
[111][6]. The authors argue that given the high post treatment overlap rate (> 70% in NSCLC)
exhibited by high 18F-FDG uptake regions identified prior to radiotherapy, targeting such regions
with higher dose could be beneficial [5]. Furthermore, studies on mice showed an improved TCP
when escalating dose to areas with high 18F-FDG uptake [120]. Researchers [41][145][93][111]
explored the possibility of linear dose escalation to sub-volumes within tumours based on 18F-FDG
uptake. Yet, the benefit of such escalation is not yet clear. Currently, a clinical trial on adaptive
dose painting investigating boosting sub-volumes with high 18F-FDG uptake in non-metastatic head
and neck cancer is being conducted by De Neve [17]. Moreover, a phase II randomised trial by De
Ruysscher and Belderbos on boosting active 18F-FDG areas in NSCLC up to at least 72 Gy compared
to escalating dose to the whole tumour volume is currently ongoing [143].
Due to the low resolution of PET (5-7mm) and the necessity to register the images with CT for
anatomical definition, some researchers suggested the use of MRI for dose painting in radiotherapy
planning [20][142][69]. MRI has the advantage of superior soft tissue contrast when compared to
CT images [142]. Diffusion weighted MRI provides information regarding tissue cellular density
while dynamic contrast enhanced MRI (DCE-MRI) gives information regarding blood flow and
microvasculature permeability. Both parameters affect radiosensitivity of the tumour and could be
used to guide dose painting [142].
Despite the attractiveness of MRI guided dose painting, there are many challenging aspects to
overcome. Target delineation based on functional MRI is still not fully explored where published
research studies investigating quantification of MRI functional parameters and target delineation are
relatively scarce when compared to PET imaging [69]. In addition, the standardisation of functional
MRI quantification is still not well established. Furthermore, accurate and reproducible positioning is
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considered more challenging in MRI based radiotherapy planning. Coils used in MRI machines would
compromise the position of the patients especially in the cases of head and neck cancer. Moreover,
MRI images are subject to distortion and lack information on electron density and still need to be
co-registered with CT images [69][80].
The applicability of MRI guided dose painting was explored by Bates et al. [14] who conducted
a simulation study to investigate whether incorporating ventilation and perfusion data from Hyper-
polarized helium-3 MRI (3He-MRI) has any benefit to NSCLC patients (stage IIIA-B) receiving
IMRT treatment. The simulated clinical scenarios included patients with functional lung deficits. The
authors reported a median reduction of 27% in dose-volume parameters for functional lung when
accounting for functional data in IMRT planning [14]. Currently, a randomised phase III trial is
being conducted by Haustermans where multiple techniques of functional MRI (T1 and T2 diffusion
weighted and DCE MRI) are used to boost focal lesions within the prostate [92].
Based on reviewed literature, PET is most likely to be the leading imaging modality in dose
painting thus it is the imaging modality considered in this project.
1.6 Texture Analysis
The texture of an image can be generally defined as the spatial variation in pixel intensity levels.
Texture can be assessed using statistical methods (histogram and grey level dependence matrices),
model based methods such as fractal models or transform based methods such as the Fourier and
the wavelet transform [97]. In medical imaging, statistical based texture analysis has made the most
significant contribution.
Intensity histograms are a representation of the distribution of pixel intensities i in an image and
they are considered first order statistical methods where global features such as mean and standard
deviation can be extracted. The features that can be extracted from intensity histograms are presented
in table (1.1) [97].
Second order statistics textural features are extracted by the analysis of grey level co-occurrence
(dependence) matrices (GLCM) [97][32]. GLCM represents the joint probability density function
P(i, j;θ ,d) of the number of times an intensity level i and an intensity level j occur in a certain
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Table 1.1 First-Order Texture Features : Based on average pixel value i where N is the number of grey
levels in the histogram. Intensity histogram analysis.
Global Texture Features Equation
Mean µ : average intensity values in an image. = ∑Ni ip(i)
Variance σ2: the spread or variation around
the mean.
= ∑Ni (i−µ)2 p(i)
Skewness: symmetry of intensity values in an
image. Skewness is zero if the histogram is
symmetrical
= σ−3 ∑Ni (i−µ)3 p(i)
Kurtosis: indication of histogram flatness. = σ−4 ∑Ni (i−µ)4 p(i)
Energy: measures uniformity of intensity val-
ues.
= ∑Ni [p(i)]
2
Entropy: represents irregularity of intensity
values distribution.
=−∑Ni p(i) log(p(i))
direction with θ = 0◦,45◦,90◦, or 135◦ at specified distance d [61]. The features that can be extracted
from GLCM are presented in table (1.2) [61], where px is the probability matrix obtained from
summing the rows in p(i, j) and py is the probability matrix from summing the columns in p(i, j).
The means and standard deviation of px and py are represented by µx, µy, σx and σy respectively. The
number of grey levels in an image is N.
Textural parameters extracted from neighbourhood grey-tone (intensity) difference matrices
(NGTDM) are considered higher order parameters which are based on the relation between a pixel
and neighbouring pixels. Run length matrices (RLNM) are considered higher order statistical methods
where RLNM consists of the number of consecutive pixels that have the same intensity level i and
which occur in a specified direction [50]. The features that can be extracted from RLNM are presented
in table (1.3) [50].
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Table 1.2 Second-Order Texture Features: Based on grey level co-occurrence matrices.
Local Texture Features Equation
Angular Second Moment (energy or unifor-
mity): measures homogeneity of intensity
value distribution in an image.
= ∑Ni, j [p(i, j)]
2
Contrast: measures amount of local variation
in intensity values.
= ∑Ni, j |i− j|2 p(i, j)
Homogeneity (inverse difference moment):
measures the homogeneity of the intensity val-
ues of the pixel pair.
= ∑Ni, j
p(i, j)
1−(i, j)2
Correlation: measures the linear dependencies
of intensity values in an image.
= ∑Ni, j
(i, j) p(i, j)−µxµy
σx σy
Entropy: measure of randomness of intensity
values in an image.
=−∑Ni, j p(i, j) log( p(i, j) )
Sum of Squares (Variance) = ∑Ni, j(i−µ)2 p(i, j)
Sum Average = ∑2Ni=2 ipx+y(i)
Sum Entropy =−∑2Ni=2 px+y(i) log( px+y(i) )
Sum Variance =−∑2Ni=2(i− sum entropy)2 px+y(i)
Difference Variance = Variance of px+y
Difference Entropy =−∑N−1i=0 px−y(i) log(px−y(i))
Information Measures of Correlation = HXY−HXY 1max [HX ,HY ] (1− exp [−2.0 (HXY 2−HXY ])2
where HXY =−∑Ni=1 p(i, j) log(p(i, j))
HX And HY are entropies of px and py
HXY 1 =−∑Ni=1 p(i, j) log(px(i) py( j))
HXY 2 =−∑Ni=1 px(i) py( j) log(px(i) py( j))
Maximal Correlation Coefficient (Second Largest Eigenvalues of Q)1/2 where
Q(i, j) = ∑k
p(i,k) p( j,k)
px(i) py(k)
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Table 1.3 High-Order Texture Features: Based on neighbourhood grey tone difference matrices.
Local Texture Features Equation
Complexity: measures amount of information
(primitives) in texture.
= ∑Ghi, j
[
(|i− j|)
n2 (p(i)+p( j))
]
× [ p(i) s(i)+ p( j) s( j)]
Busyness: measure the rate of change in inten-
sity values.
= ∑
Gh
i p(i) s(i)
∑
Gh
i, j | ip(i)− jp( j) |
Contrast: measures the variation of intensity
values in an image.
=
[
1
N(N−1) ∑
Gh
i, j p(i) p( j) (i− j)2
]
×
[
1
n ∑
Gh
i s(i)
]
Coarseness: measures the density of edges in
an image.
=
[
ε+∑Ghi
s(i)
n
]−1
Texture strength: measures how definable (dis-
tinguishable) texture primitive is.
=
∑
Gh
i, j (p(i)+p( j)) (i− j)2
ε+∑
Gh
i
s(i)
n
Regional Texture Features Equation
Short- Runs Emphasis: measures the run
length distribution emphasizing short runs by
dividing by the square of run length value.
=
∑Nj=1∑
N
i=1
p(i, j)
j2
∑Nj=1∑
N
i=1 p(i, j)
Long-Runs Emphasis: measures the run length
distribution emphasizing long runs by multi-
plying by the square of run length value.
=
∑Nj=1∑
N
i=1 j
2 p(i, j)
∑Nj=1∑
N
i=1 p(i, j)
Grey level non-uniformity: represents the sim-
ilarity of intensity values in an image.
=
∑Ni=1[∑Nj=1 p(i, j)]
2
∑Nj=1∑
N
i=1 p(i, j)
Run Length non-uniformity: measure the run
lengths similarity.
=
∑Nj=1[∑Ni=1 p(i, j)]
2
∑Nj=1∑
N
i=1 p(i, j)
Run Percentage: ratio of total numbers of runs
to the total number of possible runs measur-
ing the homogeneity of runs. For images with
most linear structure, the value of run percent-
age is lowest.
= ∑Ni, j
p(i, j)
P
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Tables (1.1, 1.2 and 1.3) present a full set of the textural features that could be measured from
first order, second order and higher order statistics. In texture analysis, the order of the extracted
feature refers to the relationship between the pixels of the extracted features. First order statistics
are extracted from the average of pixels intensity and second order statistical features are measured
based on the relationship between two pixels where higher order statistical features are based on the
relationship between more than two pixels. Therefore, first order statistical methods do not convey
spatial information, whereas second and higher order statistical methods maintain spatial information.
Textural features such as mean, variance, entropy, energy, contrast, coarseness are well understood
in regards of the information they provide of an image’s textural properties and have been heavily
used to quantify image texture in the literature. Yet, the information extracted about image texture
properties from other features such as sum entropy, sum variance, and information measures of
correlation are not clear in regards to the clinical aspect. However, these features are presented as
they could prove to be clinically important in the future and to provide the complete set of statistical
texture measures.
Traditionally, textural analysis in the medical field has been used for tissue classification [84]
such as lung pathologies [147][157], breast lesions [57], head and neck tumours [70], and glioneural
tumours [47]. Furthermore, NGTDM based textural analysis was suggested by Huan et al. [70] for
automatic delineation of target volumes in head and neck tumours for radiotherapy planning. In recent
years, statistical based texture analysis has been suggested to have prognostic value in radiotherapy.
Several textural features could be extracted from grey level dependence matrices and neighbourhood
grey tone difference matrices, yet based on reviewed literature, features that describe heterogeneity
such as contrast, energy, entropy and homogeneity have shown the most significant results in relation
to patients’ survival.
1.6.1 Texture Analysis in CT
The initial implementation of texture analysis to predict patient survival was suggested by Ganeshan
et al. [51] in 2007. The authors suggested band-pass filtering of CT images using the Laplacian
of Gaussian (LoG) filter to detect features at different anatomical scales. The LoG filter is a two-
dimensional (2D) spatial filter. It is a combination of a smoothing filter (Gaussian) to reduce noise
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and an edge detector filter (Laplacian). The Laplacian detects areas in the image where a prominent
change in the intensity occurs, hence it is mostly used as an edge detection method. When the filter
is convolved with the image, the region where the response of the filter passes through zero (zero
crossing) is the region where an intensity change is detected.
Extracting texture parameters from CT image histograms post the application of the LoG filter was
recommended by the authors given their un-complex and rotationally invariant nature despite their
spatial insensitivity. The authors performed texture analysis on CT images using in-house software
which is commercially available by the name of TexRAD (TexRAD, UK). A number of studies using
this software have been published [51][52][102][53][42][55][54][56][162]. The group suggested the
use of five LoG filters ranging from fine to coarse textures (filter widths fine = 4 image pixels and
coarse = 12 image pixels) and quantifying tumours heterogeneity by measuring the mean, standard
deviation, skewness, mean of positive pixels value (MPP), uniformity and entropy from the CT slice
with the largest cross section of the tumour. The group reported uniformity and entropy, to show the
most significant results in predicting patient survival.
A publication using TexRAD investigated whether first order textural features extracted from
staging PET/CT images, for 66 NSCLC patients were related to patient survival [153]. By quantifying
the entropy of the image which represents the pixel intensity distribution within the image, tumour
heterogeneity was assessed. To correlate the heterogeneity of the tumours to patient survival, Kaplan-
Meier (KM) curves were generated. The KM analysis is based on cumulative conditional probability
to estimate surviving a duration of time. The overall survival time is split into small time intervals
based on the observed survival time of the investigated group. For each time interval, the survival
probability P(t(q)) is measured as the number of surviving subjects at that specific time interval t(q)
divided by the sample size as shown in equation (1.7) [11].
P(t(q)) =
Number of survivals past t(q)
Sample size
(1.7)
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To generate KM curves, the subjects were divided into two groups based on the value of tumour
image entropy. In KM analysis a cut-off value (threshold value) is used to dichotomise the subjects
into the two groups. The Log-Rank test was used to test the significance of the investigated feature on
survival. In Win et al. 2013 [153], patients were assigned to groups of low and high entropy based on
the optimum threshold value obtained from a feasibility study including 54 NSCLC patients. The
entropy value that was shown to be optimum in predicting survival was a normalised value taken from
medium-filter/coarse-filter entropy values. The authors reported tumour normalised entropy to be the
only parameter significantly related (p = 0.027) to survival for patients in the curative-intent group
while tumours entropy, stage and permeability showed significant association with survival for the
palliative patients group with p = 0.042, p = 0.020 and p = 0.003 respectively.
Although the published studies using the TexRAD software [51][52][102][53][42][55][54][56][162][153]
have shown some correlation between survival and global textural parameters, they have not explained
the significance of choosing the optimum filter width and how that relates to anatomical feature
extraction. Moreover, TexRAD based studies have not validated the uniformity and entropy threshold
values used for generating KM curves. In addition, the proposed methodology by the TexRAD
group is based on using a single slice CT image with the largest cross section of the tumour, and not
considering volumetric measurements, which leads to loss of spatial information and consequently
may significantly affect texture quantification.
Correlation of patients’ survival to second order textural parameters extracted from CT data
was investigated by Vaidya et al. in 2012 [139]. The study included 27 patients diagnosed with
NSCLC confined to the thorax, where baseline 18F-FDG PET and correspondent CT were analysed.
The endpoints were set to be local recurrence with at least 6 months follow up. To account for
patient breathing artefacts, an algorithm based on the inverse filtering process was applied to acquired
images. Textural features extracted from PET/CT data included energy, contrast, entropy and local
homogeneity from co-occurrence matrices calculated for the 3D volume of the tumour. Textural
features extracted from CT images showed some correlation with loco-regional failure, yet none of
the features reached significance. The de-blurring method was applied to PET images not CT images,
so whether motion artefacts affected the power of extracted features was not determined. The authors
reported extracted textural features from PET images to have the lowest correlation with loco-regional
failure when compared to intensity volume histogram (IVH) and gross tumour volume (GTV) and
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SUV measurements. The de-blurring of PET images showed little improvement on the correlation
coefficient r (from 0.114 to 0.18 and p-value from 0.28 to 0.17) for local homogeneity. Textural
features showed a stronger correlation with local control rather than loco-regional failure whereas
IVH showed the opposite trend as reported by the authors [139].
Textural features were reported by Mattonen et al. [98][99] to predict recurrence for early stage
NSCLC patients who underwent stereotactic ablative radiotherapy (SABR). The authors reported
standard deviation, (reported as the variation of HU within the ground-glass opacity (GGO) regions
which are regions where the normal lung parenchyma density is increased with visible vessels), are
able to significantly discriminate (p = 0.0078) between patients with radiation induced injury and
patients with recurrence in a follow up CT scan acquired at 9 months with an error of 26% [98].
The authors explored the ability of second-order textural features to predict recurrence by generating
GLCM from GGO for follow up CT scans taken at 6 months for a group of 22 patients. The texture
features calculated from the 2D averaged GLCM were energy, entropy, correlation, inverse difference
moment, inertia (contrast), cluster shade, and cluster prominence. Cluster prominence and cluster
shade are measures of pixel pair grouping quantifying the symmetry (skewness in GLCM) of grey
levels in an image. The authors reported energy, entropy, and inertia to be significantly different
between groups with radiation induced injury and recurrence, with p = 0.036, p = 0.034 and p = 0.036
respectively. Respiration, co-morbidities, and any scanning factors that would affect CT density were
not considered [99]. Given that injury to lung tissue such as radiation fibrosis and pneumonitis, post
radiotherapy, resembles tumour recurrence on CT images a more analytical quantitative approach to
predict recurrence is needed.
1.6.2 Texture Analysis in PET
GLCM based texture analysis of 18F-FDG PET data has been reported to provide significant and
superior results to SUV measurements in predicting complete response (CR), partial response (PR)
and non-response (NR) to therapy, for patients diagnosed with oesophageal carcinoma as reported by
Tixier et al. [134] in 2011. The study included 41 patients where SUV measurements were compared
to global, regional and local PET textural features. The authors reported both global features and
SUV measurements to be sufficient predictors of CR but could not distinguish NR from PR. Regional
entropy was reported to be the most significant predictor in identifying and distinguishing NR, CR,
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and PR. The images of the tumour were quantised by resampling the intensity values to 16, 32, 64 or
128 set of discrete values to reduce noise and to normalise the intensities across the image. The authors
assessed the variation in quantising GLCM to discrete number of values and found no significant
difference (p>0.05) [134].
The reproducibility of PET textural analysis was evaluated by Tixier and colleagues [134][135]
comparing two baseline 18F-FDG PET scans taken 2-7 days apart for 16 patients diagnosed with
oesophageal cancer. Results showed the mean percentage difference (%DIFF) between the two studies
to be 4.7% ± 19.5% and 5.5% ± 21.2% for SUV mean and SUV maximum respectively, confirming
previous studies. Local heterogeneity parameters showed a better reproducibility with mean %DIFF
of -2% ±5.4% for entropy and 1.8% ±11.5% for homogeneity, where other textural parameters showed
lower reproducibility ranging from 40.9% for lower limit and 62.7% for upper limit [134][135].
Extraction of higher order textural features from NGTDM was investigated by Cook et al. [36]
using 48 baseline 18F-FDG PET scans for NSCLC patients treated with definitive chemoradiotherapy.
The response was assessed 12 weeks after treatment on CT using Response Evaluation Criteria in Solid
Tumours (RECIST). Coarseness, contrast, busyness and complexity were extracted from NGTDM
and compared with SUV measurements (mean, maximum, and peak), metabolic tumour volume
(MTV) and total lesional glycolysis (TLG) as predictors of response. The authors reported none of the
SUV parameters nor TLG and MTV to be a significant predictor of responders and non-responders.
Coarseness, contrast and busyness measurements were significantly different between responders
and non-responders with area under the curve (AUC) of 0.8, 0.82, and 0.72 respectively indicating a
fair distinction ability. Nevertheless, the authors did not report whether any of the texture parameters
could distinguish or predict partial response and complete response [36].
Even though recent publications have shown a correlation between heterogeneity measurements
and tissue response, the accuracy and precision of PET textural analysis is yet to be explored.
Limitations due to spatial resolution, noise, motion artefacts, image acquisition parameters and
reconstruction methods are expected to lead to a degradation of the extracted textural features and
should be addressed. A review on texture analysis in PET by Cook et al. [37] focusing on the technical
factors and clinical application supports this conclusion.
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1.6.3 Texture Analysis in MRI
Assessing tumour heterogeneity by utilising dynamic contrast enhanced MRI (DCE-MRI) in defining
tumours functional risk volume (FRV) to predict treatment outcome in cervical cancer was investigated
by Mayr et al. [100] in 2012. FRV is defined as a region of low contrast uptake where the signal
intensity is < 2.1 when compared to the image before contrast injection. The authors presented a
heterogeneity characterisation approach that consisted of generating relative signal intensity (RSI)
distributions based on the perfusion levels of individual voxels which were then tabulated in an RSI
histogram. The study included 102 patients diagnosed with cervical cancer stage IB2-IVA based on
the International Federation of Gynaecology and Obstetrics (FIGO) staging system of cervical cancer.
The total FRV was derived from perfusion heterogeneity assessment prior to chemo-radiotherapy
and during treatment in weeks 2-2.5 and 4-5. The FRV2 was measured at 2-2.5 weeks during
the chemo-radiotherapy treatment course while the FRV3 was measured at 4-5 weeks during the
chemo-radiotherapy treatment course. FRV’s were associated with disease specific survival endpoints
and primary tumour control. Patients’ median follow up was reported to be 6.8 years. The results
reported by the authors suggest FRV to be a significant early predictor of outcome in the long term.
Pre-treatment FRV was least predictive where the power of prediction increased from 24.3% to 42.5%
for FRV2 and 45.2% for FRV3 in discriminating 6-year actuarial tumour control rate and recurrences
of primary tumour [100][101]. GLCM based texture analysis in DCE- MRI [7] was reported to be
successful in discriminating responders and non-responders for 89 patients diagnosed with locally
advanced breast cancer and receiving neoadjuvant chemotherapy , its predictive value for patients
undergoing radiotherapy is yet to be determined. Nevertheless, from 14 extracted features only
contrast, difference variance and difference entropy reached significance [7].
1.6.4 Challenges in Texture Based Radiotherapy Planning
Whilst a customised radiotherapy plan based on prediction of tumour response to treatment is an
attractive idea, texture analysis is hindered by multiple challenges. Uncertainties in patient positioning,
organ motion, inter-observer variability, image acquisition parameters, reconstruction algorithms,
and texture extraction methods affect the extracted textural features and all must be investigated and
addressed. Yet, the major question is the biological origin of image texture.
36 Introduction and Background
To date, the biological basis of textural analysis remains not fully understood. In vivo studies
relating the apparent heterogeneity of tumours extracted from medical images to biological phenomena
have not been attempted yet. Ganeshan et al. [56] attempted to investigate an association of CT textural
analysis with angiogenesis and hypoxia using pimonidazole staining and hypoxia marker GLUT-1 on
surgically removed lesions. The analysis showed a correlation between the standard deviation and the
mean value of positive pixels (MPP) in the region of interest and pimonidazole staining. Uniformity
of the distribution of positive grey-level pixel values showed an inverse association with GLUT-1
while MPP showed an inverse association with CD34 expression (which represents angiogenesis) in
both contrast and non-contrast CT [56]. The study was based on measurements taken outside the
human body on surgically removed lesions (ex-vivo) and comprised of a small cohort (14 patients);
hence a strong relationship could not be inferred.
Another challenging aspect in texture analysis is the confounding results presented in the literature.
A study by Chalkidou et al [27] investigated the probability of type-I error (false positive) for studies
published between years 2000-2013 correlating textural features extracted from CT or PET images to
prognosis. Fifteen studies were corrected for adjusting the significance level and optimising the cut-off
value for survival analysis by using the Benjamini-Hochberg method. When applying the correction
factors, the results showed a 76% (range 34-99%) probability of selection bias and false positive.
Also, the majority of the published studies did not reach statistical significance after correcting for
bias.
Other factors that challenges the accuracy and reliability of texture analysis are respiratory motion
and tumour delineation.
1.6.4.1 Respiratory Motion
Although a study by Vaidya et al. [139] reported no significant difference in p-values in associating
textural features extracted from motion corrected PET and non-corrected PET images to tumour local
failure, respiratory motion leads to image blurring, inaccurate representation of tumour volume and
potentially mislocalization of lesions especially for tumours located in the thorax. A publication by
Aristophanous et al. [12] investigated target delineation in lung tumours on 4D and 3D PET images.
The authors reported the mean difference between tumour volume in 3D PET (VOL3D) and tumour
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volume in 4D PET (VOL4D) for lesions located in the lower lobe and lower mediastinum to be 50%
while the upper lobe difference was 10%. In addition, the lesions exhibiting motion > 3mm showed
a larger difference (approximately 54%) than lesions moving < 3mm (%DIFF 14%). The authors
concluded that the benefit of 4D PET volume definition is dependent on tumour location and the
range of motion [12]. While recently available PET/CT scanners have respiratory gating, there is not
a currently established method for 4D MRI in radiotherapy. Many methods have been proposed in the
literature for investigating the feasibility of 4D-MRI [25][138][136][18] yet none has been clinically
implemented. Overall, studies focusing on tumour motion are challenged by the lack of ground truth
where target delineation is subject to inter-observer variability. Further, changes in patients’ breathing
patterns and irregular breathing are complicating factors as well as patients’ movement between
consecutive scans. The magnitude of the effect of tumour motion on textural analysis is yet to be
investigated since change in the apparent tumour volume would lead to a change in measured texture
especially when the extent of motion is similar in scale to studied textural features.
1.6.4.2 Tumour Delineation
Tumour delineation critically influences treatment outcome, but whether it affects the power of
extracted textural features is still under debate. According to Kazarski et al. [107] a large cross
sectional area of the tumour is sufficiently representative and provides comparable results to whole
tumour analysis when applying histogram-filtration methods to predict survival. Yet, other studies
using texture analysis in tissue classification have reported volumetric texture analysis to be superior
to 2D analysis due to loss of spatial information [94][156][30]. Whether the precision of spatial
information is needed in predicting survival and response is still to be explored further since most
of the studies in the literature have adopted one methodology without comparison of other methods.
On the other hand, it has been reported by Mattonen et al. [99] that delineation of GGO in follow up
CT scans using expansion and contraction of 1-2 mm of the GGO had minimal effect on extracted
textural features, leading to the assumption of lower impact of delineation variability in predicting
recurrence [99].
Nevertheless, inter-observer variability in target delineation should be minimised, and semi-
automated and fully automated segmentation approaches have been suggested in the literature. Many
of the research studies have been published investigating multiple PET and MRI segmentation methods
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such as clustering, active contours and thresholding [83]. On the other hand, multimodality image
segmentation methods were suggested by El Naqa et al. [106] and Chowdhury et al. [34]. The
authors presented frameworks to link structures of interest across different imaging modalities to
aid in target delineation for radiotherapy planning. Based on the published literature, the proposed
methods suffer from shortcomings such as the lack of ground truth and their heavy dependency on
image quality, thus a recommendation cannot be easily reached. Yet, image segmentation is crucial in
radiotherapy planning and should be implemented while considering the achievable accuracy level
and the technical feasibility. Manual delineation of tumours is still considered the gold standard in
radiotherapy planning.
1.7 Radiomics
Even though a biological or a physiological basis of tumour image texture has not been established
nor a standarised methodology for performing texture analysis, in the past two years, there has
been a great interest in the field of radiomics. In radiomics, all possible quantitative image features
(400+) including shape, intensity and including but not exclusively textural features are extracted.
Studies investigating radiomics based features are not discussed given the focus of this thesis is
statistical texture analysis of tumour images. Multiple studies have been published in regards to
building predictive or prognostic models based on radiomics features extracted from CT and or PET
images yet the published studies are still suffering from the same challenges as texture analysis
[37][140][38][154][121][119][72][39].
1.8 Conclusions
Based on the reviewed literature, it is postulated that CT will be the leading imaging modality in texture
analysis given its superior resolution and its good integration into the field of radiotherapy compared
to PET. Moreover, PET’s poor resolution, high noise and tracer uptake and quantification challenges
under-powers the extracted features and could lead to pseudo-texture. MRI based texture analysis
seem an attractive idea due to its superior soft tissue contrast, yet there are many challenging aspects
to overcome. Target delineation based on functional MRI is still not fully explored where published
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research studies investigating quantification of MRI functional parameters and target delineation
are relatively scarce compared to CT imaging. In addition, the standardisation of functional MRI
quantification is still not well established. Functional MRI is still not widely available and not as fully
integrated into radiotherapy planning as CT and PET.
In order to integrate texture analysis into radiotherapy planning, a standardised method of con-
ducting texture analysis must be established and a validation of the reported findings in correlating
image texture to patient survival is fundamental. Moreover, an understanding of the physiological
implications of tumour image texture is crucial for clinical applications. Extracting quantitative image
features that are indicative of tumour biology or function could be highly beneficial in the field of
radiotherapy especially in guiding dose painting.
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1.9 Thesis Overview
The main aim of the work presented in this thesis was to investigate whether i) tumour CT images
have genuine texture defined as intratumoural heterogeneity that is characteristic of the underlying
tissue ii) whether intratumoural heterogeneity provides useful or meaningful information in regards to
tumour function and iii) whether this information is clinically relevant and could be used to guide
dose painting.
In this thesis, I present an optimised method to visualise volumetric voxel based maps of intra-
tumoural texture variations. I then show the relationship between the spatial textural information
obtained from the generated maps and tumour function. This method is optimised based on a texture
feature that was shown to correlate with patient survival. Furthermore, I investigate a characterisa-
tion of the effects of motion on texture analysis. Finally, I present the application of this proposed
methodology in guiding radiotherapy dose painting. The patient cohort consist of patients diagnosed
with advanced NSCLC. Due to the poor prognosis (5 years survival <10%) of this group of patients,
investigating new methods to aid in dose painting could be beneficial.
The work in this thesis has been carried out in collaboration with Royal Surrey County Hospital
(RSCH), Guildford Diagnostic Imaging Centre (GDI) and Alliance Medical Limited. This study
obtained local ethics approval from the Royal Surrey County Hospital NHS Foundation Trust, for the
submitted project proposal please refer to Appendix (A).
I started the work in this thesis by surveying the first commercially available software dedicated to
correlating tumour texture to patient survival; TexRAD (TexRAD, UK). In chapter 2, I present our
in-house implementation of the TexRAD algorithm and a comparison between results generated using
the two systems. I also present a validation study of the published texture analysis parameters that
were shown to be predictive of patient survival in NSCLC.
In chapter 3, a phantom study to characterise the effects of respiratory motion on extracting
textural features from CT images is presented. In the phantom study, the modulation transfer function
(MTF) was calculated for the CT scanner and for different size texture filters in static and moving
acquisitions. The results from the MTF analysis provides information about the optimum filter size
that allows maximum information to be extracted from images that are affected by respiratory motion.
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Based on the results from chapter 2 and chapter 3, I conceptualised a method that allows for
voxel based texture mapping of tumour image. In chapter 4, I present our novel methodology of
designing a voxel based texture mapping filter including; choice of texture filter, our proposed novel
method for image quantisation and choice of filter size.
The application of the volumetric voxel based texture mapping methodology on CT images of
NSCLC is presented in chapter 5 along with an investigation of the relationship between the produced
volumetric voxel based texture maps and tumour metabolism obtained from 18F-FDG PET images
for a set of ten patients diagnosed with advanced NSCLC is presented and analysed.
In chapter 6, the findings of the relationship between tumour CT image heterogeneity and 18F-
FDG uptake distribution presented in chapter 5 are used to guide dose painting for the investigated
patients. The methods and results of a comparative dose painting planning study are presented in
chapter 6. The planning study includes creating four radiotherapy treatments plans for each patient
based on: the current treatment standard of uniform dose to the tumour, a dose painting plan based on
tumour CT image heterogeneity, a dose painting plan based on tumour 18F-FDG uptake distribution
and a dose painting plan based on the combination of tumour CT image heterogeneity and FDG
uptake distribution.
In the last chapter, chapter 7, the implications of the work in this thesis are discussed in addition
to a discussion of the main conclusions and future work.

Chapter 2
First-order Statistics Texture Analysis
for Survival Prediction
2.1 Introduction
One of the main objectives in this thesis is to investigate the application of texture analysis in the field
of radiation oncology hence, a survey of the exisiting texture analysis methods in the literature was
undertaken. In this chapter, an evaluation and a validation of the first and currently, the only available
commercial software, TexRAD (TexRAD, UK), dedicated to correlation of patient survival with
tumour’s CT first-order textural features is presented [51][52][102][53][42][55][54][56]. TexRAD
software uses five Laplacian of a Gaussian (LoG) filters of different sizes to measure the entropy
of tumour images and correlates this with patients survival as has been discussed in (1.6.1). This
chapter presents two new studies: a feasibility study and a validation study. In the feasibility study, I
implemented in-house Laplacian of a Gaussian (LoG) filters that corresponds to the filters suggested
by the TexRAD group. The in-house implemented filters performance is validated against TexRAD
software filters by analysing a dataset using the two systems. In the validation study, the texture
analysis methodology and parameters using the LoG filters, that has been shown to correlate to patients
survival in non small cell lung cancer (NSCLC) and published by Win et al. [153], are investigated.
The survival analysis results from the validation study in regards to correlating first-order textural
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features extracted from tumour images after the application of the LoG filters are compared to what is
published by Win et al. 2013 [153].
2.2 Feasibility Study
2.2.1 Methods
2.2.1.1 Dataset
18F-FDG PET/CT images of 20 patients diagnosed with NSCLC were collected retrospectively in
addition to other patients information (disease stage, histopathology, survival). The patients group
had a mixed histology of eight squamous cell carcinoma, five adenocarcinoma and seven NSCLC of
unknown histology. The staging for the investigated patients was locally advanced where the TNM
staging ranged between T2N0 to T4N2. The non-contrast PET/CT images were acquired using a GE
Discovery LS scanner (GE Healthcare, UK); images were reconstructed using filtered back projection
(FBP) for the CT images. The acquisition parameters for CT images were 150kVp and 100mAs. The
reconstructed transaxial image size was 512x512 with 0.98x0.98x5.00mm3 voxel size. This study
obtained local ethics approval from the Royal Surrey County Hospital NHS Foundation Trust.
2.2.1.2 TexRAD Software
CT images for the investigated dataset were anonymised and imported into TexRAD software. The
region of interest (ROI) for analysis was defined as the primary tumour at the largest cross-section
within the CT scan as suggested by the published literature from the TexRAD group [54]. A trained
observer (the author) delineated the ROI under the supervision of a consultant radiologist (VP). Using
TexRAD software, the five available Laplacian of a Gaussian (LoG) filters were applied to the CT
tumour image. The applied LoG sizes and σ are presented in table (2.1). First-order textural features
of mean, standard deviation, entropy, kurtosis, and skewness were measured from the filtered tumour
images. The produced texture parameters were exported from TexRAD software for further analysis.
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Table 2.1 Size of the TexRAD Laplacian of Gaussian Filters.
Filter Name Filter size (mm2) σ size
ssf2 4x4 1.0
ssf3 6x6 1.5
ssf4 8x8 1.8
ssf5 10x10 2.0
ssf6 12x12 2.5
2.2.1.3 In-house Implementation of TexRAD Methodology
LoG filters that corresponds to the TexRAD filters were implemented in-house by the author based
on the information released by TexRAD group in addition to private discussion with the company’s
science director. This information only included filter size h and σ for each of the LoG filters. The
author developed the corresponding filters in Matlab software (The MathWorks, Inc, Natick, MA).
The filters were developed by first creating a 2D symmetrical matrix (x,y) using equation (2.1) where
h is the filter size. The produced matrix (x,y) was used to create the five LoG filters with σ = 1.0, 1.5,
1.8, 2.0, 2.5 using equation (2.2). The value of σ is a scaling factor related to the smoothing effect
of the filter, a larger σ will lead to a larger smoothing effect (2.2). The in-house implemented filters
are referred to as LoG2, LoG3, LoG4, LoG5, LoG6 which corresponds to ssf2, ssf3, ssf4, ssf5 and
ssf6 respectively (refer to table (2.1)). The LoG filters were then summed to zero to null the constant
component of the image as presented in equation (2.3).
(x,y) = (
−(h−1)
2
:
h−1
2
,
−(h−1)
2
:
h−1
2
) (2.1)
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LoG(x,y) =− 1
πσ4
[1− x
2+ y2
2σ2
]exp−
x2+y2
2σ2 (2.2)
LoG = LoG−∑(x,y)/h2 (2.3)
The same dataset of patients images analysed in the TexRAD software was analysed using the
in-house implemented LoG filters. The CT scans for the investigated patients were anonymised and
imported into itk-snap software [163]. The ROIs were delineated by the same trained observer (the
author) by replicating what was delineated in TexRAD software. The ROIs were copied and imported
into Matlab software (The MathWorks, Inc, Natick, MA) to apply the in-house implemented LoG
filters and to measure texture features. LoG filters are spatial filters; the filtered image is a result of
convolving the tumour CT image with the LoG filter.
2.2.1.4 Statistical and Survival Analysis
Studies published using TexRAD by groups investigating texture analysis in NSCLC [56][153],
showed global entropy (Eglobal) measured from tumour CT image post the application of LoG filters
correlates with patients survival. Hence, tumour Eglobal as shown in equation (2.4) was measured from
filtered CT tumour images. In equation (2.4), p is the probability of a voxel with intensity value i
occurring in the image and N is the number of grey levels.
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Eglobal =−
N
∑
i
p(i) log(p(i)) (2.4)
Pearson’s correlation (R) was used to invistigate the relationship between tumour entropy (cal-
culated post the application of both TeXRAD filters and in-house implemented LoG filters) and
patients survival. To test the null hypothesis that there is no correlation between entropy and survival,
regression analysis was conducted using the F-test. To calculate the 95% confidence interval (CI)
for R, R was transformed to z which has a normal distribution using equation (2.5). The 95% CI is
then calculated as shown in equation (2.6) where n is the sample size. To test the significance of the
observed correlation, tables that show critical values for R where p-value would be <0.05 were used
[11].
z =
1
2
log
(
1+R
1−R
)
(2.5)
95% CI (R) = z±1.96 1.96√
n−3 (2.6)
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In regression analysis, the slope (b) indicates the strength of the relationship, if any, between
variables. To calculate the 95% CI for the slope b, equation (2.7) was used. t0.975 is the value of
t distribution at n− 2 degrees of freedom and Se(b) is the standard error in the slope b [11]. The
standard error in the slope Se(b) is related to the standard deviation of the residual (Sres) between
observed and fitted values, it is calculated using equation (2.8) [11].
95% CI (b) = b± t0.975Se(b) (2.7)
Se(b) =
residual standard deviation(Sres)√
sum of squares for entropy
(2.8)
Receiver operator curves (ROC) were generated to examine the ability of entropy values to predict
patients’ survival for more than the median survival time of 30 months. The relationship between
entropy and patients survival was assessed using Kaplan-Meier (KM) analysis in IBM SPSS for
Windows version 22 (SPSS Inc, Chicago US). The median entropy value was used to dichotomise
subjects into groups of low and high entropy. Due to the differences between centres in regards to
CT scanners, reconstruction algorithms and scanning protocols, an absolute threshold entropy value
is difficult to establish. Win et al. 2013 [153] suggested a normalised entropy value by dividing the
entropy value measured from LoG medium filter of σ=1.5 and coarse filter of σ=2.5. In this study,
this normalised entropy method suggested by [153] was also tested for significance using the TexRAD
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filters and in-house implemented LoG. The subjects that have not experienced a terminal event were
censored in the KM analysis, meaning the total survival time cannot be accurately estimated for that
patient hence their survival time will not be considered when dividing the survival time into intervals.
Log-Rank test was performed on the KM curves to assess the significance in survival time [11],
p-value < 0.05 is considered significant. The Log-rank test calculates the distribution X2 which is the
sum of the squared difference between the observed events O ( terminal event) and expected events E
(survived subjects) divided by E as shown in equation (2.9). For a sample size of n, the p-value is
obtained for the X2 distribution with n−1 degrees of freedom.
X2 = sum(O−E)2/E (2.9)
Given TexRAD is commercial software, detailed information about the algorithms implemented
within it are not available, an exact agreement between the absolute values of measured entropy using
TexRAD filters and in-house implemented LoG filters is challenging. To assess the agreement and
consistency between entropy measurements generated by TexRAD software and in-house implemented
filters, Bland-Altman plots were generated. The difference d in the entropy value measured from
the TexRAD filter (EntropyTexRAD) and from the corresponding in-house implemented LoG filter
(EntropyLoG) is plotted against the mean of the two values (EntropyTexRAD+EntropyTexRAD/2). The
plot will show the systematic difference between the two measurements. The difference should ideally
be zero, yet systematic difference between the two measurement within the 95% confidence limit is
considered acceptable. The 95% confidence limits are calculated as d±2s where s is the standard
deviation between EntropyTexRAD and EntropyTexRAD. Moreover, the ratio between EntropyTexRAD
and EntropyLoG was calculated.
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2.2.2 Results
2.2.2.1 TexRAD Results in Comparison to In-house Implemented Filters
Figure (2.1) shows the five in-house implemented LoG filters that corresponds to the standard TexRAD
filters of sizes ranging from 4x4mm2 to 12x12mm2. Examples of a filtered CT image from TexRAD
software and from Matlab using the in-house implemented LoG filters are presented in figure (2.2) and
figure (2.3) respectively. Figure (2.2) and figure (2.3) show the response of the filters when there is an
intensity change within the image, a bright area suggests a strong change in intensity. The histogram
of the filtered image is then used to calculate the textural features of the image, hence the filtered
image is not an image of texture.
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(a) (b)
(c) (d)
(e)
Fig. 2.1 The in-house implemented LoG filters
(a) LoG2 which is 4x4mm2 with σ=1.0, (b) is
LoG3 which is 6x6mm2 with σ=1.5, (c) is LoG4
which is 8x8mm2 with σ=1.8, (d) is LoG5 which
is 10x10mm2 with σ=2.0, (e) is LoG6 which is
12x12mm2 with σ=2.5.
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Fig. 2.2 An example of the TexRAD output for one of the investigated patient where (A) shows the
delineated tumour. (B) Is the tumour filtered image using filter ssf2 (fine scale). (C) Is the tumour
filtered image using filter ssf4 (medium scale). (D) Is the tumour filtered image using filter ssf6
(coarse scale).
The results of Eglobal measured from the filtered CT image with the largest cross sectional area of
the tumour are presented in figure (2.4). Figure (2.4) shows the results from TexRAD fine, medium
and coarse filters (ssf2, ssf3, and ssf6) and the corresponding in-house implemented LoG filters(LoG2,
LoG3 and LoG6). For coarse filter (ssf6), entropy measurements could not be generated for 4 patients
as the filter could not detect changes in intensity within the ROI.
2.2 Feasibility Study 53
Fig. 2.3 An example of the output for the in-house implemented LoG filters for one of the investigated
patient where (A) shows the segmented tumour. (B) Is the tumour filtered image using filter LoG2
(fine scale). (C) Is the tumour filtered image using filter LoG4 (medium scale). (D) Is the tumour
filtered image using filter LoG6 (coarse scale).
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(a)
(b)
(c)
Fig. 2.4 Survival as a function of entropy for TexRAD filters and corresponding filters developed
in-house. (a) Fine scale filter (4x4mm2) results. (b) Medium scale filter (6x6mm2) results. (c) Coarse
scale filter (12x12mm2) results.
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Fig. 2.5 An example of the calculated ratio between entropy values measured from TexRAD filters
(EntropyTexRAD) to entropy values measured from the corresponding LoG filters (EntropyLoG) for the
medium size filter (ssf3).
The ratio between entropy values measured from using TexRAD filters (ssf2, ssf3, ssf4, ssf5,
ssf6) to the entropy values measured from the corresponding LoG filters (LoG2, LoG3, LoG4, LoG5,
LoG6) were 0.65±0.04, 0.63±0.03, 0.60±0.04, 0.57±0.07 and 0.56±0.07 respectively. The mean
of the ratios means was 0.60±0.03. An example of the calculated ratio between EntropyTexRAD to
EntropyLoG for the medium size filter (ssf3/LoG3) is presented in figure (2.5).
Regression analysis results conducted using the F-test are presented in table (2.2). A description
of the straight line fit between entropy values and survival including regression coefficient R, and
the 95% confidence levels (CI) on R and slope are provided in table (2.2). The results in table (2.2)
shows no strong correlation between entropy values extracted from tumours using TexRAD filters
and patients survival. The observed values of R doesn’t exceed the critical values of R that leads to
p<0.05. For example, for ssf2 R=0.03, for this value to be significant, R needs to be >0.45 which is
not the case. Moreover, the 95% CI for slope b goes through zero indicating no strong correlation
between the variables.
Despite the discrepancy in the absolute entropy values measured from the application of TexRAD
filters and in-house generated filters as shown in figure (2.4), the results from Bland Altman plots
presented in figure (2.6) demonstrates the two methods agree within the 95% CI.
56 First-order Statistics Texture Analysis for Survival Prediction
Table 2.2 Summary of regression analysis and correlation significance between entropy values and
survival for all TexRAD filters.
Filter Slope (b) Intercept R 95% CI (R) 95% CI (slope) R values for p<0.05
ssf2 (fine) 0.002 4.39 0.03 -0.44 to 0.45 -0.29 to 0.29 0.455
ssf3 -0.01 4.47 0.39 -0.42 to 0.49 -0.07 to 0.05 0.468
ssf4 -0.01 4.32 0.38 -0.42 to 0.47 -0.13 to 0.11 0.468
ssf5 -0.004 3.84 0.07 -0.46 to 0.47 -0.39 to 0.38 0.482
ssf6 (coarse) -0.01 3.78 0.17 -0.48 to 0.51 -0.65 to 0.62 0.497
The KM results using the median entropy value as the cut-off value obtained from each investigated
filter is presented in table (2.3). The p-value calculated using the Log-rank test reached significance
(P <0.05) for medium texture filters (ssf4) and in-house implemented filter (LoG3 and LoG4). KM
results for the medium size filters show the low entropy group to have better survival than the high
entropy group. The results from the ROC curves indicate that entropy is not a significant prognostic
parameter given that the area under the curve (AUC) is <=0.6 as shown in table (2.3). AUC values
presented in this thesis are comparable to what is reported by [55].
The p-value for the TexRAD filters and the in-house implemented filters were 0.019 and 0.04
respectively when using the normalised cut-off value of 1.233 from Win et al. [153]. The KM results
for normalised entropy values for both generated from TexRAD and in-house implemented filters are
presented in figure (2.7). For normalised entropy, the group with low normalised entropy (high overall
entropy) has a poor prognosis while the group with normalised entropy higher (low overall entropy)
than the threshold value has better survival. The censored cases in the KM plots refer to subjects that
have not experienced a terminal event.
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(a)
(b)
(c)
Fig. 2.6 Bland Altman (difference plot) for TexRAD filters and corresponded filters generated in-house.
(a) Fine scale filter (4x4mm2). (b) Medium scale filter (6x6mm2). (c) Coarse scale filter (12x12mm2).
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(a)
(b)
Fig. 2.7 Kaplan-Meier curves generated for normalised entropy values measured after applying
TexRAD filters where group 1 refers to low normalised entropy (<threshold of 1.233) and group 2
refers to high normalised entropy (>threshold of 1.233) (a) results for using filters developed in-house
(b) results from using TexRAD software.
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Table 2.3 Receiver operating characteristics (ROC) analysis results with p-value for survival analysis
using Kaplan-Meier curves for TexRAD filters notated as ssf and in-house implemented filters notated
LoG. The median entropy value was used as the threshold value for the KM analysis. (AUC = area
under the curve)
Filter AUC P-value Log Rank KM Threshold Value
ssf2 (fine) 0.52 0.53 4.4
LoG2 (fine) 0.60 0.15 6.9
ssf3 0.50 0.06 4.3
LoG3 0.41 0.02 6.7
ssf4 0.50 0.04 4.2
LoG4 0.50 0.02 6.7
ssf5 0.53 0.12 3.9
LoG5 0.40 0.06 6.6
ssf6 (coarse) 0.53 0.16 3.9
LoG6 (coarse) 0.50 0.60 6.6
2.2.3 Discussion and Conclusions
The initial results obtained from TexRAD software suggest no strong prognostic correlation between
tumour entropy and patients survival. Yet, p-values obtained from KM curves reached significance
indicating a relationship between entropy and survival. The group of patients with low entropy
(high normalised entropy) is characterised by better survival than the group of patients having high
entropy (low normalised entropy). While entropy values measured from the application of in-house
implemented LoG filters are different to the TexRAD values, results from Bland Altman plots and KM
curves illustrated that the in-house implemented LoG filters provide comparable results. Furthermore,
it is expected for the results to vary due to the lack of information regarding any image processing
that is performed within the TexRAD software. Given the technical differences in acquiring the
CT data between centres such as scanner manufacturers, reconstruction algorithms and scanning
protocols [10], it is presumed that a normalised entropy value is needed to allow for comparison and
validation between centres. The presented results showed the possibility of normalised entropy to
have a prognostic role in NSCLC. Yet, due to the small number of patients, additional data are needed
to validate the presented results and draw final conclusions. In the next section, a larger dataset is
used to validate the presented normalised entropy results.
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2.3 Validation study
2.3.1 Methods
2.3.1.1 Dataset
For this study, diagnostic 18F-FDG PET/CT scans for 49 patients diagnosed with NSCLC were
collected retrospectively. The patient group has a heterogeneous histology and TNM staging. The
group consist of 28 squamous cell, 12 adenocarcinoma and 9 of unknown NSCLC histology. The
TNM staging range was between T2N0 to T4N3. The CT scans were acquired with a peak tube
voltage of 140kVp and a current of 100mAs, and were reconstructed onto an image matrix in which
each slice contained 512x512 voxels with a voxel size of 0.98x0.98mm2. The slice thickness was 5mm.
This study obtained local ethics approval from the Royal Surrey County Hospital NHS Foundation
Trust.
2.3.1.2 Texture Analysis
The collected scans were anonymised and imported into the TexRAD software. The ROI was
delineated at the largest cross-sectional area of the primary tumour by a trained observer (the author)
under the supervision of a consultant radiologist (VP). The LoG filters available in TexRAD (table
(2.1)) were then applied to the delineated ROI. Eglobal was then calculated from the histogram of the
filtered tumour image. The entropy values were exported into Matlab software (The MathWorks,
Inc, Natick, MA) for analysis. The normalised entropy (medium-filter value/coarse-filter value) as
suggested by Win et al. 2013 [153] was calculated.
2.3.1.3 Survival Analysis
To dichotomise the patients into groups of good and poor survival, KM survival analysis was conducted
using IBM SPSS version 22.0. The threshold value for normalised entropy was set to two levels; the
median of the dataset entropy values and to the value previosuly published by [153] of 1.233. The
statistical significance of the differences between the KM survival curves for each group was then
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Table 2.4 p-value results from Log-rank test on KM curves using two different threshold
Threshold Type Median Win et al [153]
Threshold Value 1.167 1.233
P-value 0.02 0.03
assessed using the log-rank test, with the null hypothesis of no difference between the two groups.
p-values < 0.05 is considered significant.
2.3.2 Results
2.3.2.1 Survival Analysis
In the dataset of patients, at the time of analysis, the mean survival time was 21.5 months (range
3.0 to 52.0) with 34% of patients alive. Figure (2.8) shows the KM curves for the two investigated
threshold values. Table (2.4) shows the threshold values and their corresponding log-rank p-values.
Both threshold, the median value from this study dataset and the previously published threshold value
from [153] reached significance of 0.02 and 0.03 respectively. The KM curves in figure (2.8) show
patients with tumours of high normalised entropy >threshold of 1.233 (low overall entropy denoted
as group 2 in figure (2.8)) to have better survival. While patients with tumours of low normalised
entropy <threshold of 1.233 (high overall entropy denoted as group 1 in figure (2.8)) were categorised
to have poor survival. Figure (2.9) is an example of filtered CT images from two patients. The patient
in figure (2.9A) is diagnosed with squamous cell NSCLC stage T3N2 with a known survival of 3.05
months where the patient B in figure (2.9B) was also diagnosed with squamous cell NSCLC stage
T4N2 with a survival time of 35.4 months. The filtered tumour CT images shown in figure (2.9)
highlight the different textures associated with the tumours. The patient B whose tumour had high
normalised entropy (low overall entropy) was categorised into the group with good prognosis using
both investigated threshold levels. Conversely, patient A with low normalised entropy (high overall
entropy) value was categorised into the group with poor prognosis using the investigated threshold
levels.
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(a)
(b)
Fig. 2.8 Kaplan-Meier curves generated for normalised entropy values, group 1 refers to low nor-
malised entropy (<1.233) and group 2 referes to high normalised entropy (>1.233). (a) Using the
median entropy value as a threshold. (b) Using the previosuly published [153] threshold of 1.233.
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Fig. 2.9 (A) Tumour CT image with low normalised entropy and associated with poor survival group
while (B) is a tumour CT image with high normalised entropy and associated with good survival
group. (1) Is the filtered tumour image using small-sized filter. (2) Is filtered tumour image using
medium-sized filter. (3) Is filtered tumour image using larger-sized filter.
2.3.3 Discussion and Conclusions
In this chapter, an analysis of entropy as a measure of texture from CT tumour images as a potential
prognostic tool in NSCLC was presented. A validation of the in-house generated LoG filters against
the first commercial software (TexRAD) to measure tumour texture from CT images was carried
out. In the feasibility study, I showed the performance of our in-house implemented LoG filters is
comparable to that of TexRAD.
Previously published studies using the TexRAD software used optimised parameters to di-
chotomise patients into good and poor survival groups. The application of these threshold values
outside the investigated dataset was not assessed due to the variation of the obtained entropy values
given the technical differences (scanner manufacturers, reconstruction algorithms, scanning protocol)
between centres. In this chapter, I investigated the application of a derived normalised entropy value
from the study published by Win et al. [153] on a different cohort from a different centre. To test
this hypothesis, the methodology used by Win et al. [153] was applied to a new group of patient
data and the same value of normalised entropy was used as a threshold. In addition, the median
value of normalised entropy as a threshold value was also tested for significance to allow for a fair
dichotomisation of the data. The study by Win et al. [153] had a patients cohort of 66 diagnosed with
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NSCLC (16 squamous cell, 32 adenocarcinoma, 18 unspecified NSCLC) with mixed staging starting
at stage 1A to stage 4 where our patient cohort didn’t include stage 1 NSCLC. Although the PET/CT
scanner manufacturer is similar between the two studies (GE Healthcare), the scanner model and
scanning acquisition parameters are different. The Win et al.[153] study acquired the images using a
VCT-XT Discovery GE scanner with 100-150mAs, 80kVp and 3.27mm slice thickness. Images for
our study were acquired on a GE Discovery LS scanner with 100mAs, 150kVp and 5.00mm slice
thickness. Yet, the survival analysis using the optimally derived normalised entropy value from Win
et al. [153] was shown to yield significance at p<0.05 level, indicating that survival was significantly
longer in the patients whose normalised entropy was greater than 1.233. This shows that the Win et al.
[153] parameters would have yielded predictive power with this dataset. This is an important finding,
since it implies that parameters obtained from one study could potentially be used generically to
predict survival for other patients, despite the differences in patients cohort and in imaging equipment,
etc. Furthermore, using the median value of the normalised entropy as a threshold yielded significant
results as well. The preliminary results from this chapter raises a question about the physiological
underlining of tumour CT texture and whether the measured entropy value correlates with tumour
function.
To try to better understand tumour CT image texture, I propose investigating tumour image texture
on a voxel based level. Given that the texture analysis method presented in this chapter using the LoG
filters is a global method that is applied to a single CT slice and does not analyse spatial variation
in texture, I propose the use of the second-order statistical texture analysis method of grey level
co-occurrence matrices (GLCM). I propose the use of GLCM to generate a volumetric map of tumour
texture to allow the assessment of spatial variation in tumour texture in a CT image. GLCM has been
shown in the literature to discriminate between normal and abnormal (disease and cancerous) tissue
[147][15]. Furthermore, entropy measured from GLCM was reported to be significantly different
for patients who recurred after receiving stereotactic ablative radiotherapy (SABR) for NSCLC by
Mattonen et al [98] [99]. To investigate the relationship between CT tumour texture and tumour
function, I propose the comparison between the tumour’s 3D texture map and functional images of
18F-FDG PET. To do so, a novel method of generating volumetric voxel based tumour texture maps
was developed. Given that respiratory motion will degrade image quality and consequently affects
the results of texture analysis, a phantom study was conducted to determine the effect of respiratory
motion on the performance of the the different size filters. The phantom study is presented in chapter
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(3). The results from chapter (3) strongly influenced the development of our voxel-based GLCM filter
that will be presented in chapter (4). The comparison between the generated volumetric voxel based
texture maps using our developed methodology and functional data is presented in chapter (5).

Chapter 3
Effects of Respiratory Motion on
Textural Features: A Phantom Study
3.1 Introduction
In recent years, the use of texture analysis in predicting tumour response to treatment has been
suggested [10]. Yet, texture analysis in CT is dependent on image spatial resolution which is
deteriorated by respiratory motion. The aim of this work was to characterise the effects of respiratory
motion on the performance of the in-house implemented Laplacian of Gaussian (LoG) filters in
extracting textural features. Features extracted from such filters have been shown in the literature [53]
[56] and in chapter (2) to correlate with patient survival in non-small cell lung cancer (NSCLC). To
do so, we designed a phantom experiment to characterise the performance of the CT scanner and the
LoG filters at different spatial frequencies in the presence of respiratory motion. The performance of
the CT scanner and the effects on the LoG filters were characterised by measuring the Modulation
Transfer Function (MTF). The MTF provides a description of the sharpness of the imaging system.
Also, the LoG filters response at different spatial frequencies allows a better understanding of the
structure size of the extracted textural features. Moreover, characterising the response of the LoG
filters of different sizes at different spatial frequencies in the presence of respiratory motion allows us
to choose the optimum filter size to design our proposed texture mapping filter.
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In this chapter, we present our multi-spatial scale (MUSS) in-house developed phantom designed
specifically to measure the effects of spatial heterogeneity. CT images of the MUSS phantom were
acquired while static and in-motion and the MTF of the scanner system was measured using these
images. The performance of the LoG filters was also measured for the static and in-motion acquisition.
3.2 Methods
3.2.1 Phantom Design
The multi-spatial scale (MUSS) phantom was made of Polymethyl methacrylate (PMMA). PMMA
is a water equivalent material extensively used in constructing radiation dosimetry phantoms [66].
The MUSS phantom designed for this work has a size of 131x121x30mm3. The phantom has four
sections, each section contains a square lattice of a different size made to be able to resemble a
checker-board pattern. The square lattice sections included hollow cubes where the cubes can be
filled with a solution to allow arbitrary density variations to be imaged. The sizes of the cubes in the
four sections are 4x4mm2, 6x6mm2, 8x8mm2, 10x10mm2 where 4x4mm2 cube is the smallest feasible
size to manufacture and fill. The MUSS phantom design is shown in figure (3.1). The phantom has a
PMMA top that attaches to prevent the solution that fills the lattice from spilling. A plastic extension
was designed to attach the MUSS phantom to a system that simulates respiratory motion.
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3.2.2 Experimental Design
To measure the MTF of the system, for each of the four sections within the phantom, every other
cube in the square lattice was filled to produce a pattern with alternate cubes left empty as seen in
figure (3.2). This allowed measurement of the MTF as discussed in section (3.2.4). The cubes were
filled with a solution of sucrose and high purity water mixture to simulate tissue. The solution had 8%
sucrose concentration, the percentage concentration of the solution was calculated as the fraction by
weight of the sucrose.
To conduct the experiment, the phantom was attached to the motor of a dynamic thorax phantom
(CIRS Company, Virginia, USA). The dynamic thorax phantom platform was controlled via a computer
to simulate respiratory motion as shown in figure (3.3). The programmed respiratory motion followed
a sine wave with a period of 4 seconds and an amplitude of 1.00cm with a total displacement of 2cm
in the superior-inferior direction. During the experiment, the phantom was placed on solid water slabs
to raise it to the height of the motor attachment as shown in figure (3.3).
3.2.3 Data Acquisition
The MUSS phantom was scanned using a GE discovery CT scanner (GE healthcare, Ohio, USA) with
120kVp and 78mAs acquisition parameters. The reconstructed transaxial image size was 512x512
with 0.98x0.98x1.25mm voxel size. The reconstruction algorithm was Filtered Back Projection (FBP).
The phantom was first aligned using the scanner’s alignment lasers and then scanned while static, and
then in-motion using the same scanning parameters.
3.2.4 Data Analysis
The data were re-sampled in the direction of motion (coronal view) and the centre slice was chosen
for the analysis. The phantom was moving in the superior-inferior direction while being scanned,
hence the data needed to be re-sampled in this direction to analyse the effects of motion on the data.
To characterise the effects of motion on the scanner spatial resolution, the MTF of the static and the
moving data were calculated using the edge method to provide a numerical description of the imaging
system response at different spatial frequencies [77]. To evaluate the performance of the LoG filters
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Fig. 3.2 The MUSS phantom solution filling arrangement showing in red. The filling arrangement
was designed to produce a bar pattern to conduct the MTF measurements.
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(a)
(b)
Fig. 3.3 (a) The Experimental Set-up. (b) A Close-up of the MUSS phantom during the experiment.
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at different spatial frequencies in the presence of motion, the MTF of the LoG filters was calculated
using the Fourier Transform (FT). The performance of the LoG filters in combination with the scanner
resolution was assessed by measuring the MTF of the phantom filtered images using the Standard
Deviation method [46].
3.2.4.1 The Modulation Transfer Function of The CT Scanner
The MTF is the Fourier space amplitude of the response to a delta function input whereas the
line spread function (LSF) is the equivalent response in the spatial domain. MTF is the modulus
(magnitude) of the normalised frequency response of the imaging system, also known as the optical
transfer function (OTF) as shown in equation (3.1) where u and v are the spatial frequency variables.
MT F(u,v) = |OT F(u,v)| (3.1)
The OTF describes the ability of an imaging system to pass information and it consists of MTF
(the magnitude) and the imaginary part known as the phase transfer function (PTF) as shown in
equation (3.2).
OT F(u,v) = MT F(u,v)e.iPT F(u,v) (3.2)
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Fig. 3.4 A schematic illustration of MTF calculation using the edge method.
The MTF can be measured by taking the FT of the line spread function (LSF). Traditionally, the
LSF is calculated by differentiating the edge response function (ERF). The ERF is obtained by taking
a line profile through an imaged edge. In this experiment, the imaged edge was the transition region
between the sucrose-water mixture and air (filled and unfilled cube). Measuring the transition between
the high to low density region (bright to dark area on CT image) can provide an estimate of the spatial
impulse response of an imaging system. Calculating the FT of this impulse response will provide the
frequency response of the system as the MTF. A schematic illustration of MTF calculation using the
edge method is presented in figure (3.4).
To calculate the MTF of the scanner, the ERF was obtained by taking a line profile through an
edge between filled and unfilled cubes within the phantom. The ERFs were measured for the static
and in-motion data experimentally by plotting the raw data points obtained from the phantom CT
images. The scanner ERF for the static acquisition is labelled as ERFExp_static and the scanner ERF for
the moving acquisition is labelled as ERFExp_motion. Due to the noise in the acquired data, fitted ERFs
were obtained by iteratively fitting a sigmoid function to the raw data points of the ERFExp_static and
ERFExp_motion. The sigmoid function is shown in equation (3.3), where Bmax is the maximum value
for the curve, t is the slope of the curve, w50 is the midpoint of the curve and w is the point on the
sigmoid curve.
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ERFf itted =
Bmax
1+ e−t(w50−w)
(3.3)
The goodness of fit was assessed by calculating the root mean squared error (RMSE) as presented
in equation (3.4). In equation (3.4), the measured value is yi, the fitted value is y′i and N is the sample
size [11].
RMSE =
√
1
N
N
∑
i=1
(yi− y′i)2 (3.4)
The modelled ERFs are labelled ERFFitted_static and ERFFitted_motion respectively. The ERFExp_static
and the ERFExp_motion were differentiated to obtain the LSFExp_static and LSFExp_motion respectively; the
ERFFitted_static and ERFFitted_motion were differentiated to obtain the LSFFitted_static and LSFFitted_motion.
To validate the calculated LSFFitted_motion, a predicted LSF in the presence of motion (labelled
LSFPredict_motion) was calculated by convolving the LSFFitted_static with the probability density function
(PDF) of the programmed sine wave (equation(3.5)). The amplitude of the sine wave is termed R
which in this experiment is equal to 1cm while x is a sampling data point.
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PDFsine =
1
π
√
R2− x2 (3.5)
The agreement between the LSFFitted_motion and LSFPredict_motion was evaluated in the terms of the
full width half maximum (FWHM) measured from the two distributions. The FWHM is measured
as the width of a distribution at half of its maximum value. The FWHM of LSF is a measure of an
imaging system’s resolution. The scanner MTFs during the static and the in-motion acquisition were
calculated by taking the FT of the LSFFitted_static, LSFFitted_motion and LSFPredict_motion. The calculated
MTFs were labelled MTFFitted_static, MTFFitted_motion and MTFPredict_motion respectively. The agreement
between the MTFFitted_motion and MTFPredict_motion was measured by conducting a two sample t-test
and calculating the p-value for significance. The calculated MTFs were normalised by dividing the
MTF curve by its maximum value. The MTF measurement was analysed in terms of MTF50 and
MTF10. MTF50 is the spatial frequency where the MTF is reduced to 50% and MTF10 is spatial
frequency where the MTF is reduced to 10%. Traditionally, MTF50 and MTF10 are quoted given
they have been found to be good indicators of the imaging system resolution [133].
3.2.4.2 The Modulation Transfer Function of The In-house Implemented LoG Filters
The MTF of the LoG filters was calculated by taking the FT of the filters to evaluate their performance.
The LoG filters are 2D isotropic filters; the diagonal of the LoG filter was used to calculate the MTF
of the LoG filters. As presented in chapter (2), the widths of the investigated LoG filters are presented
in table (3.1). The MTF curves of the LoG filters for the static acquisition are labelled MTFLoG_static.
The MTFs of LoG filters in the presence of motion (MTFLoG_motion) were calculated by multiplying
the MTFLoG_static with the scanner’s MTFFitted_motion as shown in equation (3.6).
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Table 3.1 Size of the in-house implemented LoG filters where σ is a scaling factor related to the
smoothing effect of the filter.
Filter Name Filter size (mm2) σ size
LoG2 4x4 1.0
LoG3 6x6 1.5
LoG4 8x8 1.8
LoG5 10x10 2.0
LoG6 12x12 2.5
MT FLoG_motion = MT FLoG_static ∗MT FFitted_motion (3.6)
To validate the measured MTFLoG_static, the MTFLoG+scanner were measured for the LoG filters
using the standard deviation (SD) method by Droege and Morin 1982 [46]. The MTFLoG+scanner is
measured from the filtered images of the phantom (the image is convolved with the LoG filter); hence,
it is a measure of the LoG filters performance in combination with the scanner response. In the SD
method, the MTFLoG+scanner measurement depends on calculating the modulation M( f ) as the SD of
the voxels’ Hounsfield unit (HU) values within a region (ROI) of a cyclic bar pattern. It has been
shown by Coltman [35] that MTF can be measured by measuring the output amplitude A( f ) from
the images of a cyclic bar pattern. The output of imaging a cyclic bar pattern is a sinusoidal wave
with amplitude A0. As reported by Coltman, the MTF (labelled as MTFLoG+scanner) is expressed as in
equation (3.7). In equation (3.7), the square wave is considered as a sum of frequencies f ,3 f ,5 f , .., f c
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from the sinusoidal component of the square wave where f c is the frequency where the MTF is zero
[46].
MTFLoG+scanner =
πA( f )
4A0
, ............ f ≥ f c/3 (3.7)
Given that the square wave variance M20 = A
2, and the sinusoidal signal variance M( f )2 = 12 A
2
[46], equation (3.7) simplifies to
MTFLoG+scanner =
π
√
2
4
.
M( f )
M0
(3.8)
The M( f ) is corrected for noise by substracting the SD of a uniform region (Bg) in the phantom.
The input modulation M0 is measured as the difference between the mean of the CT numbers of the
highest response and the lowest response regions in the image [46].
To calculate MTFLoG+scanner for the LoG filters, each filter was convolved with the phantom image
and then the filtered images were used to carry out the calculations. MTFLoG+scanner was calculated
for each of the four sections in the MUSS phantom representing four spatial frequencies of 0.08, 0.1,
0.12, and 0.166 mm−1. An illustration of the background region (Bg) and the ROIs are presented in
figure (3.5). The MTFLoG+scanner was calculated for each section of the square lattice in four different
regions within the lattice and the average value was used. The error was calculated as ±1 standard
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Fig. 3.5 An illustration of the ROI regions and Bg region used to calculate the MTFLoG+scanner for the
in-house implemented LoG filters.
deviation of the four measurements. The calculated MTFs and MTFLoG+scanner were normalised by
dividing the MTF curve by the highest MTF value. The MTF measurements were quoted in terms of
MTF50 and MTF10. A list of the ERF, LSF and MTF terms used in this study are summarised in
table (3.2).
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Table 3.2 A list definitions of ERF, LSF and MTF abbreviations used in this study.
Abbreviation Definition
ERF
ERFExp_static Obtained by taking a line profile through an edge in the static phantom image
ERFExp_motion Obtained by taking a line profile through an edge in the moving phantom image
ERFFitted_static Obtained by fitting a sigmoid function to the raw data points of the ERFExp_static
ERFFitted_motion Obtained by fitting a sigmoid function to the raw data points of the ERFExp_motion
LSF
LSFExp_static Obtained by differentiating the ERFExp_static
LSFExp_motion Obtained by differentiating the ERFExp_motion
LSFFitted_static Obtained by differentiating the ERFFitted_static
LSFFitted_motion Obtained by differentiating the ERFFitted_motion
LSFPredict_motion Obtained by convolving LSFFitted_static and the PDFsine
MTF
MTFFitted_static Obtained by taking the FT of the LSFFitted_static
MTFFitted_motion Obtained by taking the FT of the LSFFitted_motion
MTFPredict_motion Obtained by taking the FT of the LSFPredict_motion
MTFLoG_static Obtained by taking the FT of the LoG filter
MTFLoG_motion Obtained by taking the multiplying MTFLoG_static by MTFFitted_motion
MTFLoG+scanner
Obtained by calculating the MTF using the SD method from the
filtered phantom image
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3.3 Results
3.3.1 The Modulation Transfer Function of The CT Scanner
The MUSS phantom re-sampled (coronal view) CT images for the static and the moving acquisitions
are presented in figure (3.6) and figure (3.7) respectively. Figure (3.8a) shows ERFExp_static and ERF
Fitted_static for the static acquisition. ERFExp_motion and ERFFitted_motion from the moving phantom CT
images are presented in figure (3.8b).
Fig. 3.6 The re-sampled CT image of the MUSS phantom for the static acquisition.
Fig. 3.7 The re-sampled CT image of the MUSS phantom for the motion acquisition.
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The experimental and modelled LSFs for the static and in-motion data are presented in figure (3.9).
The FWHM measured from LSFFitted_static and LSFFitted_motion were 1.3mm and 2.7mm respectively.
LSFFitted_static, LSFFitted_motion and LSFPredict_motion are presented in figure (3.10). As hypothesized,
the presence of respiratory motion degrades the resolution of the CT scanner as shown in figure (3.10).
The FWHM of the LSFPredict_motion (which is obtained by convolving the PDF of the programmed sine
wave with the LSFFitted_static) was 2.7mm which in agreement with the FWHM of the LSFFitted_motion.
Although there is some discrepancy between the shape of the LSFFitted_motion and LSFPredict_motion, the
FWHM of these two LSFs agree where both were measured as 2.7mm.
(a) (b)
Fig. 3.8 The ERF of the static and the moving acquisition of the MUSS phantom.
(a) (b)
Fig. 3.9 The LSF of the static and the moving acquisition of the MUSS phantom. PDF is the probability
density function.
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Fig. 3.10 LSFFitted_ static, LSFFitted_ motion and LSFPredict_ motion. PDF is the probability density function.
MTFFitted_static, MTFFitted_motion and MTFPredict_motion are presented in figure (3.11). The MTF
curves were calculated by taking the FT of LSFFitted_static, LSFFitted_motion and LSFPredict_motion respec-
tively. The MTFs presented in figure (3.11) behave as predicted where the response of the system is
superior when the phantom is static and it degrades with motion due to image blurring as expected.
The limiting resolution of the scanner measured in spatial frequency in terms of MTF50 is 0.4mm−1 ,
0.2mm−1 and 0.15mm−1 for MTFFitted_static, MTFFitted_motion and MTFPredict_motion respectively. The
MTF10 was measured as 0.6mm−1, 0.3mm−1 and 0.4mm−1 for MTFFitted_static, MTFFitted_motion and
MTFPredict_motion respectively. Given MTFFitted_motion and MTFPredict_motion appears slightly different,
there is a drop in the MTFFitted_motion due to the value going to negative before taking the modulus of
the calculated FT. To assess the statistical significance of the difference, a two sample t-test was used.
The p-value was calculated between MTFFitted_motion and MTFPredict_motion and was found to be 0.6
which is statistically insignificant.
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Fig. 3.11 The MTF measured from the static and the moving acquisition of the MUSS phantom.
3.3.2 The Modulation Transfer Function of The In-house Implemented LoG Filters
Figure (3.12) shows results of the filtered CT images of the static phantom (images convolved with
the LoG filters). The results of convolving the moving phantom CT images with the LoG filters
are presented in figure (3.13). As shown in figure (3.12), the LoG filters performance in detecting
regions of intensity changes is highest when the filter width matches the size of the structure detected.
For example, in figure (3.12b) the image was convolved with filter LoG3 which is 6x6mm2 and the
response of the filter was highest for the region with 6x6mm2 square lattice (bottom right region).
However, structures smaller than the filter size can still have a high response if their size is close to
that of the filter. The response of the filter is considered highest when the entire structure is detected
(bright region) by the filter not just the edges of a structure. Figure (3.13) demonstrates how the filter
performance is affected by motion; the blurring of structures limits the filter’s detection ability. The
smearing of the structures due to motion hinders the performance of the filters which will affect the
extraction of textural features.
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(a) (b)
(c) (d)
(e)
Fig. 3.12 The static phantom CT images filtered by
the LoG filters. (a) Image filtered with LoG2. (b)
Image filtered with LoG3. (c) Image filtered with
LoG4. (d) Image filtered with LoG5. (e) Image
filtered with LoG6. Refer to table (3.1) for filter
sizes.
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(a) (b)
(c) (d)
(e)
Fig. 3.13 The moving phantom CT images filtered
by the LoG filters where the direction of motion is
top to bottom. (a) Image filtered with LoG2. (b)
Image filtered with LoG3. (c) Image filtered with
LoG4. (d) Image filtered with LoG5. (e) Image
filtered with LoG6. Refer to table (3.1) for filter
sizes.
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The MTFLoG_static measured using the FT method and the MTFLoG+scanner measured using the SD
method are presented in figure (3.14). The error bars for the MTFLoG+scanner represents ±1 standard
deviation of the mean values of the MTFLoG+scanner measurements. The results in figure (3.14a)
for MTFLoG_static (blue dashed line) indicates that small-size LoG filter covers a wider frequency
range than larger filters. Yet, the small LoG filter performance is limited by the scanner’s MTF
given that the scanner’s MTF covers a narrower frequency range than the small LoG filter as seen
in figure (3.14a). The medium-size LoG filter appears to cover the frequency range allowed by the
scanner’s MTF as seen in figure (3.14b). The results of the MTFLoG+scanner (black points) shows that
the scanner’s resolution largest effect on the LoG performance was prominent in the high spatial
frequency (0.166mm−1) for the larger filters as seen in figure (3.14d,e). The medium-size filters MTFs
in figure (3.14b,c) show the best agreement between the MTF measured using the FT and the SD
method indicating a minimal effect of scanner’s resolution on the performance of the LoG filters.
The MTFLoG_motion results for the LoG filters measured by multiplying the MTFLoG_static and
the scanner MTFFitted_motion are presented in figure (3.15). The results in figure (3.15) show that
the performance of the LoG filters is limited by the scanner resolution in the presence of motion.
Calculating the MTFLoG_motion using the SD method was challenging due to difficulties in ROI
selection given the motion effects hence it was not included in the analysis.
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(a) (b)
(c) (d)
(e)
Fig. 3.14 MTF for the LoG filters in static using
the FT and SD methods. (a) MTF of LoG2, (b)
MTF of LoG3, (c) MTF of LoG4, (d) MTF of
LoG5, (e) MTF of LoG6.
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(a) (b)
(c) (d)
(e)
Fig. 3.15 MTF for the scanner and the LoG filters
in static and in presence of respiratory motion. (a)
MTF of LoG2, (b) MTF of LoG3, (c) MTF of
LoG4, (d) MTF of LoG5, (e) MTF of LoG6.
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Fig. 3.16 The limiting resolution quoted in terms of MTF50 for the scanner and the LoG filters during
static and the moving acquisition.
The MTF50 and MTF10 results are quoted in the spatial domain (mm) to contextualise the spatial
scale of structures that can be detected within an image. The limiting resolution of the scanner,
measured as MTF50 and MTF10, was 3.3mm and 1.6mm for the static acquisition and 6.6mm and
3.3mm for the moving acquisition respectively. The MTF50 and MTF10 for the LoG filters static
and in the presence of motion are presented in figure (3.16) and figure (3.17) respectively. The
results demonstrated a loss of information when using small-size filters due to the limiting resolution
of the scanner. As seen in figure (3.16) and figure (3.17), the static MTF50 and MTF10 (blue
points) for the 4x4mm2 LoG filter (MTF50=2.8mm, MTF10=1.3mm) were lower than the scanner’s
MTFs (MTF50=3.3mm, MTF10=1.6mm) indicating it can detect structures smaller than the scanner
resolution. In the presence of motion the small filters MTFs (MTF50=7.1mm, MTF10=3.8mm) were
higher than the scanner’s MTF (MTF50=6.6mm, MTF10=3.3mm). These results show that the smaller
filter is most affected by motion in comparison to the medium-size filters (6x6mm2 and 8x8mm2). The
medium-size filters 6x6mm2 and 8x8mm2 static MTF50 were 4.0mm and 5.0mm respectively and the
in-motion MTF50 were 6.6mm and 6.8mm respectively. The medium-size filters MTFs are the closest
to the scanner’s MTF in the presence of motion. The larger-size filters are less affected by motion due
to their narrower bandwidth as shown in figure (3.16) and figure (3.17) where the 12x12mm2 filter’s
MTF50 and MTF10 are the same in static and in presence of motion.
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Fig. 3.17 The limiting resolution quoted in terms of MTF10 for the scanner and the LoG filters during
static and the moving acquisition.
3.4 Discussion and Conclusions
The aim of the experiment was to characterise the effects of respiratory motion on the resolution of CT
images and the consequent performance of the LoG filters. The characterisation of respiratory motion
effects on different size of LoG filters allowed the conceptualization of the optimal filter size to design
a voxel based texture mapping filter to continue this project. To do so, the MTF was measured for the
CT scanner and the LoG filters from data acquired during the static and the moving acquisition of an
in-house designed phantom (MUSS phantom). The MUSS phantom has a multi-spatial scale square
lattice to reflect a desired spatial heterogeneity.
The results from the experiment presented in this chapter supports the hypothesis of a degraded
imaging system resolution when respiratory motion is present. The MTF of the in-house implemented
LoG filters were measured using the FT and the SD method. The MTFLoG+scanner results showed that
the scanner’s resolution had affected the performance of the larger-size filters particularly in the high
frequency range. Also, MTFLoG+scanner calculations could have been affected by the region selection
process: to measure the MTFLoG+scanner, the ROI was selected manually which could have affected
the results. Moreover, the MTFLoG+scanner measurement could have been affected by image noise.
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Although the M( f ) was corrected for noise by subtracting the standard deviation of the Bg region
which is the the uniform PMMA phantom, the PMMA material is not completely homogeneous.
The MTF results for the LoG filters showed that the small-size LoG filters will cover a wider
spatial frequency range when compared to the larger filters. However, the frequency range covered
by small-size LoG filters is not fully achieved due to the limiting resolution of the scanner as shown
in figure (3.14a). When motion is present, the larger filters’ frequency range will get narrower as
shown in figure (3.15e). The medium-size filters appear to behave better and cover the frequency
range allowed by the MTF of the scanner when motion is introduced.
The LoG filter is a combination of a smoothing Gaussian filter for noise reduction and a Laplacian
for intensity changes detection, the filters with larger widths (larger sigma) will have a greater
smoothing effect which is in combination with the blurring due to motion will further blur the image.
The small-size filters’ performance was shown to be mostly affected by motion in comparison as
shown in figure (3.16) and figure (3.17). The medium-size filters appeared to cover the frequency
range allowed by the combined MTF of the scanner and respiratory motion. Based on the results
presented in this chapter, a medium-size filter will be mainly investigated in mapping tumour texture
as it will be discussed and presented in chapter (4) and chapter (5).
Chapter 4
Methodology For Optimised Volumetric
Voxel Based Texture Mapping
4.1 Introduction
The purpose of this chapter is to outline and explain the proposed methodology for producing
volumetric voxel based texture maps (3D-VTM). Details of the texture filter developed by the author
for optimally generating a tumour texture map to visually assess tumour heterogeneity is presented.
An investigation of the optimum method to quantise tumour images prior to texture analysis allowing
optimum texture information extraction is introduced.
4.1.1 Second Order Statistics Texture Analysis
Grey Level Co-occurrence Matrices
Second order textural features extracted from images account for the effects of the spatial location
of a pixel intensity relative to another. These features can be calculated using the grey level co-
occurrence matrix (GLCM) [61]. The GLCM provides spatial information and has been reported in
the literature to discriminate between normal and abnormal tissue [147][15]. Furthermore, Mattonen
et al. [98][99] reported textural features measured from GLCM to be significantly different for patients
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Fig. 4.1 Schematic diagram of coordinates planes and 2D displacement vectors.
Table 4.1 2D displacement angles in GLCM.
Direction (θ ) Displacement Euclidean Distance
0◦ ±(d,0) d
90◦ ±(0,d) d
45◦ ±(d,d) √2d
135◦ ±(-d,d) √2d
who experienced disease recurrence after receiving stereotactic ablative radiotherapy (SABR) for
NSCLC. I propose the use of GLCM to assess tumour heterogeneity on a voxel by voxel basis by
producing volumetric voxel based maps of the tumour image.
The GLCM Pθd (i, j) is a two dimensional (2D) histogram of grey values i and j. P
θ
d (i, j) specifies
the probability that a pixel with a grey level j is located at a distance d and direction θ from a pixel
with grey level i at a total of N grey levels. For analysis in 2D images, θ = 0◦,45◦,90◦,135◦ as seen
in figure (4.1) and table (4.1) [61]. The diagonal of the GLCM represents the probabilities that 2
neighbour pixels have the same grey value. A total of 14 textural features can be extracted from the
co-occurrence matrix as reported by [61] and listed in table (1.2) in chapter (1).
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Fig. 4.2 schematic diagram showing all 13 possible
direction of connecting voxels.
Fig. 4.3 Schematic diagram showing angles be-
tween spherical polar coordinates.
In this thesis, the traditional 2D GLCM was extended to three dimensional (3D) space to ac-
commodate the volumetric imaging data. To do so, the GLCM was calculated from the 3D volume
in 3 directions (x,y,z) as seen in figure (4.2). The displacement between voxels position will be
denoted as d(x,y,z). Given that a voxel is surrounded by 26 neighbouring voxels in the 3D space, the
displacement between voxels can be calculated in 13 directions. Using the Euclidean distance at d=1,
the displacements can be characterized using 2 angles; θ is the angle between the x and y plane and Φ
is the angle between the voxels of interest and the z plan as shown in figure (4.3). Φ is calculated
using equation (4.1). The displacement vectors for all 13 possible directions are summarized in table
(4.2).
CosΦ=
x1x2+ y1y2+ z1z2√
x21+ y
2
1+ z
2
1
√
x22+ y
2
2+ z
2
2
(4.1)
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Table 4.2 Volumetric angle displacement in 13 possible directions in GLCM calculation.
Direction (θ ,Φ) Displacement Euclidean Distance
(0◦,90◦) ±(d,0,0) d
(90◦,90◦) ±(0,d,0) d
(-,90◦) ±(0,0,d) d
(45◦,90◦) ±(d,d,0) √2d
(135◦,90◦) ±(-d,d,0) √2d
(90◦,45◦) ±(0,d,d) √2d
(90◦,135◦) ±(0,d,-d) √2d
(0◦,45◦) ±(d,0,d) √2d
(0◦,135◦) ±(d,0,-d) √2d
(45◦,54.6◦) ±(d,d,d) √3d
(135◦,54.6◦) ±(-d,d,d) √3d
(45◦,125.3◦) ±(d,d,-d) √3d
(135◦,125.3◦) ±(-d,d,-d) √3d
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4.2 Volumetric Voxel-based Texture Mapping
4.2.1 Voxel Based GLCM
Traditionally, GLCM is used as a single-value method where one GLCM is calculated for an image
and a single textural feature value is extracted from it. In this thesis, the GLCM method was extended
to 3D (x,y,z) and implemented as a voxel based method. The GLCM was calculated in 13 different
directions for each voxel in the tumour to generate a 3D voxel based map (3D-VTM). The textural
features were extracted from each voxel’s GLCMs and are then averaged and assigned to the voxel to
generate tumour texture maps. Three sizes of the GLCM neighbourhood region (filter size) in (x,y,z)
are proposed: 3x3x3 voxels (small), 5x5x3 voxels (medium) and 7x7x3 voxels (medium). Given that
the CT data are acquired where the slice thickness is a few mm thick, the smallest z which was 3
voxels is chosen for all filter sizes. Using a small neighbourhood region to calculate GLCM statistics
is arguably preferable to extract most textural information in the image. Yet, based on the results from
chapter (3), the small-size filter performance is hindered by the effects of respiratory motion. Thus, a
medium-size GLCM neighbourhood regions of (5x5x3 voxels) and (7x7x3 voxels) are suggested to
overcome noise and blurring due to respiratory motion. The GLCM neighbourhood region will not
filter the image, it will calculate the occurrences of intensity value pair within that region to create
the GLCM and then the feature can be calculated from it. For simplicity, the GLCM neighbourhood
region size is referred to as GLCM filter size in this thesis. This method was implemented in-house
using Matlab software (The MathWorks, Inc, Natick, MA).
Given that volumetric voxel-based texture mapping calculates textural information for each voxel
relative to its neighbours, edge voxels will not have enough neighbouring voxels for the analysis. For
this reason, the region of interest, was dilated in the 3D space by a dilation factor by voxels (dfv) as
presented in equation (4.2) where h is the filter size. This added margin was removed after the texture
map was produced.
d f v =
h−1
2
(4.2)
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4.2.2 Feature Extraction
Several textural features could be extracted from GLCM, yet based on the reviewed literature
[98][99][10] and the results from the study presented in chapter (2), entropy has shown the most
significant results in relation to patients’ outcome and overall survival. Textural features extracted
from images are a measure of the spatial variation in intensity which is a reflection of the information
content in the image. Measuring entropy (equation 4.3) is a robust method to characterise image
information [73]. In this study, entropy is proposed as a surrogate for texture to produce texture maps
representing image structure information. Entropy is a measure of disorder and it is suitable to assess
intratumoural heterogeneity.
Entropy =−
N
∑
i=1
N
∑
j=1
P(i, j)logP(i, j) (4.3)
4.2.3 Quantisation of Tumour Image Information
To reduce noise and computation power when using the GLCM method, the image region of interest
was quantised to N number of grey levels. This process involved 2 steps; the choice of the N levels
and the choice of quantisation method. These will be discussed in the following sections.
Quantisation Level N
Traditionally, the quantisation level N is commonly a power of two (8, 16, 32, 64, 128, 256) when
using the GLCM method. In previously published studies in texture analysis in relating textural
features to treatment outcome, the choice of the quantisation level was either set to the highest possible
number hypothesizing it will better encode the image information [48] or multiple N levels were
investigated to yield the best results [70]. In machine learning studies, a training data set is used to
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choose the quantisation level N that provides the best result for the required output [70]. In this thesis,
a novel method of choosing an optimum quantisation level is presented. In image information theory,
the image data are compressed into bits to reduce redundancy and represent the image without loss of
information. The information content in an image is given by equation (4.4) where p is the probability
of an event and in this case a grey level occurring in an image. Thus, to calculate the optimum number
of effective quantisation level N, I propose the use of log2 of the Region of Interest Intensity Range
(maxi−mini) as shown in equation (4.5). The maximum intensity value within the region of interest is
maxi while the minimum intensity value is mini. Although one might argue using the whole intensity
range to quantise the ROI in GLCM, the ROI contains statistical noise and blurring thus fluctuation in
voxels intensity values for the same tissue is expected; hence, quantisation is required.
I(p) = log2(p) (4.4)
Ne f f ective = ⌊log2(maxi−mini)⌋ (4.5)
Quantisation Methods
In previously published studies [10], uniform quantisation (UQ) was implemented to quantise the
image prior to texture analysis. Uniform quantisation scales the image IMG(x) based on the minimum
(mini), maximum (maxi) and the range of the intensity values i (maxi−mini+) within the tumour
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image as presented in equation (4.6) [73]. If IMG(x) = mini, V (x) is set to 1.
V (x) =
⌊
N× IMG(x)−mini
maxi−mini
⌋
(4.6)
I propose the use of optimum Lloyd Max quantisation (LMQ) method to quantise the ROI before
GLCM calculations. The LMQ is an iterative non uniform quantiser where multiple combinations of
transition levels tk and reconstruction levels rk are investigated to determine the optimal quantisation
level tL. The quantiser maps the continuous variable x into a discrete variable x
′
where the boundries of
the bins are determined by the transition levels tk and the value for the voxels assigned to the bins are
determined by the reconstruction levels rk. The decision of these levels are based on minimising voxel
to voxel mean square error ε as presented in equation (4.7), where tL is the investigated quantisation
levels and px(x) is a continous probability density function [73].
ε =
∫ tL+1
t1
(x− x′)2 px(x)dx (4.7)
Equation (4.7) is re-written as equation (4.8) where L is the investigated quantisation level.
ε =
L
∑
i=1
∫ ti+1
ti
(x− ri)2 px(x)dx (4.8)
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to minimise ε , it is differentiated in regards to tk and rk and the partial derivatives is set to zero.
∂ε
∂ tk
= (tk− rk−1)2 px(tk)− (tk− rk)2 px(tk) = 0 (4.9)
∂ε
∂ tk
= 2
∫ tk+1
tk
(x− rk)px(x)dx = 0, ..............1≤ k ≤ L (4.10)
Given tk−1 ≤ tk it leads to
tk =
(rk + rk−1)
2
(4.11)
rk =
∫ tk+1
tk xpx(x)dx∫ tk+1
tk px(x)dx
(4.12)
Equations (4.11) and (4.12) will be solved simultaneously to find the optimum transition levels tk
and reconstruction levels rk that minimize the ε between the original distribution x and the quantised
distribution x
′
. Equations (4.11) and (4.12) demonstrate that the optimum tk will be centrally located
between the optimum rk. This optimisation process was stopped when the mean squared error (MSE)
reached < 10−7 between iterations.
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4.3 Code Development
The volumetric voxel based texture mapping methodology proposed by the author in this chapter was
implemented in Matlab software (The MathWorks, Inc, Natick, MA) version R2012a by the author.
The code starts with segmenting the region of interest in 3D from the image. The same region of
interest is then segmented with an added margin by dilating the original region of interest using the
dilation factor by voxels. The Ne f f ective is then calculated from the original region of interest without
the added margin. The LMQ is then applied with a Ne f f ective number of bins, this will iteratively
search for multiple combinations of transition levels tk and reconstruction levels rk to minimise the
MSE between the original and the quantised image. The LMQ is stopped when the MSE reaches
< 10−7 between iterations. Once the optimised combinations of transition levels tk and reconstruction
levels rk are found, they are used to quantise the region of interest plus the added margin. The
volumetric voxel based texture mapping is then conducted on the quantised region of interest plus the
margin using the in-house written software by the author by iteratively taking each voxel in the region
of interest and calculating the GLCM between that voxel and the voxels in the 3D neighbourhood
region using a for loop. A total of 13 GLCMs are calculated for each voxels where the code written
by the author rotates the neighbourhood region in 13 different possible ways in the 3D space. From
each GLCM, entropy is calculated and then the value of the average entropy measured from the 13
GLCMs are assigned to the voxel of interest. Finally, the added margin is removed and the volumetric
voxel based map is saved in a mat. file. The code written by the author requires an average of 0.02
seconds per voxel for GLCM calculations on an Intel(R) Core(TM) i5-2500 CPU@3.30GHz.
4.4 Discussion
An optimised method and a framework to produce volumetric voxel based texture maps was presented
as shown in a flow diagram in figure (4.4). This 3D-VTM method allows the visualisation and
investigation of textural spatial variation within tumours. The proposed methodology suggests the
application of a spatial textural filter GLCM that has been proven in the literature to be able to
distinguish between different tissue types [98][99][147][15]. The size of the GLCM filter proposed
is based on the results from chapter (3) which shows that filter performance will be limited by the
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scanner resolution and the presence of motion, hence, a filter size that is larger than the scanner
resolution in the presence of motion is required.
An important step in conducting texture analysis is image quantisation. Tumour image quantisation
encodes the information content within the image which may significantly affects the texture analysis
results. The image quantisation consists of two steps, the quantisation method and choice of the
optimum quantisation levels. The texture analysis work published in medical imaging used a uniform
quantisation method where the image is quantised based on the minimum and maximum intensity
value within the image not considering where most of the intensity values reside within the image
histogram. I proposed the use of the optimum LMQ method and given the non-linearity of the LMQ
this will allow a better sampling of where most of the image information occurs. Previously published
work [48] investigated multiple quantisation levels of power two to report results without offering
an un-biased method to choose the optimum number of quantisation levels. In machine learning
approaches, all possible combinations of textural features and quantisation levels are investigated to
reach the desired results. Yet, to independently examine tumour texture, an optimised standardised
method is needed to avoid bias and that is what we presented in this chapter.
Furthermore, measuring tumour texture at the edge of the tumour image where there is a lack of
neighbouring voxels was not addressed in the literature. In this thesis, we suggest an added margin
equal to h−1/2 that we termed a dilation factor by voxels (dfv). Even though we choose to assess
tumour heterogeneity on a voxel basis by measuring tumour image entropy for reasons discussed in
section (4.2.2), our proposed methodology can be used to extract any other textural features and the
framework we presented can be adapted to use other textural filters.
4.5 Conclusions
The emerging proposition of texture analysis of tumour images as a biomarker for survival and local
control in the field of radiotherapy calls for a thorough investigation of tumour image texture. This
investigation requires the establishment of an un-biased independent standardised method to conduct
texture analysis on tumour images. In this chapter, we presented our proposed methodology to
generate volumetric voxel based texture maps of tumour images to visualise and assess the spatial
variation of heterogeneity within tumour images. The implementation of our method on patients
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tumour images and the relation of the produced 3D-VTMs to tumour function will be presented in the
next chapter. In chapter (5), we will also evaluate the benefits of our proposed methodology over the
standard methods.
4.5 Conclusions 105
Fig. 4.4 A flow chart of our proposed methodology.

Chapter 5
CT Volumetric Voxel Based Texture
Mapping and 18F-FDG Uptake
Distributions
5.1 Introduction
Work published in the literature in recent years has shown evidence that tumour image texture
correlates with patients survival [10]. Furthermore, entropy measured from tumour CT images has
been shown to correlate with patients survival [51][52][102][53][42][55][54][56], and see also chapter
(2). A deeper understanding of tumour CT image entropy and its relationship to the physiology of
the tumour is much needed. In the previous chapter (chapter 4) I presented our novel optimised
method to measure and visualise tumour image texture on a voxel by voxel basis which provides
information about the textural spatial variations within the tumour image. This chapter presents the
implementation of the proposed volumetric voxel based texture maps (3D-VTM) methodology.
3D voxel based heterogeneity maps were generated and analysed for ten patients diagnosed
with non-small cell lung carcinoma (NSCLC) and presented in this chapter. We also evaluate
the value of our proposed optimised quantisation algorithm over the standard approach. We then
present a quantitative comparison of 3D-VTMs with tumour 18F-fluoro-deoxy glucose (18F-FDG)
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uptake distributions from PET scans to assess the relationship between CT intratumoural textural
heterogeneity and tumour function measured as glucose metabolism. In this chapter, we present
the first evidence that CT intratumoural heterogeneity measured from 3D-VTM provides potentially
useful information on biological variations.
5.2 Methods
5.2.1 Patients Cohort
Data for a group of ten patients diagnosed with advanced NSCLC between years 2009-2012 were
collected retrospectively. This group of patients had been treated with radical radiotherapy for primary
tumours ranging in size from 34 to 372cm3, with a mean of 135.4cm3. Patient characteristics are
summarised in table (5.1). This study obtained local ethics approval from the Royal Surrey County
Hospital NHS Foundation Trust.
The patients investigated in this study can be divided into two sub-groups; those diagnosed with
necrotic tumours and those whose tumours were not necrotic. Fast growing solid tumours cannot
fulfil the metabolic needs of the growing tumour, thus part of the tumour will lack blood supply
which induces hypoxia (lack of oxygenation). Hypoxia has been associated with tumour resistance to
treatment and poor prognosis [108]. This state of hypoxia will eventually lead to tumour necrosis;
tumour tissue that lacks functionality [103][114][104]. The relationship between hypoxia and 18F-
FDG uptake is complex and contradicting results have been published in the literature on whether
18F-FDG uptake correlates to tumour hypoxia. It has been reported that hypoxic tumour requires
more glucose leading to a higher 18F-FDG uptake within the tumour. However, conflicting results
have been reported on whether there is an overlap between hypoxic regions and high 18F-FDG uptake
regions [90]. Given that a prolonged state of hypoxia will eventually lead to necrosis, tumours can
progress from having a high-density, high-metabolism, high 18F-FDG core (brightest at the centre
on PET), to having a low 18F-FDG necrotic core with surrounding shell of 18F-FDG avid cells (a
bright ring surrounding dark centre on PET). A non 18F-FDG avid region within the tumour could
indicate lack of disease, hypoxic region or could indicate that disease has progressed to the point
of necrosis. Necrotic areas may include or be adjacent to areas containing chronically hypoxic but
5.2 Methods 109
Table 5.1 Patients characteristics of the group of ten patients investigated in this study. The patients
are divided into two sub-groups; those diagnosed with non-necrotic tumours (1-5) and those whose
tumours were necrotic (6-10), each sub-group was ordered by tumour size. (SCC=squamous cell
carcinoma, Adeno=adenocarcinoma)
Pt.no Age Gender TNM Stage Tumour Size cm3 Histology 18F-FDG Distribution
1 83 Male T2N0M0 34.7 SCC Homogenous
2 74 Male T2N1M0 37.4 SCC Intense Homogenous
3 51 Male T2N1M0 52.7 Adeno Homogenous
4 66 Male T2N2M0 55.4 Adeno Homogenous
5 59 Male T2N2M0 152.5 SCC Homogenous
6 76 Male T3N0M0 71.5 SCC Heterogeneous necrosis/hypoxic
7 70 Male T2aN2M0 113.5 SCC Cavitated + necrosis/hypoxic
8 61 Female T3N2M0 123.6 SCC Patchy Heterogeneous/hypoxic
9 69 Male T4N2M0 339.9 SCC Heterogeneous necrosis/hypoxic
10 52 Male T3N2M0 372.8 SCC Heterogeneous with necrosis/hypoxic
still viable tumour cells, and it is impossible to clearly demarcate the transition [59]. Hypoxic and
necrotic tissues are identified by the lack of 18F-FDG uptake within the solid tumour and a decrease
in CT Hounsfield units (HU) in comparison to the other regions of the tumour. An example of a
hypoxic/necrotic region from one of our cohort’s PET/CT images is shown in figure (5.1).
5.2.2 Image Acquisition
All ten patients underwent a radiotherapy planning CT scan in addition to a non-contrast CT scan
on a 18F-FDG PET/CT scanner; these data were collected retrospectively for analysis. I denote
the planning CT scan by CTplan, and the CT component of the PET/CT scan as CTPET. For the
CTplan, a GE LS RT16 scanner (GE Healthcare, UK) was used with 120kVp and 331mAs acquisition
parameters. The reconstructed transaxial image size was 512x512 with 0.98x0.98x2.5mm3 voxel
size. The reconstruction algorithm was Filtered Back Projection (FBP). The patients underwent
the radiotherapy planning CT 55 days (mean) after the PET/CT scan. The PET/CT images were
acquired using a GE Discovery LS scanner (GE Healthcare, UK); images were reconstructed using
an Ordered Subset Expectation Maximisation (OSEM) algorithm for PET and FBP for CTPET. The
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Fig. 5.1 (a) Fused 18F-FDG PET/CT image showing a hypoxic/necrotic region within the tumour. (b)
The corresponding CT image. (c) The corresponding 18F-FDG PET image.
acquisition parameters for CTPET were 150kVp and 100mAs. The reconstructed transaxial image
size was 512x512 with 0.98x0.98x5.00mm3 voxel size for the CTPET images and 128x128 image size
with 3.91x3.91x5.00mm3 voxel size for the PET images. The injected activity for 18F-FDG PET
imaging was 400±40 MBq. The 18F-FDG PET images were converted to SUV maps by multiplying
the uptake in each voxel (Bq ml−1) by the patient’s weight divided by the decay-corrected injected
activity [164].
5.2.3 Region of Interest Segmentation
The primary tumour was segmented from the CTPET and 18F-FDG PET images to generate the 3D-
VTMs as the CTPET and 18F-FDG PET images have been acquired at the same time point; this will
enable a meaningful comparison between 3D-VTMs and 18F-FDG uptake distributions. To segment
the primary tumour, which is represented by gross tumour volume (GTV), the GTV contour [2]
delineated by a consultant radiation oncologist was transfered from CTplan to the PET/CT scan. This
was carried out by registering the CTplan and CTPET scans using a B-spline deformable registration
method [122].
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5.2.3.1 Image Registration
To segment the primary tumour represented by the GTV from the CTPET and the 18F-FDG PET
images, the CTPET was registered to the CTplan. The obtained transformation matrix was then applied
to the 18F-FDG PET images where the GTV was segmented from the PET images to segment the
GTV from the 18F-FDG PET images and consequently allow the comparison between the produced
3D-VTMs and 18F-FDG uptake distribution. CTplan and the PET/CT scan were both obtained with
patients arms up, yet the CTplan was conducted on a flat table while the CTPET table was curved.
The registration process included two steps; an intitial rigid registration step and then a deformable
registration step. Rigid registration was initially performed to align the images centers and linearly
interpolate the image size as descriped in [45]. Deformable registration was then carried out using
B-spline method [116][122]. A detailed description of B-spline deformable registration is presented
in appendix (B). The Plastimatch C++ library was used to conduct the registration process [122].
Validation of Image Registration
The image registration results were validated by obtaining a difference image between the CTplan and
the registered CTPET. Given the CTPET and the 18F-FDG PET images are obtained at the same patient
position at the same time points, the two scans are already registered. A qualitative assessment of the
registered scans and the difference images was carried out by an experienced consultant radiologist
(VP) and the author. The lack of structure in the difference image indicates a good registration.
Very small structure in the difference image away from where the tumour occurred was considered
acceptable since it is away from the region of interest. The work flow of the deformable registration
process is presented in figure (5.2) using images from our patients cohort.
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5.2.3.2 Generating Volumetric Voxel Based Texture Maps
Volumetric Voxel Based Texture Maps (3D-VTMs) were generated for the tumours segmented from
the CTPET using our proposed methodology presented in chapter (4). Prior to tumour segmentation,
the primary tumour volume (GTV) was dilated by the dilation factor dfv (refer to equation (4.2)).
The tumour volume was quantised using the standard uniform quantisation (UQ) method used in the
published literature and our proposed optimum LMQ quantiser. Different quantisation levels N were
investigated; using our proposed method of log2 of Tumour Intensity Range and using the traditional
power of 2 quantisation levels (8, 16, 32, 64, 128, 256) for both of the quantisation methods. The three
proposed GLCM filter sizes (3x3x3 voxels, 5x5x3 voxels and 7x7x3 voxels) were implemented and
used to generate the 3D-VTMs. As discussed before in (4.2.2), to assess intratumoural heterogeneity,
local entropy (entropy per voxel) was calculated from each GLCM per voxel and assigned to that
voxel to generate the 3D-VTMs.
5.2.4 Comparison with 18F-FDG Uptake Distributions
The SUV maps generated from the tumour 18F-FDG distribution were thresholded to 34%, 40%, 50%,
60%, 70% and 80% of SUVmax (these volumes were labelled SUV34, SUV40, SUV50, SUV60,
SUV70, and SUV80). The thresholded SUV maps were overlaid on the produced texture maps to
investigate the relationship between 18F-FDG uptake and CT intratumoural hetrogeneity. The 34%
threshold of SUVmax has been used as the minimum threshold as previous studies have validated this
threshold for tumour delineation in PET imaging for lung tumours [141][5]. The Overlap Fraction
(OF) and Dice Similarity Coefficient (DSC) were calculated to quantify the overlap and the similarity
of the 18F-FDG distribution and CT intratumoural spatial heterogeneity. OF is calculated as the
overlap volume divided by the SUV threshold volume as shown in equation (5.1). DSC is twice the
overlap volume divided by the sum of the two volumes of interest as shown in equation (5.2) [4][73].
To test the validity of the findings, the 3D-VTMs images were rotated by 45◦ and the DSC was
re-calculated. In this case the coefficient should decrease substantially. Furthermore, the DSC between
the primary tumour GTV contour and SUV threshold values were calculated to test the sensitivity of
our proposed method. To assure the registration did not affect the analysis, a 3D-VTM was produced
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for a patient from our cohort from the un-registered CTPET, the OF and DSC were calculated between
the produced 3D-VTM and the 18F-FDG uptake from the original PET scan.
OF =
Vol1∩Vol2
VolSUV
(5.1)
DSC =
2× (Vol1∩Vol2)
Vol1+Vol2
(5.2)
5.3 Results
5.3.1 Image Registration
A difference image between the CTplan and the registered CTPET for each of the ten patients is
presented in figure (5.3). As seen in figure (5.3), there is lack of structure (image mostly uniform) in
the difference image which indicates a good registration. There is a little structure (bright area) where
the scanner couch is and that is due to the fact that the PET/CT was conducted on a curved couch
where as, the CTplan was conducted on a flat couch. Yet, in the region where the tumour is located,
the registration algorithms performance is considered acceptable.
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Fig. 5.3 Difference image between the static and
the registered image.
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5.3.2 Tumour Image Quantisation
The range of the intensity values within the segmented tumours was 970-1788 Hounsfield units (HU)
with a mean of 1357 HU. Using log2 Tumour Intensity Range, the optimum quantisation level of
power two is 8 levels. The histograms calculated from using the UQ and LMQ methods to quantise
the tumour image for two patients from the investigated cohort are presented in figure (5.4) and
figure (5.5). Figure (5.4 a) and figure (5.5 a) are the normalised histograms using the whole intensity
range within the tumour. The LMQ method optimises the transition tk and reconstruction levels rk to
minimise the MSE between the original and the quantised histogram. Whilst the UQ method will
uniformly assign the intensity values between the maximum and minimum of the image intensity
range. The histograms calculated by using the UQ and LMQ methods to quantise the tumour image
using the optimised quantisation level 8 are presented in figure (5.4 b) and figure (5.5 b). When
the tumour image was quantised to 8 levels, the UQ method led to most of the information in the
image to be deposited in one bin whilst the LMQ method allowed a better representation of image
information as shown in figure (5.4 b) and figure (5.5 b). As the quantisation level increases to 16, the
two histograms generated from the UQ and LMQ methods started to be more similar. The similarity
between the two methods histograms increased with increasing the quantisation level until they looked
almost identical at quantisation level 256 as seen in figure (5.4 c-d) and figure (5.5 c-d).
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Fig. 5.4 An example of tumour image normalised histograms at different quantisation levels N. (a) Is
the normalised histogram using the original intensity range within the tumour without quantisation.
(b) Is the normalised histogram using 8 quantisation levels. (c) Is the normalised histogram using 16
quantisation levels. (d) Is the normalised histogram using 32 quantisation levels. (e) Is the normalised
histogram using 64 quantisation levels. (f) Is the normalised histogram using 128 quantisation levels.
(g) Is the normalised histogram using 256 quantisation levels.
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Fig. 5.5 An example of tumour image normalised histograms at different quantisation levels N. (a) Is
the normalised histogram using the original intensity range within the tumour without quantisation.
(b) Is the normalised histogram using 8 quantisation levels. (c) Is the normalised histogram using 16
quantisation levels. (d) Is the normalised histogram using 32 quantisation levels. (e) Is the normalised
histogram using 64 quantisation levels. (f) Is the normalised histogram using 128 quantisation levels.
(g) Is the normalised histogram using 256 quantisation levels.
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5.3.3 3D Voxel Based Texture Maps
Figure (5.6) shows the produced 3D-VTMs for the segmented tumour using the standard uniform
quantisation method for a patient from the investigated cohort using different quantisation levels.
Figure (5.7) shows the produced 3D-VTMs for the segmented tumour using our proposed LMQ
method for the same patient using different quantisation levels. As shown in figure (5.7), using the
optimised quantisation level (N=8) in combination with the optimum LMQ method led to a clear
textural pattern within the 3D-VTM while increasing the quantisation levels did not. Furthermore, as
shown in figure (5.6), using the standard uniform quantisation method did not yield any noticeable
textural pattern at any of the investigated quantisation levels.
The produced 3D-VTMs using our proposed optimised quantisation method at the three inves-
tigated filter sizes are presented in figure (5.8) for one of the patients from this study cohort. As
hypothesized, the small-filter size (3x3x3 voxels) will lead to a noisier texture map as shown in (5.8 a)
while the larger-size (7x7x3 voxels) filter will have more smoothing effect as shown in figure (5.8
c). The 3D-VTMs produced from the medium-size filter (5x5x3 voxels) were used to continue the
analysis of the maps. Given the slice thickness of the CT image is 2.5mm, the medium filter size in
mm will be 5x5x7.5mm3.
Figure (5.9), presents examples of the generated 3D-VTMs for three of the ten patients with
different imaging characteristics. Patient 4 had a small tumour with homogeneous 18F-FDG uptake,
Patient 7 had a medium-sized tumour with necrotic centre, and Patient 10 had a large tumour exhibiting
heterogeneous 18F-FDG uptake with necrotic regions. Figure (5.9 a) shows the 18F-FDG PET/CT
images with the delineated GTV contour used to segment the primary tumour region. When generating
the 3D-VTMs using the uniform quantisation method, most of the CT tumour information was scaled
into a single bin which leads to a limited amount of information as shown in Figure (5.9 b). Figure
(5.9 c) is the 3D-VTM generated using the optimum LMQ method allowing a better sampling of
the intensity range within the tumour which led to a clear textural pattern. Areas of low entropy
value (dark) represent homogeneous regions where brighter areas of high entropy values represent
heterogeneous regions. The 18F-FDG uptake distribution is shown in Figure (5.9 d). From visual
inspection of Figure (5.9 c,d), there is a clear visual overlap between low entropy (zero entropy) and
high 18F-FDG uptake.
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(a) Delineated Tumour
(b) N=8 (c) N=16 (d) N=32
(e) N=64 (f) N=128 (g) N=256
Fig. 5.6 An example of a 2D slice from the produced 3D-VTM using the UQ method for Patient 10
with different quantisation levels N.
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(a) Delineated Tumour
(b) N=8 (c) N=16 (d) N=32
(e) N=64 (f) N=128 (g) N=256
Fig. 5.7 An example of a 2D slice from the produced 3D-VTM using the LMQ method for Patient 10
with different quantisation levels N.
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(a) Filter size=3x3x3 voxels
(b) Filter size=5x5x3 voxels
(c) Filter size=7x7x3 voxels
Fig. 5.8 An example of a 2D slice from the produced 3D-VTM using the LMQ method for Patient 10
at different filter sizes.
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5.3.4 Comparison with 18F-FDG Distribution
The results for assessing the degree of correlation between regions of zero entropy and 18F-FDG
distribution by calculating OF and DSC are presented in figure (5.10). The OF and DSC results show
that regions with high 18F-FDG uptake (≥50% SUVmax) correlate with zero entropy regions. The
correlation between ≥50% SUVmax volume and zero entropy region is as high as 84% for OF and
75% for DSC. The results presented in figure (5.10 a) shows a clear trend of an OF increase as the
SUV threshold increases in 9 of the 10 patients (Patient 10 is an outlier). The mean OF between zero
entropy regions and SUV34 for the 9 patients is 53±15%. The mean OF gradually increases to reach
65±12% at SUV50 and 86±20% for SUV80, indicating the high SUV regions (≥50% of SUVmax)
are encompassed within the zero entropy regions while the SUV34 region is extending outside the
zero entropy region.
The DSC between zero entropy regions and 18F-FDG distributions in figure (5.10 b) shows an
interesting trend where tumours having a homogeneous 18F-FDG uptake (solid lines in figure (5.10
b) as stated in table (5.1) had a DSC peak around SUV50 with a mean of 60±11% and then decreased
to reach a mean of 25±25% for SUV80, whilst tumour volumes expressing a heterogeneous 18F-FDG
uptake with necrotic regions (dashed line in figure (5.10)) had the highest DSC for SUV34 with a
mean of 53±10% and continued to decrease as the SUV threshold volume increased.
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Fig. 5.10 (a) The Overlap Fraction between regions of zero entropy within the GTV and SUV for
different SUV% thresholds. b) The DSC between regions of zero entropy within the GTV and SUV
for different SUV% thresholds. Solid lines are patients with homogeneous 18F-FDG distribution
within tumours while dashed lines are patients with heterogeneous necrotic tumours.
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For Patient 10, the OF between zero entropy region and high 18F-FDG region fell to 30% even
though the high SUV regions occur in the vicinity of zero entropy region as was shown in figure (5.9).
The discrepancy between zero entropy region and 18F-FDG uptake for Patient 10 occurs mostly in
the inferior part of the tumour. Figure (5.11) illustrates 2 slices as examples from the inferior part of
the tumour for patient 10 where the discrepancy between the 3D-VTM and 18F-FDG uptake occurred.
This discrepancy is due to the necrotic region in the tumour where there is a minimal 18F-FDG uptake
yet the 3D-VTM recognises the necrotic region as part of the tumour as seen in figure (5.11 a2) and
(5.11 a3). Based on discussions with the consultant nuclear medicine radiologist (VP), the large mass
on the CT image shown in figure (5.11 a1) which has low 18F-FDG uptake (figure (5.11a2)) could be
attributed to either collapsed lung or necrotic tissue. In this case, the location of the non 18F-FDG
avid mass on CT and the density changes measured in HU across this mass suggests this part of the
tumour is hypoxic/necrotic. This explains the observed trend in DSC in figure (5.10 b) between zero
entropy region and 18F-FDG distribution for necrotic tumours with heterogeneous 18F-FDG uptake.
The 3D-VTM recognises the necrotic/hypoxic regions in the solid mass as part of the tumour while
the 18F-FDG uptake is minimal as demonstrated in Figure (5.11 a).
Furthermore, for Patient 10, the delineation of the GTV included a part of the liver to accommodate
the extent of the tumour as explained by the consultant radiation oncologist (VE). This is shown in
figure (5.11 b1); this region appears homogeneous with zero entropy in the 3D-VTM which introduces
a bias in the OF and DSC results.
The validity of the findings was tested by rotating the 3D-VTMs 45◦ and re-calculating the DSC
between zero entropy regions and differently thresholded regions of SUVmax. The DSC values
decreased greatly to below 10−3 indicating the strength of the correlations observed. Moreover, the
DSC between the primary tumour contour and the SUVmax thresholded regions was highest for
SUV34 with a mean of 53±10% and continued to drop without the peak previously observed for the
zero entropy region for all the patients. The mean DSC between the primary tumour contour GTV
and SUV50 was 36±10%.
The 3D representation of the overlap between GTV, zero entropy region and ≥50% SUVmax
region for the ten patients investigated in this study is presented in figure (5.12) and figure (5.13).
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Fig. 5.11 Two examples of 3D-VTM performance from Patient 10 PET/CT scan (A) Demonstrates the
performance of the 3D-VTM in the case of necrotic tumour tissue. (B) Illustrates the implication of
including normal homogeneous structures within the GTV. (1) Is the CTPET image, (2) is the 18F-FDG
uptake distribution, and (3) is the produced texture map using the proposed LMQ method.
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Fig. 5.12 The 3D representation of the GTV, zero
entropy volume and SUV≥50% volume demon-
strating the overlap between them for patients char-
acterized with a homogeneous 18F-FDG uptake.
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Fig. 5.13 The 3D representation of the GTV, zero
entropy volume and SUV≥50% volume demon-
strating the overlap between them for patients char-
acterized with a heterogeneous 18F-FDG uptake.
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5.3.5 Registration and 3D-VTMs
To ensure the registration did not have a large effect on our results, a 3D-VTM was generated from
the unregistered 18F-FDG PET/CT scan for one patient from our cohort. The GTV was delineated on
the CTPET by a trained observer (the author) using the contour from the CTplan as a guide. The results
for the DSC analysis for the registered and unregistered 3D-VTM are presented in table (5.2). The
results in table (5.2) indicates that the registration didn’t affect the similarity between zero entropy
region and SUVmax thresholded regions, the mean difference was 0.7±0.6. The OF analysis between
the unregistered 3D-VTM and 18F-FDG uptake are presented in table (5.3). The mean difference
between the OF for the registered and un-registered 3D-VTM and the different thresholded SUV
regions was 2.6±1%. The results in table (5.2 and 5.3) show the registration had a minimal effect on
the DSC and OF.
Table 5.2 Dice Similarity Coefficient (DSC) for Patient 8.
SUV Threshold Percentage Registered 3D-VTM Unregistered 3D-VTM
34% 57.0% 57.0%
40% 54.0% 54.0%
50% 46.1% 46.7%
60% 30.4% 32.4%
70% 15.3% 16.3%
80% 6.1% 5.7%
Table 5.3 Overlap Fraction (OF) for Patient 8.
SUV Threshold Percentage Registered 3D-VTM Unregistered 3D-VTM
34% 66% 65%
40% 68% 66%
50% 72% 69%
60% 76% 73%
70% 80% 76 %
80% 80% 77%
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5.4 Discussion
The growing interest in utilising texture analysis to predict tumour response to treatment is likely to
benefit from a deeper understanding of tumour texture. To date, the published studies in quantifying
tumour texture in relation to treatment response and patient survival are based on single-value texture
analysis methods. These methods are based on extracting a single value for textural features from the
tumour volume and testing possible correlations. Moreover, an optimum method of quantising tumour
images prior to texture analysis which is crucial in measuring texture is not presented in previously
published studies.
In this study, I presented a novel method of producing a visual 3D-VTM from CT tumour images
using a designed optimised quantisation method where the benefit of this quantisation method is
clearly presented in addition to the significance of the produced texture maps. The non-linearity of
the proposed LMQ method allows a better sampling of where most of the intensity values (HU) exist
whilst the standard uniform quantisation method does not. Our results showed a clear CT textural
pattern within the solid tumour using our algorithm. The results highlight the significance of optimised
quantisation of tumour volume in texture analysis which has not been addressed in previous studies
in this field. Furthermore, the presented method in this study does not require a machine learning
approach to optimise parameters and achieve the presented results.
Our results show regions with zero entropy value within the primary tumour correlate with high
18F-FDG uptake regions where as the primary tumour contour did not. Factors such as mis-registration
and respiratory motion could cause some discrepancies between the 3D-VTMs and the 18F-FDG
distribution. Yet, the presented OF and DSC results shows a good agreement between the high SUV
and zero entropy regions where the high SUV regions are mostly encompassed by the zero entropy
regions. In addition, our OF and DSC results based on unregistered CT scans and the correlation
between tumour local entropy and 18F-FDG distribution demonstrates how the registration effect was
minimal.
Furthermore, as shown in figure (5.11 a) our proposed 3D-VTM method has the promising
potential to detect necrotic tissue within the tumour where there is a lack of 18F-FDG uptake. This
potential of our method to detect parts of the tumour that are non 18F-FDG PET avid has significant
implications in the field of radiation oncology. Since the distinction between hypoxic and necrotic
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tissues in 18F-FDG PET/CT is not possible, there could be a possible benefit of dose escalation to
those hypoxic/necrotic regions given the possibility of viable tumour cells within hypoxic/necrotic
regions. Hence, to extract the maximum information from tumour images, the combination of the
3D-VTM and PET and CT images may be needed. Furthermore, CT images are routinely acquired for
cancer patients in diagnosis, staging, radiotherapy planning and follow up; establishing a standardised
CT based texture analysis method has the potential to be highly beneficial.
In the next chapter, I present the application of my method in dose painting in radiotherapy. In chapter
(6), I present the results of a dose escalation radiotherapy planning study to regions with zero entropy
within the tumour image in comparison to dose escalation based on regions of high SUV (≥50%SUV)
and the combination of both volumes. I also compare the dose escalation planning studies to the
current standard of uniform dose planning.
5.5 Conclusion
Our study presents a method to generate a visual 3D map of variations in CT image texture within
a tumour using an optimised quantisation method to visualise the textural contents within tumours
without the use of machine learning techniques. The preliminary results of implementing our proposed
3D-VTM method show a clear textural pattern within CT tumour images correlating to tumour glucose
metabolism and hypoxic/necrotic region detection suggesting valuable information from tumour CT
texture analysis, particularly for hypoxic/necrotic tumours. Using our presented method to visualise
tumour texture could have multiple applications in radiotherapy especially in dose boosting which
could provide information that complements the conventional CT images and functional images.
Chapter 6
Radiotherapy Planning Based on
Functional Imaging and Texture
Analysis
6.1 Introduction
Patients diagnosed with advanced non-small cell lung carcinoma (NSCLC) have poor prognosis,
with five years survival at <10% despite the application of new radiotherapy techniques [26]. In
recent years, targeting regions within the tumour with a higher radiation dose based on the biological
properties of the tumour has been suggested to improve local control in aggressive cancer types
[16][6]. This technique is called dose painting. Given that 18F-FDG PET is widely used in cancer
imaging and studies have shown a correlation between high 18F-FDG uptake regions and treatment
resistance, it has been suggested to escalate the radiation dose to high 18F-FDG uptake regions within
the tumour [6][5]. The results we presented in chapter (5) show a good agreement between areas of
low CT heterogeneity (zero entropy) and high 18F-FDG uptake in tumour. Consequently, CT texture
mapping could be used to define regions for dose escalation in NSCLC. Furthermore, the presented
results showed that the 3D-VTMs may detect necrotic/hypoxic regions within the tumour that are non
18F-FDG avid. Thus, dose escalation to these necrotic/hypoxic regions could be beneficial due to the
possibility of viable tumour cells within these regions.
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In this chapter, I present the application of the 3D-VTMs method in guiding dose painting by
contours (simultaneous integrated boost) in NSCLC. I conducted a study comparing simultaneous
integrated boost (SIB) radiotherapy plans to uniform dose plans for patients diagnosed with advanced
NSCLC. The boost volumes were identified based on: i) CT intratumoural spatial heterogeneity
obtained from the 3D-VTMs, ii) 18F-FDG uptake distribution within the tumour, and iii) the combi-
nation of both. The SIB plans were compared against each other and against a uniform dose plan in
regards to clinical feasibility and conforming to normal tissue dose constraints. The main aims of this
study were as follows:
• To evaluate the feasibility of dose escalation in advanced NSCLC while keeping normal tissue
dose within the acceptable limits.
• The possibility of delivering an adequate dose to the high 18F-FDG uptake regions by planning
based on the 3D-VTMs.
• To investigate the feasibility of dose boosting based on the combined information from the
3D-VTMs and the tumour’s 18F-FDG uptake.
This was achieved by the following steps:
• Creating a dose optimisation template; includes upper and lower radiation dose limits to target
volumes and normal tissue. This template was used to create the uniform dose plans and the
SIB plans.
• Using the optimised template, a uniform dose plan of 64Gy in 32 fractions (the standard current
practice) for ten patients diagnosed with advanced NSCLC was created.
• Delineation of three boost volumes based on tumour CT image entropy, 18F-FDG uptake
distribution and the combination of both.
• Using the optimised template, for each of the three boost volumes, a SIB plan was created to
deliver 84Gy to the boost volumes and 64Gy to the remaining planning target volume (PTV) in
32 fractions for the same ten patients.
• An analysis of the four treatment plans created was conducted.
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Table 6.1 Patients characteristics of the group of ten patients investigated in this study. The patients
are divided into two sub-groups; those diagnosed with non-necrotic tumours (1-5) and those whose
tumours were necrotic (6-10), each sub-group was ordered by tumour size. (SCC=squamous cell
carcinoma, Adeno=adenocarcinoma)
Pt.no Age Gender TNM Stage Tumour Size cm3 Histology 18F-FDG Distribution
1 83 Male T2N0M0 34.7 SCC Homogenous
2 74 Male T2N1M0 37.4 SCC Intense Homogenous
3 51 Male T2N1M0 52.7 Adeno Homogenous
4 66 Male T2N2M0 55.4 Adeno Homogenous
5 59 Male T2N2M0 152.5 SCC Homogenous
6 76 Male T3N0M0 71.5 SCC Heterogeneous necrosis/hypoxic
7 70 Male T2aN2M0 113.5 SCC Cavitated + necrosis/hypoxic
8 61 Female T3N2M0 123.6 SCC Patchy Heterogeneous/hypoxic
9 69 Male T4N2M0 339.9 SCC Heterogeneous necrosis/hypoxic
10 52 Male T3N2M0 372.8 SCC Heterogeneous with necrosis/hypoxic
6.2 Methods
6.2.1 Patients Data
The data from the patient cohort investigated in chapter (5) were used in this study. The patient cohort
included ten patients diagnosed with inoperable advanced NSCLC (T2-T4, stage II-III). As previously
presented in chapter (5), the investigated patient characteristics are summarised in table (6.1). This
group of patients had received chemo-radiotherapy in the Royal Surrey County Hospital between
year 2009-2012. The data from the radiotherapy planning CT scan, and the PET/CT scan for the ten
patients were collected retrospectively. The planning CT scan is labelled (CTplan) and the CT part of
the PET/CT scan is labelled CTPET. For details of image acquisition parameters for the planning CT
scan and the PET/CT scan please refer to (5.2.2). The generated 3D-VTMs in chapter (5) for this
group of patients were used in this study. This study obtained local ethics approval from the Royal
Surrey County Hospital NHS Foundation Trust (RSCH).
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6.2.2 Treatment Planning Study
The radiotherapy contours [2] as delineated by a consultant radiation oncologist (VE) were transferred
from CTplan to the PET/CT scan by registering the CTplan and CTPET scans using a B-spline deformable
registration method [122]. For a detailed description of the registration process, please refer to
(5.2.3.1).
To create the treatment plans, firstly, uniform dose plans of 64Gy in 32 fractions were created
for the ten investigated patients. The PTV for the uniform dose plan was already delineated by the
radiation oncologist. For the boost plans, the boost volumes were first identified and then a margin was
added to create the boost planning target volumes. The prescribed dose in the boost plans was 84Gy
to the boost volume and 64 Gy to the remaining PTV in 32 fractions. The organs at risk (OAR) dose
constraints for the uniform dose plans and the boost plans were decided based on the local clinical
protocol of the RSCH which is based on published literature and guidelines [86][49][82][152][95][96]
as will be discussed in the following sections. These organs at risks are spinal cord, oesophagus,
normal lung (both lungs-CTV), and heart. Although the bronchial tree is not an established OAR
for the 64Gy in 32 fractions radiotherapy course or for boosting in lung cancer, I investigated the
tolerance dose to the bronchial tree given the high dose escalation in the boost plans. A detailed
description of the treatment planning methodology is presented in the following sections.
6.2.2.1 Uniform Dose Plans
The CTplan scans for the ten investigated patients combined with the radiotherapy contours were
imported into the treatment planning system (TPS) Eclipse version 13.6 (Varian Medical Systems,
Palo Alto, USA) at the RSCH. For the uniform dose plan, the dose was prescribed to the original
planning target volume (PTVprimary_UnCrop) as delineated by the consultant oncologist (VE). The
PTVprimary_UnCrop includes the radiologically visible primary tumour known as the gross tumour
volume (GTV) plus a 0.5cm margin to account for microscopic disease extension (clinical target
volume (CTV)) and a 1cm around the CTV to account for setup uncertainties. These margins are
based on the RSCH local protocol; the CTV margin is not necessarily isotropic and it can be adjusted
based on clinical judgement. Given that the investigated patient cohort had central tumours, the
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PTVprimary_UnCrop was cropped 10mm away from the spinal cord (SC) and 3mm away from the
oesophagus to avoid high dose to these structures. The new target volume is labelled as PTVprimary.
The uniform dose plans were created by the author under the supervision of the head of radio-
therapy dosimetry in the RSCH (CS). Using volumetric modulated arc therapy (VMAT) planning
technique, two half arcs were used to create the VMAT plans with a prescribed dose of 64Gy in
32 fraction (the current standard practice) to the PTVprimary for the ten investigated patients. An
optimisation planning template was created by setting the tolerance dose to the organs at risk (OARs)
and the prescribed dose to the PTVprimary. The dose constraints to the OARs were set according to
the local protocol of the RSCH. The protocol is derived from published guidelines and literature
[86][49][82][152][95][96]. Table (6.2) presents the dose constraints used in this study.
The optimisation planning template was iteratively adjusted on using two of the ten investigated
patients and once an acceptable plan was created using the template, the optimised template was used
to create the plans for the rest of the patient cohort. The algorithm used for dose calculation was
Analytical Anisotropic Algorithm (AAA) version 11.0 and the optimisation algorithm was Photon
optimiser version 13.6. These algorithms are implemented in the TPS and a detailed description is not
publicly available by the software manufacturer.
Table 6.2 The dose constraints to organs at risk used in this study.
Organ Volume Constraints
Spinal Cord 0% Dose <45Gy
Oesophagus 0.5cm3 Dose <60Gy
Normal Lung
65%
45%
35%
Dose <5Gy
Dose <10Gy
Dose <20Gy
Heart 33% Dose <60Gy
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6.2.2.2 Simultaneous Integrated Boost Plans
The simultaneous integrated boost (SIB) is a treatment technique where different doses per fraction
are delivered to different target volumes simultaneously. In this study, there were two target volumes;
PTVprimary and the boost volume.
For the SIB plans, three boost volumes were delineated within the gross tumour volume (GTVprimary).
The boost volume based on the 3D-VTMs was delineated as the region of zero entropy within the
3D-VTMs and was labelled GTVentropy. GTVentropy was delineated (using automatic thresholding)
on the 3D-VTM of the tumour CT image and then the contour was transferred to the CTplan. The
boost volume based on the 18F-FDG uptake was delineated as the region of the tumour’s PET image
having ≥50% of SUVmax and was labelled GTVFDG. GTVFDG was delineated (using automatic
thresholding) on the 18F-FDG PET tumour image and then the contour was transferred to the CTplan.
The two boost volumes; GTVentropy and GTVFDG were combined into the third boost volume labelled
GTVentropy+FDG. The boost volumes delineation was achieved using an in-house written Matlab
software (The MathWorks, Inc, Natick, MA) in combination with the computational environment for
radiotherapy research (CERR) software [43]. The boost volumes structure set were imported into the
TPS.
The boost volumes; GTVentropy, GTVFDG and GTVentropy+FDG were smoothed by filling any
cavities 0.5< cm3. A margin of 3mm was added to the GTVentropy, GTVFDG and GTVentropy+FDG to
get the boost PTVs to account for physical uncertainties. The boost volumes plus the added margin
were labelled; PTVentropy_UnCrop, PTVFDG_UnCrop and PTVentropy+FDG_UnCrop respectively. Given the
tumours are mostly central tumours (close to the mediastinum), the boost PTVs were cropped 10mm
away from the spinal cord (SC) and 3mm away from the oesophagus allowing dose escalation while
conforming to the OARs’s constraints. The modified PTVs were labelled PTVentropy, PTVFDG and
PTVentropy+FDG.
For each patient, three SIB plans were created based on the three boost volumes; PTVentropy,
PTVFDG and PTVentropy+FDG and were labelled Boostentropy, BoostFDG and Boostentropy+FDG respec-
tively. The SIB plans were created using the VMAT technique with two half arcs and a prescribed
dose of 84Gy in 32 fractions to the boost volume and 64Gy in 32 fractions to the PTVprimary. The
prescribed dose 84Gy was advised by the collaborator consultant radiation oncologist (VE) as it
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is the highest safe escalation dose in NSCLC reported in a phase II trial [21]. The dose planning
optimisation template for the OARs from the uniform dose plan was used to create the SIB plans.
A dose objective for the boost target volumes was added to the existing template. To ensure the
part of the PTVprimary not included in the boost volume received an adequate dose (95% of 64Gy),
a new structure was created by subtracting the boost volume from the PTVprimary and was labelled
PTVprimary-Boost. The PTVprimary-Boost was set to receive 64Gy. A ring region was created 2cm around
the PTVprimary with objective dose of ≤95% of 64Gy allowing dose escalation to the boost volumes
while keeping the dose to the surrounding area to a minimum. The uniform dose plans and the SIB
plans were discussed, assessed and approved by the collaborator consultant radiation oncologist (VE).
6.2.2.3 Dose to The Bronchial Tree
The Bronchial tree (BT) is the branching of the main airway to the lungs known as the bronchus; an
example of a BT delineation on a CT scan is presented in figure (6.1). High radiation dose to the BT
has been shown to cause high grade toxicity for patients treated for central tumours when treated with
image guided stereotactic ablative radiation therapy (SABR). SABR is the delivery of a very high
radiation dose to a small image-defined lesion in a small number of fractions; maximum of 60Gy in 8
fractions for NSCLC.
In NSCLC, SABR is the standard practice to treat small peripheral tumours and not central
tumours given that the phase II trial showed an 83% freedom from high toxicity at two years for
peripheral tumours compared to 54% for central tumours. The side effects included bronchial stenosis
(narrowing of the bronchus) and thus a dose avoidance region (no fly zone) of 2cm around the BT is
needed for treating NSCLC with SABR. Since central tumours are in a very close proximity to the
BT, SABR treatments are difficult to deliver and the standard treatment is still the conventional 2-3Gy
per fraction [28][89].
A dose constraint or limit for the BT in the conventional 64Gy in 32 fractions or for dose escalation
studies in central lung tumours has not been published in the literature. Yet, given the high dose in
the boost plans (84Gy in 32 fractions), I investigated the dose tolerance for the BT as an additional
consideration in this study. An extrapolated dose limit was calculated from the SABR guidelines
to the conventional fractionation to evaluate the dose received by the BT. To do so, the biologically
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Fig. 6.1 The Bronchial tree as delineated on the planning CT. The axial view is shown on the left, the
sagittal view is shown on the top right and the coronal view is shown on the bottom right.
effective dose was calculated based on the linear quadratic (LQ) model of the probability of cell
survival (S) post irradiation. The LQ equation for cell survival (S) is presented in equation (6.1) where
n is the number of fractions and d is the dose per fraction [79].
S = exp(−αnd−βnd2) (6.1)
The biological effect of the irradiation E is represented by the term (αnd+βnd2) where α and β
are parameters representing irreparable and repairable cell damage respectively (refer to 1.3.3.1). To
get the biologically effective dose (BED), E is divided by α . This simplifies to :
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BED = E/α = nd
[
1+
d
α/β
]
(6.2)
From equation (6.2), the total equivalent dose nd can be calculated using equation (6.3).
BED/
[
1+
d
α/β
]
= nd (6.3)
To calculate the total equivalent dose (EQD) in a different fractionation scheme, equation (6.4) is
used.
EQD = nd =
BED
1+ dα/β
(6.4)
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The dose limit in the SABR guidelines states that 0.5cm3 of the BT should receive <44Gy in 8
fractions [89][28]. To calculate the dose limit for the BT in 84Gy in 32 fractions, equation (6.2) was
used as seen in equation (6.5).
n1d1
[
1+
d1
α/β
]
= n2d2
[
1+
d2
α/β
]
(6.5)
For equation (6.5), an α/β of 3Gy was used, d1 = 44Gy/8, n1 = 8 and n2 = 32 and solved for d2.
The calculated dose limit for the BT for 84Gy in 32 fractions is 71.5Gy to 0.5cm3 of the BT.
Given the tumours in our patient cohort are central tumours and very close to the BT, it is
hypothesized that the BT may receive a dose higher than 71.5Gy for the SIB plans but not for the
uniform dose plan where the prescribed dose is 64Gy. New boost volumes were created by cropping
the PTVentropy, PTVFDG and PTVentropy+FDG 3mm away from from the BT to investigate the possibility
of delivering an escalated dose while limiting the dose to the BT. The new boost volumes were labelled
PTVentropy-BT, PTVFDG-BT and PTVentropy+FDG-BT. This extrapolated dose limit was not considered
in the dose optimisation template for creating the four treatment plans rather it was an exploratory
analysis.
The definitions of the different GTV, PTV and plan abbreviations used in this study are summarised
in table (6.3).
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Table 6.3 List of definitions of GTV, PTV and treatment plans abbreviations used in this study.
Abbreviation Definition
GTVprimary The gross tumour volume which represents the visible primary tumour.
GTVentropy The zero entropy sub-volume within the GTVprimary.
GTVFDG The ≥50%SUVmax sub-volume within the GTVprimary.
GTVentropy+FDG The combination of the GTVentropy and GTVFDG.
GTVOverlap The overlap between the GTVentropy and GTVFDG.
PTVprimary_UnCrop The planning target volume of the primary tumour.
PTVprimary PTVprimary_UnCrop cropped 10mm away from SC and 3mm away from the
oesophagus.
PTVentropy_UnCrop The planning target volume of the zero entropy sub-volume within the
GTVprimary.
PTVentropy PTVentropy_UnCrop cropped 10mm away from SC and 3mm away from the oe-
sophagus.
PTVFDG_UnCrop The planning target volume of the ≥50%SUVmax sub-volume within the
GTVprimary.
PTVFDG PTVFDG cropped 10mm away from SC and 3mm away from the oesophagus.
PTVentropy+FDG_UnCrop The combination of PTVentropy and PTVFDG.
PTVentropy+FDG PTVentropy+FDG_UnCrop cropped 10mm away from SC and 3mm away from the
oesophagus.
PTVOverlap The overlap between the PTVentropy and PTVFDG.
PTVentropy-BT PTVentropy cropped 3mm away from the BT.
PTVFDG-BT PTVFDG cropped 3mm away from the BT.
PTVentropy+FDG-BT PTVentropy+FDG cropped 3mm away from the BT.
Uniform Dose Plan Treatment plan where a uniform dose of 64Gy is prescribed to the PTVprimary,
considered the current standard treatment for NSCLC.
Boostentropy Plan SIB plan with an escalated dose of 84Gy to the PTVentropy.
BoostFDG Plan SIB plan with an escalated dose of 84Gy to the PTVFDG.
Boostentropy+FDG Plan SIB plan with an escalated dose of 84Gy to the PTVentropy+FDG.
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6.2.3 Analysis of The Plans
The size of the generated boost volumes and the overlap volume between PTVentropy and PTVFDG
were measured. The dose distribution was calculated for the four created treatment plans. A dose
volume histogram (DVH), which provides information about the dose received by a volume of an
organ, was generated for each of the OARs and the target volumes from each of the four plans [79].
The dose to the OARs and their compliance with the dose constraints presented in table (6.2) were
calculated from each plan. The statistical significance between dose received by the OARs in the
four treatments plans was measured using Wilcoxon signed rank test. The p-value was adjusted
using Bonferroni correction for multiple comparisons (0.05/3=0.017), the difference is considered
statistically significant if p<0.017.
To quote and compare the dose received by the target volumes, the dose received by 95% (D95)
of the PTVprimary, PTVentropy, PTVFDG and PTVentropy+FDG volumes were calculated. Although a
100% coverage of the target volume with the prescribed dose is desired [76] [2], in IMRT planning, it
has been reported that allowing a small part of the target volume to receive slightly less dose leads
to a better dose distribution that conforms to the shape of the critical organs adjacent to the target
volume [22][160][58]. A “near-minimum” dose is considered a more robust and clinically meaningful
measure of target coverage than a point minimum [68]: in this study, I calculated the dose received by
99%, 98% and 95% of the target volumes. Given that the calculated dose at the target boundaries
between tissues of different densities is strongly affected by uncertainties in dose calculations, the
D95 may be the most robust of these [68][60]. The D99, D98 and D95 all showed similar trends
between plans; I therefore present here the D95 as an indicator of target coverage for each plan.
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6.3 Results
6.3.1 Target Volumes
The sizes of the GTVs and PTVs for each of the ten investigated patients are presented in table
(6.4) and table (6.5) respectively. The mean size of GTVprimary for the ten investigated patients was
140±120cm3, the mean size of GTVentropy was 30±20cm3, the mean size of GTVFDG was 20±20cm3
and the mean size of the GTVentropy+FDG was 40±30cm3. The mean size of the overlap volume
between GTVentropy and GTVFDG (GTVOverlap) was 10±10cm3. As discussed in (5.3.4), the mean
overlap between GTVentropy and GTVFDG was 65±12% for patients 1-9. Patient 10 was considered an
outlier due to the reasons discussed in (5.3.4). An example of the delineated GTVprimary, GTVentropy
and GTVFDG for one of the patients from our cohort is presented in figure (6.2).
Fig. 6.2 An example of the GTVprimary, GTVentropy and GTVFDG for a patient from our investigated
cohort (Patient 3).
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Table 6.4 The GTV size for the ten investigated patients. For definitions of the listed GTV structures,
please refer to table (6.3). The results for the mean±SD are quoted in significant digits.
Volume Size cm3
Pt.no GTVprimary GTVentropy GTVFDG GTVentropy+FDG GTVOverlap
1 34.7 4.4 3.8 6.3 2.0
2 37.4 11.1 7.9 12.0 7.1
3 52.7 10.5 9.1 13.4 6.3
4 55.4 16.0 10.0 17.6 8.7
5 152.5 50.0 29.6 57.0 23.5
6 71.5 26.8 21.6 35.1 13.7
7 113.5 20.9 19.1 31.4 9.6
8 123.6 38.8 16.1 42.9 12.3
9 339.9 66.8 48.7 80.7 35.0
10 372.8 57.7 56.4 104.1 15.7
Mean±SD 140±120 30±20 20±20 40±30 10±10
Median 92.5 23.8 17.6 32.2 10.9
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For the PTVprimary_UnCrop, the mean size for the ten investigated patients was 387.7cm3 with a
range of 147.4-819.3cm3. Cropping the PTVprimary_UnCrop 10mm from the spinal cord and 3mm away
from the oesophagus compromised the PTVprimary_UnCrop for eight of the ten patients (for Patient 1
and Patient 6 the PTVprimary_UnCrop was not compromised). The mean size of the PTVprimary for the
eight patients was 380.5cm3 with a range of 147.4-802.1cm3. The mean %volume cropped from
the PTVprimary_UnCrop was 1.2% with a range of 0.02-4.2%. For the three boost volumes, cropping
away from the spinal cord and oesophagus only affected Patient 5 (cropped volume was 2.7%) for
PTVentropy, Patient 10 for PTVFDG (cropped volume of 0.2%) and consequently Patient 5 and Patient
10 for the PTVentropy+FDG (cropped volume of 0.3% each).
For the planning target volumes, the mean size of the PTVprimary was 380±210cm3, the mean size
of the PTVentropy was 60±50cm3, the mean size of the PTVFDG was 50±30cm3 and the mean size of
the PTVentropy+FDG was 80±60cm3. The mean size of the overlap volume between the PTVentropy and
PTVFDG (PTVOverlap) was 30±20cm3.
Table 6.5 The PTV size for the ten investigated patients. For definitions of the listed PTV structures,
please refer to table (6.3). The results for the mean±SD are quoted in significant digits.
Volume Size cm3
Pt.no PTVprimary PTVentropy PTVFDG PTVentropy+FDG PTVOverlap
1 152.6 13.5 10.5 18 6.4
2 147.4 22.3 17.5 24.1 16.1
3 391.6 26.4 24.6 34.5 16.8
4 201.3 31.0 25.0 35.9 20.7
5 588.4 96.2 58.1 106.7 50.2
6 239.7 53.3 39.3 62.5 30.8
7 353.5 48.2 45.0 63.3 31.3
8 434.9 69.9 34.8 75.5 30.0
9 493.3 124.1 79.8 132.8 72.0
10 802.1 147.9 118.3 218.1 58.4
Mean±SD 380±210 60±50 50±30 80±60 30±20
Median 372.5 50.7 37.1 62.9 30.4
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6.3.2 Treatment Planning Study
The four plans (uniform dose plan, Boostentropy, BoostFDG and Boostentropy+FDG) created for each
patient using the optimised template were shown to be clinically feasible. The dose to OARs were
within the tolerance limits and the target volume received an adequate dose as will be discussed in the
following sections. An example of the calculated dose distributions for one of the patients from our
cohort is presented in figure (6.3).
(a) Uniform Dose Plan (b) Boostentropy Plan
(c) BoostFDG Plan (d) Boostentropy+FDG Plan
Fig. 6.3 An example of a dose distribution from the four created radiotherapy plans for Patient 7 from
the investigated cohort. (a) Is the uniform dose plan. (b) Is the Boostentropy Plan. (c) Is BoostFDG Plan.
(d) Is the Boostentropy+FDG Plan. The axial view is shown on the left, the sagittal view is shown on the
top right and the coronal view is shown on the bottom right.
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6.3.2.1 Dose to Organs at Risk
The dose volume histogram (DVH) was generated for the OARs by calculating the dose received by
the organ to ensure compliance with the set dose restrictions. An example of a DVH of the OARs
from the four treatment plans for a patient from our cohort is presented in figure (6.4).
Fig. 6.4 An example of the OARs DVH from the four treatment plans for Patient 7 from our investigated
cohort.
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The dose to the spinal cord was <45Gy for all the patients in all the four plans conforming to
the tolerance dose. The mean sizes of the volume receiving 5Gy (V5) for the normal lung were
46.8±12.7%, 47.0±12.6%, 45.7±12.3% and 46.8±12.7% for the uniform dose plan, Boostentropy
plan, BoostFDG plan and Boostentropy+FDG plan respectively. The V5 for the normal lung for each
patient in the four treatment plans is presented in figure (6.5).
V5 of The Lungs
Fig. 6.5 The volume of the normal lung that is receiving 5Gy (V5) in the four treatment plans. (a) Is
the volume calculated from the non-necrotic/hypoxic tumours plans. (b)Is the volume calculated from
the necrotic/hypoxic tumours plans. The dashed line is the tolerance volume.
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The mean size of the volume receiving 10Gy (V10) for the normal lung was 28.9±8.1%,
29.5±8.4%, 29.0±7.8% and 28.8±8.1% for the uniform dose plan, Boostentropy plan, BoostFDG
plan and Boostentropy+FDG plan respectively. The V10 for the normal lung for each patient in the four
treatment plans is presented in figure (6.6).
V10 of The Lungs
Fig. 6.6 The volume of the normal lung that is receiving 10Gy in the four treatment plans. (a) Is the
volume calculated from the non-necrotic/hypoxic tumours plans. (b)Is the volume calculated from the
necrotic/hypoxic tumours plans. The dashed line is the tolerance volume.
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The mean size of the volume receiving 20Gy (V20) for the normal lung was 21.1±5.8%,
21.0±5.8%, 21.0±6.0% and 20.9±5.9% for the uniform dose plan, Boostentropy plan, BoostFDG
plan and Boostentropy+FDG plan respectively. The V20 for the normal lung for each patient in the four
treatment plans is presented in figure (6.7).
V20 of The Lungs
Fig. 6.7 The volume of the normal lung that is receiving 20Gy in the four treatment plans. (a) Is the
volume calculated from the non-necrotic/hypoxic tumours plans. (b)Is the volume calculated from the
necrotic/hypoxic tumours plans. The dashed line is the tolerance volume.
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The mean size of the V60 (volume receiving 60Gy) of the heart was 1.3±2.0%, 1.4±2.2%,
1.3±2.0% and 1.4±2.3% for the uniform dose plan, Boostentropy plan, BoostFDG plan and Boostentropy+FDG
plan respectively. The V60 for the heart for each patient in the four treatment plans is presented in
figure as shown in figure (6.8). The dose received by 0.5cm3 of the oesophagus for all the patients in
the four treatment plans is presented in figure (6.9). Figure (6.9) shows that the dose to the 0.5cm3 of
the oesophagus is within the tolerance limit (<60Gy) for all the patients in the four treatment plans.
V60 of The Heart
Fig. 6.8 The volume of the heart that is receiving 60Gy (V60) in the four treatment plans. (a) Is the
volume calculated from the non-necrotic/hypoxic tumours plans. (b)Is the volume calculated from the
necrotic/hypoxic tumours plans. The dashed line is the tolerance volume.
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Dose to The Oesophagus
Fig. 6.9 The maximum dose to 0.5cm3 of the oesophagus in the four treatments plans. (a) Is the
dose calculated from the non-necrotic/hypoxic tumours plans. (b) Is the dose calculated from the
necrotic/hypoxic tumours plans. The dashed line is the tolerance dose.
The dose received by the spinal cord, normal lungs, heart and oesophagus are all within the set
tolerance dose for all the patients in the four treatments plans. For Patient 10, the lung V5 was slightly
higher (mean 73.7%±1.7) than the tolerance volume of 65%. This is due to the large size of the
tumour (largest tumour in our cohort) yet, it was still considered clinically acceptable. The Wilcoxon
rank test showed that there was no significant statistical difference between the dose received by the
OARs in the SIB plans compared to the uniform dose plan, all p-values were >0.017. The results show
that the dose to the OARs in the four treatment plans are all within the tolerance limits. Furthermore,
the dose escalation in the boost plans was achieved without a significant increase in the dose to the
OARs in comparison to the uniform dose plan.
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6.3.2.2 Dose to The Planning Target Volumes
The DVH for each of the planning target volumes in each of the four treatment plans was calculated.
An example of the generated DVH for PTVprimary, PTVentropy, PTVFDG and PTVentropy+FDG in the
uniform dose plan, Boostentropy plan, BoostFDG plan and Boostentropy+FDG plan are presented in figure
(6.10).
(a) DVH of the PTVprimary (b) DVH of the PTVentropy
(c) DVH of the PTVFDG (d) DVH of the PTVentropy+FDG
Fig. 6.10 An example of a DVH from the four created radiotherapy plans for Patient 5 from the
investigated cohort.
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The D95 of the PTVprimary was ≥60.8Gy (95% of 64Gy) in the uniform dose plan for all the
patients with a mean of 61.8±0.7Gy. The mean D95 of the PTVprimary_UnCrop was 61.5±0.8Gy. The
D95 of the PTVprimary_UnCrop was ≥60.8Gy (95% of 64Gy) for nine of the ten patients. For Patient
5, the PTVprimary_UnCrop was compromised by 4% of it’s volume, consequently, the D95 for the
PTVprimary_UnCrop for this patients was 93% of the prescribed dose (59.9Gy). Yet, for the other nine
patients, the D95 of the PTVprimary_UnCrop and PTVprimary received 95% of the prescribed dose as
shown in figure (6.11). The D95 of the PTVprimary_UnCrop-Boost and PTVprimary-Boost in the SIB plans
were ≥60.8Gy (95% of 64Gy) for all the patients.
Fig. 6.11 The dose received by 95% of the PTVprimary_UnCrop and PTVprimary volume in the uniform
dose plan. (a) Is the dose calculated from the non-necrotic/hypoxic tumours plans. (b)Is the dose
calculated from the necrotic/hypoxic tumours plans. The dashed line is the 95% of the prescribed
dose.
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For the SIB plans, 95% of the PTVentropy, PTVFDG and PTVentropy+FDG received≥79.8Gy (95% of
84Gy) for all the ten patients in their corresponding plans; Boostentropy, BoostFDG and Boostentropy+FDG
with a mean of 82.3±0.2Gy, 82.35±0.37Gy and 82.14±0.3Gy respectively. The results in figure
(6.12-6.14) shows the D95 of the boost PTVs; PTVentropy, PTVFDG and PTVentropy+FDG in each of
the three SIB plans (Boostentropy, BoostFDG and Boostentropy+FDG). The mean D95 of the PTVentropy
was 82.1±0.8Gy, 68.9±5.5Gy, 82.5±0.2Gy in the Boostentropy, BoostFDG and Boostentropy+FDG plans
respectively. For the PTVFDG, the mean D95 was 75.2±4.4Gy, 82.3±0.4Gy, 82.4±0.4Gy in the
Boostentropy, BoostFDG and Boostentropy+FDG plans respectively and D95 for the PTVentropy+FDG was
76.5±4.1Gy, 69.6±5.9Gy, 82.1±0.3Gy in the Boostentropy, BoostFDG and Boostentropy+FDG plans
respectively. Given the boost volumes are within the PTVprimary, they received the same dose as the
PTVprimary in the uniform dose plan as discussed previously.
Figure (6.12) shows that when boosting based on PTVFDG (red squares), the D95 of the PTVentropy
for only one patient received ≥79.8Gy (95% of 84Gy) which is expected given the boost volumes
based on entropy were larger than the boost volumes based of 18F-FDG uptake for all the investigated
patients (refer to table 6.4 and 6.5). When boosting based on the combination of entropy and 18F-FDG
uptake boost volumes (PTVentropy+FDG, the green triangles), both PTVentropy and PTVFDG D95 was
≥79.8Gy (95% of 84Gy) as presented in figure (6.12 and 6.13). Given that PTVentropy+FDG was larger
than PTVentropy and PTVFDG, when boosting based on the PTVentropy (blue circles), the D95 of the
PTVentropy+FDG was ≥79.8Gy for only four patients and for only one patient when boosting based on
PTVFDG (red squares) as shown in figure(6.14). As seen in figure (6.13), when boosting based on the
PTVentropy (blue circles), the PTVFDG D95 received a dose of ≥79.8Gy for three patients while the
other seven patients received 80-92% of the prescribed dose. Since one of the aims of this study was
to assess whether the high 18F-FDG regions receives an adequate dose when boosting based on the
tumour’s entropy, figure (6.15) shows that when boosting based on the PTVentropy, the GTVFDG D95
was covered with ≥79.8Gy for nine of the ten patients. Patient 10 is considered an outlier due to the
reasons discussed in (5.3.4).
158 Radiotherapy Planning Based on Functional Imaging and Texture Analysis
D95 of The PTVentropy
Fig. 6.12 The dose received by 95% of the PTVentropy volume in the three created SIB plans. (a) Is
the dose calculated from the non-necrotic/hypoxic tumours plans. (b)Is the dose calculated from the
necrotic/hypoxic tumours plans. The dashed line is the 95% of the prescribed dose.
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D95 of The PTVFDG
Fig. 6.13 The dose received by 95% of the PTVFDG volume in the three created SIB plans. (a) Is
the dose calculated from the non-necrotic/hypoxic tumours plans. (b)Is the dose calculated from the
necrotic/hypoxic tumours plans. The dashed line is the 95% of the prescribed dose.
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D95 of The PTVentropy+FDG
Fig. 6.14 The dose received by 95% of the PTVentropy+FDG volume in the three created SIB plans. (a)
Is the dose calculated from the non-necrotic/hypoxic tumours plans. (b)Is the dose calculated from
the necrotic/hypoxic tumours plans. The dashed line is the 95% of the prescribed dose.
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D95 of The GTVFDG
Fig. 6.15 The dose received by 95% of the GTVFDG volume in the three created SIB plans. (a) Is
the dose calculated from the non-necrotic/hypoxic tumours plans. (b)Is the dose calculated from the
necrotic/hypoxic tumours plans. The dashed line is the 95% of the prescribed dose.
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6.3.2.3 Dose to The Bronchial Tree
The dose received by 0.5cm3 of the bronchial tree (BT) for each patient in the four treatment plans is
presented in figure (6.16). For the uniform dose plan, the dose received by the BT was within the
tolerance dose. For the SIB plans, the BT dose was within the calculated limit for Patient 2 and Patient
6 only while it exceeded the extrapolated dose limit for the rest of the patients. As per the discussion
with the collaborator radiation oncologist (VE), a higher dose to the BT could be clinically acceptable
to achieve a full coverage of the boost volumes which are considered to be the more aggressive part
of the tumour. Moreover, since a tolerance dose to the BT or toxicity from BT irradiation in the
conventional 64Gy in 32 fractionation or dose escalation studies in lung cancer were not reported or
investigated in the literature, modification of the created treatment plans was not considered clinically
necessary. However, as an exploratory assessment, I investigated the effects of modifying the boost
volumes to avoid a high dose to the BT.
When modifying the boost PTVs (cropped 3mm away from the BT), the mean size of the cropped
volume for PTVentropy (PTVentropy CBT %Vol) and PTVentropy+FDG (PTVentropy+FDG CBT %Vol) for the
eight patients was 3.2% with a range of 0.6-7.5% and 3.8% with a range of 1.0-7.5% respectively. In
the case of PTVFDG, only six volumes needed to be modified, the mean size of the cropped volume
for PTVFDG (PTVFDG CBT %Vol) for the six patients were 4.4% with a range of 1.1-9.2%. The results
for the boost volumes sizes after cropping away from the BT are presented in table (6.6, 6.7 and 6.8).
The plan was re-optimised for one of the patients to test the feasibility of achieving a high boost
dose with restricting the dose to the BT. A total dose of 84Gy in 32 fractions was prescribed to the
PTVentropy-BT. The dose to the BT was reduced to 70.7Gy to 0.5cm3 of the BT by under-dosing 4.5%
of the PTVentropy. The results from this patient shows that it is feasible to deliver an escalated dose
to central tumours with restricting dose to the BT but with the expense of compromising the target
volume. However, even the compromised area of the boost target still receives a dose higher than that
in the standard treatment.
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Dose to The Bronchial Tree
Fig. 6.16 The maximum dose to 0.5cm3 of the bronchial tree in the four treatment plans. (a) Is the
dose calculated from the non-necrotic/hypoxic tumours plans. (b)Is the dose calculated from the
necrotic/hypoxic tumours plans. The dashed line is the tolerance dose.
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Table 6.6 Sizes of the PTVentropy in cm3 and the size after cropping away from the BT. PTVentropy CBT
%Vol = the percentage cropped volume from PTVentropy. The results for the mean±SD are quoted in
significant digits.
Patient Number PTVentropy cm3 PTVentropy-BT cm3 PTVentropy CBT %Vol
1 13.5 13.4 0.7
2 22.3 22.3 0.0
3 26.4 24.4 7.5
4 31.0 29.9 3.5
5 96.2 91.9 4.5
6 53.3 53.3 0.0
7 48.2 46.4 3.7
8 69.9 67.6 3.3
9 124.1 122.3 1.4
10 147.9 147.0 0.60
Mean±SD 60±50 60±50 3±3
Table 6.7 Sizes of the PTVFDG in cm3 and the size after cropping away from the BT. PTVFDG CBT
%Vol = the percentage cropped volume from PTVFDG. The results for the mean±SD are quoted in
significant digits.
Patient Number PTVFDG cm3 PTVFDG-BT cm3 PTVFDG CBT %Vol
1 10.5 10.0 4.7
2 17.5 17.5 0.0
3 24.6 24.6 0.0
4 25.0 23.4 6.4
5 58.1 56.9 2.0
6 39.3 39.3 0.0
7 45.0 43.7 2.8
8 34.8 31.6 9.2
9 79.8 79.8 0.0
10 118.5 117.2 1.1
Mean±SD 50±30 40±30 3±3
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Table 6.8 Sizes of the PTVentropy+FDG in cm3 and the size after cropping away from the BT.
PTVentropy+FDG CBT %Vol = the percentage cropped volume from PTVentropy+FDG. The results for the
mean±SD are quoted in significant digits.
Patient Number PTVentropy+FDG cm3 PTVentropy+FDG-BT cm3 PTVentropy+FDG CBT %Vol
1 18.8 17.4 3.3
2 24.1 24.1 0.0
3 34.5 33.6 2.6
4 35.9 33.3 7.5
5 106.7 101.7 4.9
6 62.5 62.5 0.0
7 63.3 60.4 4.6
8 75.5 71.3 5.5
9 132.8 131.1 1.3
10 218.1 216.0 1.0
Mean±SD 80±60 80±60 3±3
6.4 Discussion
In the previous chapter, I showed the relationship between the volumetric voxel based heterogeneity
(local entropy) measured from CT images of NSCLC tumours and tumour’s 18F-FDG uptake measured
from PET images. Tumour’s 18F-FDG distribution have been suggested to guide dose painting in
NSCLC given that 18F-FDG uptake have been shown in the literature to relate to tumour’s recurrence.
In this chapter, I investigated the possibility of using the generated 3D-VTMs from NSCLC CT
images in dose painting as a surrogate for tumour metabolism. To do so, I created three simultaneous
boost plans (SIB) based on tumour metabolism (18F-FDG uptake), tumour CT image entropy (3D-
VTMs) and the combination of both. A dosimetric analysis and a comparison between the plans was
conducted. Moreover, I investigated the clinical feasibility of dose boosting in NSCLC by comparing
the boost plans to a uniform dose plan.
The SIB plans were compared against a uniform dose plan of 64Gy in regards to dose to organs at
risk (OARs). The results illustrated the possibility of dose escalation in NSCLC without exceeding
the clinical dose limit to the OARs. In this study, I also considered the dose to the BT. Although the
BT doesn’t have an established dose restriction in the published literature for 64Gy in 32 fractions or
dose escalation studies in central lung tumours, high radiation dose to the BT has shown to cause high
grade toxicity in SABR trials. A dose limit for the BT was extrapolated from SABR guidelines. The
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results showed that in the SIB plans, the dose to the BT exceeded the extrapolated limit. Modifying
the boost PTVs decreased the dose to the BT to the acceptable level yet it led to a compromised
coverage of the boost PTVs. Based on the discussion with the consultant radiation oncologist (VE),
given this group of patients have a chance of preserving lung function, a total high dose to the BT
could be accepted in order to adequately cover the boost volumes. Overall, the three SIB plans have
been shown to be clinically feasible without a significant increase in the dose to OARs compared to
the uniform dose plan.
A dosimetric comparison was conducted between the three SIB plans (Boostentropy, BoostFDG and
Boostentropy+FDG) to assess the dose received by the high 18F-FDG regions when boosting based on
the tumour CT image local entropy. The boost volume PTVFDG were found to be smaller than the
boost volume PTVentropy for all the ten investigated patients hence, 95% of PTVentropy was not covered
by 95% of the prescribed dose when boosting based on PTVFDG except in one case. When boosting
based on PTVentropy, the D95 of the PTVFDG was 95% of the prescribed dose for three patients while
the others received between 80-92% of the prescribed dose. Yet, the D95% of the GTVFDG was
covered by 95% of the prescribed dose for all the investigated patients excluding Patient 10 due to
reasons discussed in section (5.3.4). The results indicates that when boosting based on tumour CT
image local entropy, the high 18F-FDG regions will receive an adequate dose. Since CT images are
the basis for radiotherapy planning and dose calculation, these results are quite crucial in showing the
potential of our proposed method to be used for dose painting in NCSLC.
Moreover, dose escalation in Boostentropy+FDG plans for all the investigated patients have been
shown to be clinically feasible and conform to OARs dose constraints despite the larger boost volume.
Due to uncertainties in 18F-FDG PET imaging such as partial volume effect and registration errors
and the challenges in volumetric texture mapping (discussed in (5.3.4)), boosting the combination of
the boost volume identified by the two methods with an adequate margin might be desired to cover
what could be the most aggressive part of the tumour. In chapter (5), I showed a preliminary evidence
of the possibility of the 3D-VTMs to detect the necrotic/hypoxic regions within the tumour hence,
boosting based on PTVentropy or PTVentropy+FDG could be beneficial since it covers the high 18F-FDG
regions and the necrotic/hypoxic part of the tumour that might still have viable cells within it.
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6.5 Conclusions
In conclusion, dose escalation to boost volumes based on tumour CT image local entropy, tumour
18F-FDG uptake and the combination of both are shown to be clinically feasible without significantly
increasing the dose to OARs. The results presented in this chapter demonstrated one application
of our proposed volumetric texture mapping method. I demonstrated that high 18F-FDG regions
within the tumour can be covered with at least 95% of the prescribed dose when boosting based on
tumour CT image local entropy, thus showing the potential of our method in the area of dose painting.
Yet, boosting based on the combination of tumour CT entropy and 18F-FDG uptake could be more
desirable to cover both metabolically active and necrotic/hypoxic region within the tumour.

Chapter 7
Discussion, Conclusions and Future
Work
7.1 Overview
In this final chapter, the key results and the implications of the presented work are discussed. In
addition, the main conclusions and proposed future work are presented.
7.2 Textural Features as Biomarkers for Patient Survival
The emerging proposition in the field of oncology of using tumour image features as biomarkers for
patient survival, calls for thorough investigation and validation. Initial results relating tumour image
texture to treatment outcome and patient survival are promising. Predicting tumour response prior to
radiotherapy could potentially allow stratification of patients to high and low risk groups where high
risk groups may be targeted with more aggressive treatment courses. In addition, predicting recurrence
earlier from follow-up scans would be valuable for planning medical intervention as early as possible.
However, the field of texture analysis lacks standardisation of methods leading to contradictions
in the reported findings and difficulties in comparing results. Furthermore, the number of textural
features that can be extracted from radiological images are numerous, yet only some showed an
association, or correlation, with patient survival or response to treatment. The significance of these
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textural features should be investigated and the causal relationship between these features and outcome
prediction/survival should be understood before moving forward. Whilst the aim of this work was not
to correlate textural features to patient survival, a validation of the optimised, normalised threshold
value for entropy (a texture feature that showed correlation to patients survival in NSCLC in the
published literature) was carried out. The aim of this was to assess and evaluate the robustness of the
optimised normalised entropy threshold value as a prognostic tool for NSCLC patient survival. Our
results reached statistical significance when using the threshold value from the published literature on
our patients cohort. This is an important finding implying that parameters obtained from one study
could potentially be used generically to predict survival for other patients, despite the differences in
patients cohort and in imaging equipment. In addition, these results validate entropy as a potential
biomarker for patient survival.
7.3 Spatial Measurement on Intratumoural Heterogeneity
The studies presented in the literature correlate a single-value texture feature to treatment outcome,
or patient survival, without taking into account the spatial information within the tumour image. To
investigate whether the tumour CT image has textural variations within it, I developed a methodology
to map tumour image texture volumetrically on a voxel by voxel basis. In the process, key challenges
were addressed as will be discussed in the following sections.
7.3.1 Texture Filter Design
Based on the reviewed literature, GLCM has been shown to be able to distinguish between cancerous
and normal tissue [147][15]. Moreover, features extracted from GLCM were reported to be signifi-
cantly different for lung cancers that recured compared to those that did not [98][99]. GLCM provides
spatial information and can be implemented as a volumetric voxel based method which was the goal
of this work.
To choose the GLCM neighbourhood region size (filter size), many aspects needed to be acknowl-
edged. The filter needed to be an odd number of voxels so each voxel can have a uniform number of
neighbouring voxels. This leads to the smallest possible 3D filter size of 3x3x3voxels. However, the
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size of the extracted texture features is limited by the scanner resolution. Also, image blurring due
to respiratory motion will degrade the image quality. To tackle this, an in-house designed phantom
was constructed to reflect different levels of spatial scale. The phantom was used in an experiment to
characterise and quantify the resolution of the CT scanner and the effects of respiratory motion on
extracting texture features. The results from the experiment were used to make a decision about the
optimum filter size. Hypothetically, one would argue that the use of the smallest filter size is desirable
yet due to technical limitations of the scanner resolution and the effects of respiratory motion, small
sized filters are not necessarily favourable. Thus, medium sized filters offer a trade-off between
extracting the maximum textural information on the smallest spatial scale possible and corresponding
to the scanner resolution.
Measuring tumour image texture at the edge of the tumour, where there is a lack of neighbouring
voxels, is another challenging issue. In this thesis, I suggested an added margin equal to the size of
the filter subtracted by one and divided by two. This margin is to be removed after the 3D-VTM is
generated. However, edge voxels may have an enhanced response (higher entropy value) especially
in the case of lung tumours due to the different tissue properties between normal lung and tumours.
Another approach was to generate the 3D-VTMs without adding a margin and then removing the edge
voxels from the generated map however, this might lead to loss of information.
7.3.2 Image Quantisation
An important step in conducting texture analysis is image quantisation. Image quantisation encodes
the information content within the image which may significantly affect the texture analysis results.
Most of the published studies have used a uniform quantisation method which scales the tumour image
into an equal number of bins between the minimum and maximum intensity. The investigated number
of bins reported in the literature was a power of two (8, 16, 32, 64, 128, 256). These quantisation levels
were explored and the one that yielded significant results in regards to patient survival and outcome
prediction was reported. A standard method of choosing the quantisation level is not established.
A study by Leijenaar et al. [87] attempted to address this issue by theoretically suggesting a
method for quantising 18F-FDG PET tumour image specifically (and not CT). In [87], two methods of
quantising the SUV values prior to feature extraction were investigated. The two investigated methods
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were using a fixed bin size (B) or using a fixed number of bins (D). The discretisation values used for
the bin width B were: 0.05, 0.1, 0.2, 0.5 and 1.0 SUV and the discretisation values for bin number D
were: 8, 16, 32, 64 and 128. Forty-four textural features from grey-level matrices were extracted from
pre-treatment 18F-FDG PET tumour images of 35 patients diagnosed with NSCLC. To assess the
consistency of the extracted textural features values, the pairwise intra-class correlation coefficient
(ICC) was calculated between the feature values extracted using the two investigated quantisation
methods. To evaluate the interpretation of the texture feature, patients were ranked (high to low texture
feature value) based on the texture value extracted from pre-treatment images and ranked again based
on the texture feature changes between pre-treatment and during treatment images (during the second
week on radiotherapy treatment). The difference in patients ranking was quantified by calculating
pairwise correlation. Spearman’s rank correlation coefficient (ρ) was calculated between pairwise
correlation of patients rankings with ρ>0.9 considered an acceptable agreement. Leijenaar et al. [87]
reported that ρ for the inter-class correlation was <0.85, thus all textural features depend on SUV
discretisation. Furthermore, they reported only 20 features to be unaffected by the discretisation
method in regards to patient ranking. The authors did not justify the suggested quantisation levels D
or bin width B rather it was stated as an arbitrary selection. Furthermore, consistency of the extracted
feature value does not necessarily mean accuracy as it could be a reflection of the properties of the
feature calculation itself rather than the quantisation technique. The authors proposed the fixed bin
width method to maintain a constant intensity resolution within the quantised image, yet this is only
advised for SUV quantisation and can not be generalised to other modalities. The authors justification
of this approach is that the 18F-FDG PET image does not have a set range of SUV values rather it is
patient dependent, whilst CT values are normalised based on the attenuation coefficients of water and
air, where the same range of values exist for all scanned patients [87]. Moreover, the authors did not
provide any evidence that their proposed quantisation technique leads to meaningful or significant
results while our proposed quantisation methodology justifies the use of the quantisation level and
shows the benefits in producing meaningful texture maps.
Another study by Vallieres et al. 2015 [140] used the Lloyd-Max quantiser to quantise fused PET
MR images and extract single texture feature values from soft tissue sarcoma images. The textural
features were also extracted from non fused 18F-FDG PET images and T1 and T2 MR images. The
authors investigated different quantisation levels (8, 16, 32 and 64) and reported 64 levels to yield the
highest Spearman’s rank correlation in predicting lung metastasis for the MR images and the fused
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PET MR images. For the 18F-FDG PET images, the use of 16 quantisation levels yielded the highest
Spearman’s rank correlation in predicting lung metastasis. Moreover, Vallieres et al. 2015 [140]
reported that using the Lloyd-Max quantiser for the 18F-FDG PET images, T1 and the fused PET
MR images yielded the highest Spearman’s rank correlation with the p-value reaching significance.
However, for the T2 MR images, the highest Spearman’s rank correlation was observed when using
the uniform quantiser yet the p-value did not reach significance. The authors did not provide an
explanation of why the reported quantisation levels and quantisation methods yielded significant
results for some type of images while it did not for others. It is important to acknowledge that the
texture features were extracted from images that have been pre-processed using wavelet band-pass
filtering, isotropic resampling and were also normalised before the use of the quantiser [140]. These
heavy pre-processing steps makes assessing the benefits of the implemented quantisation methodology
and the produced results difficult.
On the other hand, our proposed quantisation method addresses the two aspects of quantisation
i) choice of quantisation level and ii) quantisation method where justifications and evidences of the
benefits of our proposed methodology were provided.
7.3.3 Choice of Extracted Feature
The number of textural features that can be extracted from an image is numerous, some studies have
reported up to forty features. However, most of the extracted textural features are not well understood
in regards to the information they provide. Some studies investigated all possible texture features,
some investigated selected features and the reported prognostic power of the investigated features
varied in the literature. Regardless of the lack of standardisation in performing texture analysis and a
validation or an explanation of the reported findings, a move towards the field of prognostic radiomics
has taken place in the last two years. Radiomics encompasses all quantitative features that can be
extracted from an image including, but not exclusively texture features. Other features include shape
and intensity features. Up to 440 features have been reported in the literature.
A study by Aerts et al. [3] assessed the prognostic value of 440 radiomic features extracted from
CT images of lung, and head and neck tumours obtained from 878 patients of mixed TNM staging. In
[3], based on the feature characterstics, the radiomics features were split into four groups: tumour
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image intensity, shape, texture, and multiscale wavelet. The investigated patients dataset was split into
one training dataset and three validation datasets. The training set was labelled Lung1 and had 422
NSCLC patients. The validation datasets were labelled as follows: Lung2 had 225 NSCLC patients,
H&N1 had 136 patients diagnosed with head and neck small cell carcinoma and H&N2 had 95
patients diagnosed with head and neck small cell carcinoma obtained from a different centre [3]. The
CT images were quantised by setting an equal bin width of 25 HU. The median value of the extracted
feature was used as a threshold value for Kaplan-Meier analysis on the training dataset Lung1. The
same median value was used to validate the prognostic power of the extracted features on the validation
datasets. The authors [3] reported only sixty-six (15%) features from the 440 investigated features to
yield significant survival results in the three validation sets (Lung2, H&N1, H&N2). The authors also
reported that features describing tumour heterogeneity were correlated with worse survival outcome in
all the investigated patients. To build a prognostic model and remove feature redundancy, the authors
choose the best performing feature from the four groups of the radiomic features. These features were:
energy (describes tumour density) from the image intensity group, shape compactness (how compact
the tumour shape is) from the shape group, grey level non-uniformity (describes tumour heterogeneity)
from the texture group and grey level non-uniformity (also describes tumour heterogeneity) from
the multi-scale wavelet group. The generalisation of the area under the curve from ROC known as
the concordance index (CI) was used to validate the four features on the validation datasets. The
results reported a CI of 0.65, 0.69 and 0.69 for Lung2, H&N1 and H&N2 respectively. The CI for
tumour volume was 0.63, 0.68 and 0.65 for Lung2, H&N1 and H&N2 respectively for the prognostic
radiomics model. The CI for the TNM staging was 0.60, 0.69 and 0.66 Lung2, H&N1 and H&N2
respectively. Combining the radiomics features with the volume or TNM staging did not increase the
reported CI except for H&N1 when radiomics was combined with TNM (CI was 0.70). The reported
results did not correct for tumour size or volume which may affect the quantification of the extracted
features. Moreover, an explanation of the observed correlation between the extracted features and
prognosis was not provided by the authors.
In this thesis, the decision was to investigate entropy which is a well understood and a robust
feature that describes the information content in an image. Moreover, entropy is a measure of
heterogeneity and it is a suitable feature to show intratumoural spatial heterogeneity. Also, entropy
measured from tumour CT images has been shown to correlate with patient survival in this thesis and
in multiple studies for different tumour sites.
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7.4 Intratumoural Heterogeneity and Tumour Function
The physiological origin that could be the cause of the reported correlation between tumour image
texture and survival is yet to be understood. Some authors justified the observed correlation as a
reflection of the tumour biological heterogeneity [42]. As texture can be roughly defined as the spatial
variation within an entity, tumour texture can be argued to be representative of tumour heterogeneity.
Tumour heterogeneity can be recognised on a cellular level and on a structural level. CT imaging
has a resolution of ≈1mm, thus cellular heterogeneity can not be observed from CT images. Given
that tumours invade nearby tissue, this could lead to tumour structural heterogeneity which may be
reflected on a CT image. The results from the implementation of our proposed methodology shows
that radiologically uniform tumours have regional textural variations. I hypothesized that this observed
intratumoural heterogeneity is structural tumour heterogeneity. This is supported by the comparison
between the 3D-VTMs and 18F-FDG PET uptake images. As the high 18F-FDG uptake regions
within the tumours overlapped with the homogeneous regions of the 3D-VTMs, this may indicate that
the more aggressive parts of the tumour are structurally different than the less metabolically active
parts on CT images.
7.5 Clinical Applications
The non-invasive nature of medical imaging in informing about tissue characteristics provides great
potential and applications in the clinical settings. CT imaging is a well-established modality in
the oncological diagnosis/staging, treatment and follow up work-flow. However, the assessment of
CT images have been mostly qualitative and subjective. The introduction of fast computers and
advanced technology made rapid archiving, processing and quantitative analysis of medical images an
attainable reality. Since then, numerous studies investigated the use and integration of quantitative
tumour image analysis into clinical practice. The presented results are encouraging, yet on the other
hand, an understanding and a thorough validation of the reported findings is needed. In this thesis,
I proposed a methodology of visualising 3D voxel based texture maps of tumours with a novel
application in guiding dose painting. The presented results demonstrated high FDG regions within the
tumour volume are covered with 95% of the prescribed dose when boosting based on the image of
intratumoural heterogeneity from the CT scan.
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Extracting quantitative information that is indicative of tumour function from CT images is
highly beneficial given CT imaging is routinely acquired for cancer patients and widely available
and integrated into the clinical practice. Yet, a validation on a larger dataset is needed before such
an approach is realised. Also, validating the biological origin of the observed tumour image texture
is challenging, relating tumour image texture to tumour pathology by collecting tissue samples may
make this possible.
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7.6 Conclusions
• Tumour heterogeneity measured as entropy from a CT image showed a correlation with
overall patient survival for those diagnosed with NSCLC. An established threshold value in
the literature from a different study was utilised in this work. This suggests the possibility of
using parameters from a different study to predict patient survival despite differences in patient
cohort and imaging parameters.
• Intratumoural spatial heterogeneity measured from CT images of NSCLC showed a clear textu-
ral pattern relating to tumour glucose metabolism, therefore, suggesting valuable information
may be obtained from this approach.
• Image quantisation has been shown to significantly affect texture analysis. The proposed
optimised image quantisation method in this thesis allowed the visualisation of meaningful
textural content within tumour images without the use of machine learning or classification
techniques.
• The scale of the extracted textural features has been demonstrated to be limited by the imaging
system resolution. Moreover, image blurring due to motion has been demonstrated to measur-
ably affect the performance of the texture analysis. Respiratory gating or motion correction
methods are needed to minimise the loss of information resulting from this.
• The clinical application of our proposed methodology in radiotherapy dose painting demon-
strated that high 18F-FDG regions within the tumour can be covered with an adequate dose
when boosting based on CT image intratumoural heterogeneity. Furthermore, dose escalation
in NSCLC was shown to be clinically feasible while keeping the dose to the OARs within
accepted limits.
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7.7 Future work
• Investigating other textural features using the volumetric voxel based texture mapping method
and their relationship to tumour function.
• Investigating the relationship between intramural heterogeneity measured from the 3D-VTMs
and hypoxia by comparing the 3D-VTMs to hypoxia tracer uptake distributions imaged with
PET.
• Investigating and validating the proposed methodology on a larger dataset and other tumour
sites such as head and neck.
• The use of motion corrected data to avoid the motion effects for both generating the 3D-VTMs
and for target volume delineation.
• Investigating the relationship between the zero entropy region within the 3D-VTMs and tumour
recurrence and treatment outcome.
• Incorporating machine learning techniques into volumetric voxel based texture mapping espe-
cially for feature selection.
• The application of 3D-VTMs in longitudinal treatment follow-up data to discriminate between
scar tissue (fibrosis) post irradiation and tumour recurrence. This is currently a part of an on
going MD project of Iain Phillips in the Royal Surrey County hospital using the methodology
developed in this thesis. This new project aims to investigate whether the 3D-VTMs can
distinguish between fibrosis and tumour recurrence for patients who have received SABR
treatment for early stage lung cancer. The 3D-VTMs are generated for the whole lung volume
due to difficulties in delineating region of interest in post-irradiation lung. To quantise the
whole lung, the quantisation reconstruction levels and partitions are based on the quantisation of
the original tumour volume prior to treatment. Moreover, the HU information is combined with
the 3D-VTMs to provide additional information about tissue properties. Example preliminary
results are presented in figure (7.1).
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Fig. 7.1 (a) A follow-up CT image of the thorax three years post treatment. (b) The corresponding
3D-VTM for the whole lung. (c) The corresponding 3D-VTM with incorporating the HU information
showing the tumour recurrence as a high intensity region (white).
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Objectives: To determine whether functional imaging (FI) and texture analysis (TA) may be
used in planning radiotherapy dose painting for patients diagnosed with non-small cell lung cancer
(NSCLC) who are treated with external beam radiotherapy.
Hypothesis: Dose painting based on the combination of functional imaging (FI) and texture
analysis (TA) will produce a non-uniform dose distribution that is measurably and significantly
different to dose painting based on FI alone and to dose distribution produced by the current standard
of prescribing a uniform dose distribution.
Study Population Summary: The proposed service evaluation study population is 10 patients
who have been treated for non-small cell lung cancer (NSCLC) with external beam radiotherapy in
the past two years.
Endpoints:
Primary Agreement of dose painting dose distribution based on functional imaging combined with
texture analysis to dose painting based on FI alone and the current standard of a uniform dose
distribution. The level of agreement will be quantified in terms of difference in target volumes and
mean dose to the target volume and normal tissues.
Secondary To model the change in tumour control probability (TCP) and normal tissue complication
(NTCP) as a result of FI with TA based dose painting.
To test whether FDG PET and texture analysis provide equivalent information or the combination of
both produce significantly different results.
To investigate the level of confidence for observed difference in tumour’s texture between complete
responders and partial responders six months post treatment.
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1 Background A retrospective study using staging PET scan, planning CT scan, and follow up
CT scan of patients treated for non-small lung cancer (NSCLC) with external beam radiotherapy. The
study will evaluate the use of FDG functional imaging (FI) and texture analysis (TI) in radiotherapy
dose painting against the current planning techniques. This is a computer modelling and image
analysis study that uses scan data of a set of patients.
1.1 Dose Painting in Radiotherapy Traditionally, a uniform dose distribution to the tumour has
been prescribed in radiotherapy treatment. However, It has been shown that tumours are biologically
heterogeneous in regards to their cellular density, proliferation and oxygenation [1-2]. To account for
the tumour’s biological heterogeneity, the delivery of a non-uniform dose distribution by applying
a biological dose painting method has been suggested in the literature. The escalation of dose to
sub-volumes of increased tumour burden and heterogeneity is hypothesized to increase tumour control
probability (TCP). Molecular and functional imaging, such as positron emission tomography (PET)
and magnetic resonance imaging (MRI), are strong candidates to guide the dose painting and enable
dose escalation. The recent advancement in inverse treatment planning for radiotherapy seen in
intensity modulated radiotherapy (IMRT) has made the delivery of a non-uniform dose distribution
with a superior physical conformity achievable [2]. Dose painting can be achieved by two main
approaches, dose painting by contours (DPBC) and dose painting by numbers (DPBN). In DPBC, one
or more boost volumes are delineated which would represent biologically active sub-regions within
the tumour. Boost volumes will receive a higher dose than the rest of the tumour volume either by
redistributing the dose or by prescribing additional dose [3].DPBN is achieved by prescribing the dose
on pixel by pixel basis, assuming a linear relationship between pixel intensity and dose [4]. Meijer et
al. [5] reported the maximum dose achieved with DPBC and DPBN was comparable in a retrospective
study for NSCLC patients. Although DPBN has the advantage of delivering high peak doses at certain
pixels, South et al. [6] has shown that by redistributing the dose in head and neck cancer patients
using two to five compartments, the maximum achievable TCP is reached.
Dose painting based on Fluorodeoxyglucose (18F-FDG) has been suggested to be most suitable due
to the moderately well-established and extensively validated protocols for the use of 18F-FDG PET in
oncology compared to other PET tracers and functional MRI. Although 18F-FDG is a non-specific
radiotracer that cannot be attributed to a specific biological phenomenon, it reflects glycolysis and
tumour metabolism with a relatively high sensitivity. Moreover, it is widely available and the most
commonly used radiotracer in cancer imaging compared to other radiotracers. The use of alternative
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PET tracers suffer from limitations due to the lack of available clinical data and limitations in regards
to their sensitivity and specificity [7], plus their limited availability and high cost.
1.2 Texture Analysis Textural analysis is an emerging method and it is used to assess tumour het-
erogeneity by extracting textural features (e.g., contrast, skewness, entropy, homogeneity, uniformity)
from intensity histograms and co-occurrence matrices of CT, PET and MRI images. The Intensity
histogram is a representation of the distribution of pixel intensities in an image from where global
features of the image can be extracted such as the mean and standard deviation. On the other hand,
second order statistics texture analysis is achieved by co-occurrence matrices. Co-occurrence matrix
consist of the number of times an intensity level x and an intensity level y occur in a certain direction
[8].Another method for extracting higher order textural features is run length matrices. Run length
matrices consist of the number of consecutive pixels that have the same intensity level and which
occur in a specified direction [9]. Co-occurrence matrix based textural analysis has been used in the
field of medical imaging for tissue classification [10]. Recently, it has been proposed that texture
analysis has prognostic or predictive roles in cancer therapy (chemotherapy, radiotherapy or both)
[11]. Tumours heterogeneity features have been reported to have a superior predictive power than
PET or MRI measurements alone [11-13]. Yet, whether textural features can be used to identify
areas of increased tumour burden or resistance to radiation is still to be determined. Moreover, the
applicability of textural analysis in radiotherapy planning and dose painting is yet to be investigated.
And even though recent studies have shown a correlation between heterogeneity measurements and
tissue response, the accuracy and precision of textural analysis based on PET data is yet to be explored.
1.3 Current Standard and Proposed Method Patients diagnosed with NSCLC are treated with
external beam radiotherapy where a uniform dose distribution is prescribed to the target volume. A
planning CT scan is used to guide the radiotherapy treatment planning. An FDG PET scan is often only
used for staging at time of diagnosis. The proposed service evaluation study will determine whether the
combination of functional information obtained from PET scans and texture measurements extracted
from CT and PET scans may be used to guide radiotherapy planning. Prescribing a non-uniform dose
distribution where the regions of increased heterogeneity or tumour burden, will receive a higher
dose relative to other regions in the tumour volume will be modelled. The local failure for late stage
NSCLC patients who received radiotherapy treatment as per current standard is reported to be as high
as 70% [14]. Dose painting by contours in radiotherapy is a technique that has the potential to allow
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targeted dose escalation in NSCLC radiotherapy treatment where TCP is not presently good with the
expectation of improved outcome. Furthermore, DPBC can be planned using commercially available
treatment planning system. The goal of this work is to produce a radiotherapy treatment planning
method for NSCLC that has the potential to be used to treat RSCH patients, using the imaging and
treatment technology available at this centre.
2 Study Design: A retrospective study evaluating the use of functional imaging (FI) and texture
analysis (TA) for dose painting in non-small-cell lung cancer patients (NSCLC) who are treated with
external beam radiotherapy against the current standard.
2.1 Study Procedures As a retrospective service evaluation study, no procedures will be carried
out on patients involved. The study will involve computer modelling and image analysis of patients’
PET and CT scans. The service evaluation study will involve obtaining existing staging FDG PET
images; radiotherapy planning CT scans, and follow up CT scans for 10 patients who have been
treated for NSCLC with external beam radiotherapy. These scans are obtained as part of standard
patient management.
After retrospectively seeking consent for predetermined candidates, we will allocate a code to all
images prior to inclusion to ensure anonymity. The staging FDG PET scan will be extracted and
encoded and a quantitative analysis will be carried out to determine the tracer uptake variation. A
dose distribution based on the measured uptake variations will be prescribed. The PET scan and the
planning CT will be analysed to extract texture information regarding tumour heterogeneity. Intensity
histograms from two dimensional (2D) images will be used to extract first order statistics texture
measurements while co-occurrence matrices and run length matrices will be used as measurements of
higher order statistics. The project will involve the extension of the traditional 2D texture measure-
ments to three dimensional (3D) texture analyses to be used in identifying sub-volumes of increased
heterogeneity and tumour burden referred to as boost volume. Using the combination of uptake
distribution with texture features a boost volume will be delineated and a dose distribution will be
prescribed (for planning study, not to be used clinically). Another dose distribution will be prescribed
where the boost volume delineation will be based on functional information alone. The dose will be
prescribed so that the boost volume will receive an escalated dose to a level where the normal tissues
dose limits are not exceeded. A treatment plan (not to be used clinically) will be generated for the
different dose prescriptions discussed above. The dose distribution for each plan will be evaluated
201
based on the mean dose delivered to target volume and boost volume, the volume of the tumour
target and the boost volume, tumour control probability (TCP), normal tissue complication probability
(NTCP) models and dose volume histograms (DVH). The results will test the hypothesized benefit
of dose painting. The patients’ coded data will be transferred into a password secured server at the
University of Surrey’s Centre for Vision, Speech, and Signal Processing (CVSSP) where access will
only be granted to members of the study group.
3 Objectives: To determine whether functional imaging (FI) and texture analysis (TA) may be
used in radiotherapy dose painting for patients diagnosed with non-small lung cancer (NSCLC) and
who are treated with external beam radiotherapy.
Primary
• To determine whether the planned distribution for dose painting based on FI with TA is
significantly different to the distribution for dose painting based on FI alone and the current
standard of uniform dose distribution.
Secondary
• To model the change in tumour control probability (TCP) and normal tissue complication
(NTCP) as a result of FI and TA based dose painting.
• To test whether FDG PET and texture analysis provide equivalent information or both are
needed for optimal planning of dose painting.
• To investigate the level of confidence for observed difference in tumour’s texture between
complete responders and partial responders.
4 Statistical Consideration:
4.1 Endpoints
Primary
• Level of agreement of dose painting dose distribution based on FI with TA to dose painting
based on FI alone and the current standard of uniform dose distribution. The planned dose
distributions will be compared with respect to the boost volume delineated and the maximum
achievable dose to that volume.
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Secondary
• Change in tumour control probability (TCP) and normal tissue complication (NTCP) as a result
of FI and TA based dose painting.
• Determine whether FDG PET and texture analysis provide equivalent information or both are
needed.
• Investigate the statistical level where a significant change is seen in tumour’s texture between
complete responders and partial responders.
4.2 Analysis Method
Primary endpoint: the boost volume (regions to receive an escalated dose) delineated based on FI
alone, and FI with TA, as well as the maximum delivered dose to those regions will be reported as
significantly different if the variation falls outside the 95% confidence limits (P less than 0.05).
Secondary endpoint: relationship between areas of increased heterogeneity in pre-radiotherapy
scans and areas of partial- respondance in follow-up scans using functional information alone, and
texture analysis with functional information using similarity coefficient.
The change in calculated TCP using linear quadratic model and NTCP for normal lung and other
mediastinal organs (oesophagus, heart,. . . etc) for dose painting plans based on FI, FI with TA, and the
standard treatment.
4.3 Sample Size Based on the previous work of Bradley et al. [15] the mean percentage difference
between the delineated tumour volume for NSCLC when using CT alone and using CT/PET was
reported to be 57%. Hence, a percentage difference equal to or above 50% with power = 80% can be
observed with sample size N = 10 patients [16].
The study will compare radiotherapy plans based on FI alone and FI with TA against the standard
planning technique. The difference between the two dose painting plans will be reported significant if
the minimum difference falls outside two standard deviations (k = 2) of the mean value at the 95%
confidence level.
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5 Study Organisation:
Chief Investigator: Dr Veni Ezhil MRCP FRCR
Co-Investigators:
Prof Philip Evans
Ms Sheaka Alobaidli
Dr Chris South
Dr Sarah McQuaid
Prof Andrew Nisbet
Dr Vineet Prakash
Dr Chris South and Dr Sarah McQuaid will provide access to CT and PET data and will allocate a
study number to each patient to anonymize patient images.
Miss Alobaidli will be responsible for image analysis and generating dose distributions and treatment
plans (not to be used clinically) while assisting with data collection and anonymization.
204 FiNiTe Project Protocol
References
[1] P. Vaupel, K. Schlenger, C. Knoop and M. Höckel. Oxygenation of human tumors: Evaluation of
tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res.
51(12), pp. 3316-3322. 1991.
[2] C. C. Ling, J. Humm, S. Larson, H. Amols, Z. Fuks, S. Leibel and J. A. Koutcher. Towards multi-
dimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Radiotherapy
and Oncology 47pp. 551-560. 2000.
[3] K. S. C. Chao, W. R. Bosch, S. Mutic, J. S. Lewis, F. Dehdashti, M. A. Mintun, J. F. Dempsey, C.
A. Perez, J. A. Purdy and M. J. Welch, K. S. C. Chao, W. R. Bosch, S. Mutic, J. S. Lewis, F. Dehdashti,
M. A. Mintun, J. F. Dempsey, C. A. Perez, J. A. Purdy and M. J. Welch. A novel approach to overcome
hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. International
Journal of Radiation Oncology Biology Physics 49pp. 1171-1182. 2001.
[4] S. M. Bentzen, S. M. Bentzen. Theragnostic imaging for radiation oncology: Dose-painting by
numbers. 6pp. 112-117. 2005
[5] G. Meijer, J. Steenhuijsen, M. Bal, K. De Jaeger, D. Schuring and J. Theuws, G. Meijer, J.
Steenhuijsen, M. Bal, K. De Jaeger, D. Schuring and J. Theuws. Dose painting by contours versus
dose painting by numbers for stage II/III lung cancer: Practical implications of using a broad or sharp
brush. Radiotherapy and Oncology 100(3), pp. 396-401. 2011.
[6] C. P. South, P. M. Evans and M. Partridge, C. P. South, P. M. Evans and M. Partridge. Dose
prescription complexity versus tumor control probability in biologically conformal radiotherapy. Med.
Phys. 36(10), pp. 4379. 2009.
[7] M. E. Phelps. Positron emission tomography provides molecular imaging of biological processes.
Proceedings of the National Academy of Sciences 97(16), pp. 9226-9233. 2000.
[8] R. M. Haralick, K. Shanmugam and I. Dinstein, R. M. Haralick, K. Shanmugam and I. Dinstein.
Textural features for image classification. IEEE Trans. Syst. Man Cybern. 3(6), pp. 610-621. 1973.
[9] M. M. Galloway. Texture analysis using grey level run lengths. 1974.
[10] V. Kumar, Y. Gu, S. Basu, A. Berglund, S. A. Eschrich, M. B. Schabath, K. Forster, H. J. W. L.
Aerts, A. Dekker, D. Fenstermacher, D. B. Goldgof, L. O. Hall, P. Lambin, Y. Balagurunathan, R. A.
Gatenby and R. J. Gillies. Radiomics: The process and the challenges. Magnetic Resonance Imaging
30pp. 1234-1248. 2012.
[11] F. Tixier, C. C. Le Rest, M. Hatt, N. Albarghach, O. Pradier, J. Metges, L. Corcos and D. Visvikis.
205
Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts
response to concomitant radiochemotherapy in esophageal cancer. Journal of Nuclear Medicine 52(3),
pp. 369-378. 2011.
[12] N. Mayr, J. Zhang, M. Knopp, W. Yuh, Z. Huang, J. Wang, S. Lo, J. Fan, J. Grecula, S. Sammet,
C. Sammet and G. Jia. Characterizing tumor heterogeneity with functional imaging and quantifying
high-risk tumor volume for early prediction of treatment outcome: Cervical cancer as a model. Int. J.
Radiat. Oncol., Biol., Phys.83(3), pp. 972-979. 2012.
[13] G. J. R. Cook, C. Yip, M. Siddique, V. Goh, S. Chicklore, A. Roy, P. Marsden, S. Ahmad and
D. Landau. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer
associated with response and survival after chemoradiotherapy? Journal of Nuclear Medicine 54(1),
pp. 19-26. 2013.
[14] P. Fournel, E. Dansin, M. Bozonnat, J. Daurés, F. Mornex, M. Pérol, G. Robinet, P. Thomas, P.
Souquet, H. Léna, A. Vergnenégre, J. Delhoume, J. Le Treut, J. Silvani and Groupe Lyon-Saint-Etienne
d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie. Randomized phase III trial of
sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced
non-small-cell lung cancer: Groupe lyon-saint-etienne d’oncologie thoracique-groupe français de
pneumo-cancérologie NPC 95-01 study. Journal of Clinical Oncology 23(25), pp. 5910-5917. 2005.
[15] J. Bradley, W. L. Thorstad, S. Mutic, T. R. Miller, F. Dehdashti, B. A. Siegel, W. Bosch and R. J.
Bertrand, J. Bradley, W. L. Thorstad, S. Mutic, T. R. Miller, F. Dehdashti, B. A. Siegel, W. Bosch and
R. J. Bertrand. Impact of FDG-PET on radiation therapy volume delineation in non–small-cell lung
cancer. International Journal of Radiation Oncology Biology Physics 59(1), pp. 78-86. 2004.
[16] R. P. A’Hern. Sample size tables for exact single-stage phase II designs. Stat. Med. 20(6), pp.
859-866. 2001.

Appendix B
B-spline Deformable Registration
The B-spline deformable registration algorithm maps the voxels in the moving image M (CTPET) to
the static image S (CTPlan) generating a displacement field g using cubic B-spline curves in such
M(x,y,z) = g(S(x,y,z))
B-spline registration has two steps, 1) B-spline interpolation 2) cost-function gradient computation.
In B-spline interpolation the image volume is partitioned into equal sized regions by aligning a control
grid over the voxel grid. The algorithm calculates control points to describe the voxel’s movement
between the moving and the static image. These control points are uniformly spaced and aligned
with the voxel grid. Interpolation using piecewise continuous B-spline basis functions between
control points was used to generate displacement vectors. The algorithm minimises the mean squared
cost function C shown in equation (B.1). The cost function C calculates the square of the intensity
difference between static image S and moving image M via numeric optimisation [116][122].
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C =
1
N∑z ∑y ∑x
(S(x,y,z)−M(x+ vx,y+ vy,z+ vz))2 (B.1)
To minimise C, the algorithm calculates the spline coefficients T . The spline coefficient Tx,l,m,n in
equation (B.2) defines the x component of the displacement vector for one of the control points that
influence the voxel movements. Equation (B.2) calculates the x component of the displacement vector
for a voxel located at (x,y,z)
vx(x,y,z) =
3
∑
l=0
3
∑
m=0
3
∑
n=0
βl(u)βm(v)βn(w)Tx,l,m,n (B.2)
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β is the uniform cubic B-spline basis function shown in equation (B.3).
βl(u) =

(1−u)3
6 : l = 0
3u3−6u2+4
6 : l = 1
−3u3+3u2+3u+1
6 : l = 2
u3
6 : l = 3,
(B.3)
In equation (B.2), βl(u) is the basis function along the x-direction and it is calculated using
equation (B.3). Where u is equal to
u = xNx −
⌊
x
Nx
⌋
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The dimensions of the gridded region that is segmented within the volume by B-spline are
Nx,Ny,Nz and the indices of the voxel of interest that is located at (x,y,z) are xt ,yt ,zt . Similarly, to
calculate βm(v) and βn(w), v and w are calculated as
v = yNy −
⌊
y
Ny
⌋
w = zNz −
⌊
z
Nz
⌋
The displacement vector field is termed v⃗. A vector field can be defined using coefficients T
of finite number of control points. Registration is an optimisation problem where a cost function
can be defined to quantify the similarity between the images of interest. B-spline registration is
performed where T coefficients are iteratively defined at the control points then B-spline interpolation
is conducted and the cost function C is evaluated. To generate the next set of coefficients T , the change
in cost function C termed cost function gradient ∂C∂T is calculated for each control point. The cost
function gradient ∂C∂T equation is presented in (B.4-B.7). The gradient is calculated for control point at
this grid coordinates (k,λ ,µ). The voxel coordinates within the region grid are termed (a,b,c).
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∂C
∂Tk,λ ,µ
=
1
N
64 blocks
∑
(x,y,z)
∂C
∂ v⃗(x,y,z)
∂ v⃗(x,y,z)
∂T
(B.4)
∂ v⃗(x,y,z)
∂T
=
3
∑
l=0
3
∑
m=0
3
∑
n=0
βl(u)βm(v)βn(w) (B.5)
∂C
∂ v⃗(x,y,z)
= 2× [S(x,y,z)−M(x+ vx,y+ vy,z+ vz)]▽M(x,y,z) (B.6)
∂C
∂Tk,λ ,µ
=
1
N
Nz
∑
c
Ny
∑
b
Nx
∑
a
∂C
∂ v⃗(x,y,z)
3
∑
l=0
3
∑
m=0
3
∑
n=0
βl
(
a
Nx
)
βm
(
b
Ny
)
βn
(
c
Nz
)
(B.7)
To find the T coefficient values that minimises the cost function C, the limited memory Broyden-
Fletcher-Goldfarb-Shanno (L-BFGS), quasi-Newton optimiser is used [165]. Detailed description of
the L-BFGS method is presented in [24] and [165]. The coefficients are updated for each iterations
and the cost and gradients are computed until the cost function C has converged.
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